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Portal hypertension and cirrhosis: the role of inflammation and nitric oxide
Patients  with  cirrhosis  characteristically  develop  haemodynamic  changes  which 
include  increased  cardiac  output,  decreased  systemic  vascular  resistance  and 
paradoxically,  increased portal pressure.  Studies to date  largely  in  animal  models, 
have suggested that a decrease in hepatic nitric oxide may be important. The studies 
described in this thesis provide evidence for significantly elevated portal pressure in 
alcoholic  hepatitis  patients,  who  were  shown  to  have  a  marked  additional 
inflammatory response on the background of cirrhosis, and a more severe expression 
of  disease.  Studies  in  patients  and  a  galactosamine  rodent  model  confirmed  a 
decrease  in  endothelial  nitric  oxide  synthase  (NOS)  activity  in  the  context  of 
inflammatory  liver  injury.  Following  on  from  these  observations,  further  studies 
explored the role of potential regulators of NOS which may have accounted for its 
decrease in activity in liver disease.
Studies  of asymmetric  dimethylarginine  (ADMA),  an  endogenous  NOS  inhibitor, 
showed that  it was  markedly  increased  in  liver failure  in both patients  and  in  an 
animal  model.  The  data  suggested  this  may  result  from  a  decreased  metabolism 
(through  reduced  expression  of  its  metabolizing  enzyme,  dimethylarginine- 
dimethylaminohydrolase)  or/and  increased  synthesis  by  protein  arginine 
methyltransferases. ADMA was shown to correlate with severity of portal pressure, 
and with  increased organ failure and death in decompensated cirrhosis,  suggesting 
that it may have a potential use as a biomarker of disease severity.
Other novel regulators of endothelial NOS were also explored including the recently 
described potential NOS inhibitor, NOSTRIN (nitric oxide synthase traffic inducer). 
It was demonstrated that NOSTRIN was up-regulated at both message and protein 
levels  in  liver disease patients  and this was most marked in those with  additional 
inflammation.  A  further  novel  observation  was  the  identification  of a  variant  of 
NOSTRIN which was only found in cirrhosis patients and not in normal liver tissue. 
The findings from these studies provide a better understanding of the importance of 
inflammation in the context of vascular dysfunction in cirrhosis and highlight some 
potential novel therapeutic targets.
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General Introduction1.1 Alcohol and liver disease
References to alcohol and its effects date back to  1543, and the term 'al-kuhl’ was 
used by Arabic chemists to refer to substances such as essences that were obtained 
by distillation. In a healthy human, ethyl alcohol is metabolized at the rate of about 7 
grams (or about 9ml.) per hour, a little less than the amount in an average measure of 
spirits.  Larger quantities or drinking faster leads to an accumulation of alcohol for 
the  liver to  process.  In  heavy  drinkers,  which  comprise  8  %  of men  and  3  %  of 
women  in the  UK, there  is an  increased risk of developing alcoholic  liver disease 
(ALD). According to figures from the Alcohol related Working Party of The British 
Liver Trust, alcoholic liver disease accounts for greater than 50 % of presentations of 
UK liver disease and is responsible for 44% of all cirrhosis related mortality, with 
the resultant economic burden that this entails, [http://www.britishlivertrust.org.uk/]
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Figure 1.1: Over the last decade, there has been a marked increase in the number of 
cases of alcohol related cirrhosis. (1)
Within the last 3 decades, figures from the UK Dept, of National Statistics suggest 
that there has been a four-fold increase in mortality from liver cirrhosis in 45-54 year
17old men and an eight-fold cirrhosis mortality increase in 35-44 year old men, largely 
attributable  to  ALD.  Alcoholic  cirrhosis  was  the  primary  indication  for  liver 
transplantation in the UK between  1996 and 2000, with an estimated £24 million for 
direct  transplant  costs.  However,  the  pathophysiology  of severe  ALD,  as  seen  in 
alcoholic  hepatitis,  is  poorly  understood  with  treatment  modalities  being  largely 
supportive and with a lack of consensus on more specific interventions.
There is a significant heterogeneity in the severity of presentation of clinical disease 
and in the susceptibility of individuals to ALD. There is believed to be a nebulous 
“threshold”  of daily  amount  and  length  of time  of alcohol  intake  that  has  to  be 
exceeded, in order to develop ALD. This has been proposed as being a daily intake 
of  alcohol  over  10  to  12  years  with  doses  in  excess  of  40-80g/day  for  males 
(equating to 3-6 cans of 350ml of beer) and of 20-40g/day for females. (2) The lower 
thresholds  are  now  widely  accepted,  especially  with  the  increased  recognition  of 
high alcohol intake amongst younger drinkers, especially young women. Despite the 
need for a threshold with respect to dose and length of time for the development of 
ALD,  there is not a particular amount of alcohol that will predictably cause ALD. 
Among long-term alcohol abusers, the majority will develop fatty liver, whilst  10- 
35%  present with  alcoholic  hepatitis  and  8-20%  will  develop  alcoholic  cirrhosis, 
albeit these two histological forms of the disease often co-exist on a biopsy.
Risk factors that increase the likelihood of developing alcoholic liver disease include 
quantity of alcohol consumed,  (3) female gender,  (4) obesity,  (5)concomitant viral 
infection (especially hepatitis C), (6) and genetic factors including polymorphisms in 
metabolizing  enzyme  systems  and  inflammatory  mediators.(7)  Thus,  alcohol 
probably works as a  ‘potential hepatotoxin’, with the development of liver disease 
depending on the balance of host attributes and co-existing external factors.
181.2 Pathophysiology of alcoholic liver disease
1.2.1 Consequences of alcohol metabolism:
Ethanol  is  metabolized  by  2  major  pathways:  (i)  oxidation  to  acetaldehyde  by 
cytosolic  alcohol  dehydrogenase  with  subsequent  oxidation  to  acetate  by 
mitochondrial  aldehyde  dehydrogenase,  coupled  to  the  reduction  of nicotinamide 
adenine  dinucleotide  (NAD)  to  NADH;  (ii)  metabolism  by  the  cytochrome  P450 
system (CYP2E1) which also generates acetaldehyde, in addition to numerous free- 
radicals.  Acetaldehyde  is  thought  to  have  a  direct  toxic  effect  on  cells  by  the 
formation  of  protein  adducts  by  binding  to  cysteine  residues.  These  modified 
proteins may then evoke an immune response and the production of auto-antibodies 
perpetuating  an  inflammatory  response.  (8)  The  change  in  redox  state  (increased 
NADH  formation)  impairs  normal  carbohydrate  and  lipid metabolism,  whilst also 
decreasing the supply of adenosine triphosphate (ATP) to cells. Gluconeogenesis is 
also impaired leading to the diversion of generated Acetyl CoA, to ketogenesis and 
the synthesis of free fatty acids. The inhibition of mitochondrial p-oxidation coupled 
with the additional inhibitory effect on lipolysis by acetate, leads to hepatic steatosis 
and the generation of reactive oxidant species through lipid peroxidation. (9) Loss of 
normal  mitochondrial  function  (10)  together  with  protein  adduct  formation  (11) 
contributes  to  derangements  in  apoptotic  signalling  pathways  and  progression  of 
liver injury.
1.2.2 The role of endotoxin and pro-inflammatory cytokines:
Several lines of evidence suggest that alcohol promotes gut permeability to bacterial 
translocation  and  an  increase  in  measured  levels  of endotoxin.  (12,  13)  Bacterial 
lipopolysaccharide  (LPS)  then  binds  to  Kupffer  cells  through  inducible  receptors
19such  as  CD 14  and  Toll-like  receptor-4  causing  Kupffer  cell  activation,  (14) 
transducing  signals  to  the  cytoplasm,  culminating  in  activation  of nuclear  factor- 
kappa B (NFkB). Activated NFkB promotes an up-regulation of production of pro- 
inflammatory  cytokines  such  as  Tumour  necrosis  factor  alpha  (TNFa)  and  the 
neutrophil  attracting  chemokine,  interleukin-8  (IL-8).  (15)  The  liver  inflammation 
that ensues is perpetuated by the further generation of neutrophil oxidative burst and 
protease production,  (16)  and the  continued pro-apoptotic  drive  through  increased 
mitochondrial  permeability  transition,  promoted  by  TNFa.  (17,  18)  Furthermore, 
alcohol appears to “prime” peripheral blood mononuclear cells to increase cytokine 
generation in response to LPS stimulation, whilst also sensitising hepatocytes to the 
inflammatory and pro-apoptotic effects of cytokines. (9) The concept of priming and 
sensitisation  to  a  “second  hit”  of  injury  such  as  endotoxin  implies  a  series  of 
sequential events in the progression of liver injury following alcohol exposure.
A schematic representation of this concept of a ‘second hit’  is represented in figure
1.2.
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Figure  1.2  This  cartoon  illustrates  the  concept  of the  primary  stimulus  for  liver 
injury  resulting  from  the  metabolism  of alcohol  with  the  generation  of reactive 
oxygen  species  (ROS)  and protein  adducts  that promote  inflammatory  injury  and 
apoptosis. However, an increase in gut permeability and consequent translocation of 
endotoxin,  promotes  a  ‘second hit’  resulting in the activation of pro-inflammatory 
signals that are perpetuated by neutrophil activation.
1.2.3  Contribution of inflammation in alcoholic cirrhosis
As stated above, chronic alcohol ingestion has been suggested to increase intestinal 
permeability and the resultant translocation of bacterial products from the intestinal 
lumen to the mesenteric circulation and its lymphatics induces regional and systemic 
production  of  pro-inflammatory  cytokines.  (19)  Furthermore,  it  has  been 
demonstrated that  peripheral  blood mononuclear cells  in alcoholic  cirrhotics upon 
bacterial  challenge  within  regional  lymph  nodes,  undergo  a  priming  activation 
resulting  in  significantly  increased  spontaneous  and  lipopolysaccharide  (LPS)- 
stimulated  release  of  tumour  necrosis  factor  alpha  (TNFa),  compared  with
21monocytes from healthy volunteers.  (20) In patients with severe alcoholic hepatitis 
(AH), elevated plasma TNFa concentrations on admission are believed to be up to 
an  82%  predictor of mortality  compared with  100  %  survival  in  patients  without 
elevated levels of TNFa. (21)
1.2.4  The role of TNFa
TNFa  is  a  17-  kilo  Dalton  cytotoxic  protein  produced  largely  by  activated 
macrophages,  after  exposure  to  endotoxin  or  tissue  injury.  TNFa  is  thought  to 
increase  vascular  permeability  and  promotes  neutrophil  migration  to  the  site  of 
inflammation and injury by stimulating the production of chemokines such as 11-8 by 
Kupffer  cells  and  hepatocytes  (22),  whilst  also  enhancing  neutrophil  adhesion  to 
vascular endothelium. (23) TNFa also has a direct role in promoting apoptosis and 
necrosis, which may involve increased mitochondrial pore transition. (18)
The importance of TNFa in the pathogenesis of alcoholic liver disease is highlighted 
by  2  studies  in  intragastric  alcohol  fed  animal  models:  Yin  and  colleagues  (24) 
studied alcohol fed TNF receptor knock-out mice and demonstrated significant liver 
injury and raised alanine aminotransferases only in wild type and TNF receptor-II 
knock-out mice. This highlights the importance of alcohol induced injury via a TNF 
receptor-I pathway.  A similar model of enteral fed male Wistar rats treated with a 
neutralizing  anti-  TNFa  antibody  demonstrated  significant  attenuation  of hepatic 
inflammation and necrosis, and a reduction in macrophage inflammatory protein-2, 
suggesting  that  TNFa  may  drive  subsequent  neutrophil  responses  to  evoke  liver 
injury. (25)
221.3  Vascular derangements in cirrhosis
Patients  with  decompensated  alcoholic  liver  disease  (a  precipitation  of  clinical 
deterioration of underlying cirrhosis by factors such as infection or bleeding) exhibit 
a  characteristic  hyperdynamic  circulation  which  is  manifest  by  increased  cardiac 
output (CO), a dilated and hyporesponsive peripheral circulation with low systemic 
vascular  resistance  (SVR),  portosystemic  shunting,  increased  portal  pressure,  and 
reduced organ  blood  flow.  These factors are responsible for the complications and 
mortality  associated with portal  hypertension with which  patients  often present  to 
hospital, namely: variceal bleeding, hepatorenal failure, hepatic encephalopathy and 
circulatory dysfunction. (26)
A  wealth  of evidence  suggests  that  complications  of portal  hypertension  do  not 
appear  until  the  portal  pressure  gradient  (measured  between  the  portal  vein  and 
hepatic  veins)  rises  above  10-12  mmHg  (normal  values:  1-5  mmHg).  (27,  28) 
Conversely,  lowering portal pressure below this threshold value is associated with 
prevention of most portal hypertensive complications. (29)
1.3.1  Pathophysiology of  portal hypertension
The portal pressure gradient is the result of the interaction between the portal blood 
flow and vascular resistance that opposes that flow in accordance with Ohm’s law, as 
defined by the relationship:
AP  = Q x R
in which AP  is the portal pressure gradient, Q the total portal venous blood flow and 
R the vascular resistance of the portal  venous  system.  Thus,  an  increase  in portal 
pressure  can  result  from  changes  in  portal  blood  flow,  vascular  resistance  or  a 
combination of both.
231.3.1.1  Splanchnic vasodilatation in portal hypertension
Increased  portal  venous  inflow  is  the  result  of marked  arteriolar vasodilatation  in 
splanchnic organs draining into the portal vein. This is  likely to represent a multi­
factorial process involving neurogenic, humoral and local vaso-active mechanisms. 
(30) Amongst the most studied vasodilators include glucagon, (31) and nitric oxide 
(NO),  as first suggested by Vallance and Moncada.  (32) More recent studies have 
shown  that  patients  with  cirrhosis  have  increased  plasma  levels  of nitrates  and 
nitrites  (NOx),  especially  noted  in  the  portal  vein,  (33)suggesting  that  in  these 
patients there is enhanced release of NO from the splanchnic bed. The mechanisms 
postulated for this increased NO release relate to changes in endothelial nitric oxide 
synthase  (eNOS)  expression  following  increased  shear  stress,  (34)  and  TNFa 
mediated  increased  availability  of the  eNOS  co-factor,  tetrahydrobiopterin.  (35) 
Other proposed mechanisms include effects on NO production following activation 
of  cannabinoid  CB1  receptors  caused  by  increased  levels  of  the  endogenous 
cannabinoid anandamide in advanced cirrhosis. (36)
In  association  with  splanchnic  vasodilatation,  patients  with  advanced  cirrhosis 
characteristically develop peripheral vasodilatation with reduced peripheral vascular 
resistance. This leads to activation of endogenous neurohumoral systems resulting in 
sodium retention, expansion of plasma volume and an increase in cardiac output, all 
elements known to drive the development of ascites and the hepatorenal syndrome. 
(37) It is these elements that further contribute to the splanchnic hyperaemia which 
together with an increase in portal vascular resistance, are believed to contribute to 
portal hypertension in what has been termed the “forward flow” theory. (38)
241.3.1.2  Increased intrahepatic resistance
Early concepts of increased intrahepatic resistance in cirrhosis related to the belief 
that  liver  ultra-structural  changes  induced  by  fibrosis  altered  liver  blood  flow. 
However,  currently,  beyond  these  mechanical  factors  there  is  believed  to  be  an 
important  contribution  from  a  dynamic  component  provided  by  hepatic  sinusoids 
and smooth muscle cells of portal venules that are able to constrict in a reversible 
and graded manner in response to several agonists. (39) Constriction of sinusoids is 
mediated largely through the contractile properties of activated stellate cells which 
are  located  in  the  peri-sinusoidal  space  and  whose  pseudopodia  wrap  around  the 
sinusoids causing constriction in response to vasoactive factors such as endothelin  1  
and angiotensin II which are increased in cirrhosis. (40, 41) By contrast, it has been 
shown  that  synthesis  of  NO  is  decreased  and  unable  to  compensate  for  this 
abundance in vasoconstrictors. (42-44)Thus in liver disease, the ‘normal’ balance in 
vasoconstrictors  and  vasodilators  are  deranged  leading  to  an  endothelialopathy 
manifest  as  increased  vascular  tone.  This  is  further  compounded  by  exaggerated 
stellate  cell  activity promoted by  inflammatory  signals  such as  TNFa,(45)  further 
increasing intrahepatic resistance, resulting in the so-called ‘backward flow’  theory 
of portal  hypertension.  This  might  suggest  a  rationale  for  using  vasodilators  to 
reduce portal hypertension. However, when drugs such as isosorbide-5-mononitrate 
have  been  used,  they  also  create  some  degree  of systemic  and  further  splanchnic 
vasodilatation,  inducing  hypotension,  and  a  further  deleterious  effect  on  regional 
blood flow. (46) There is thus an apparent paradox between systemic vasodilatation 
and relative increases in hepatic vascular resistance that needs to be reconciled,  in 
spite  of  factors  such  as  NO  contributing  to  both  phenomena-  too  much  in  the 
systemic circulation, and too little within the liver.
251.4  Nitric oxide biology
NO, an endothelial derived relaxing factor, is synthesized by a family of three nitric 
oxide  synthases  (NOS):  the  constitutively  expressed  isoforms,  endothelial  NOS 
(eNOS)  and  neuronal  NOS  (nNOS),  and  an  inducible  form  (iNOS).  (47)  Among 
these  isoforms,  eNOS  is  the  major  enzymatic  source  of  the  vascular  NO 
overproduction  in  the  arterial  circulation  (35).  Endothelium  derived  NO  is 
synthesized  from  the  amino  acid  L-arginine  by  the  action  of eNOS,  yielding  L- 
citrulline as a by-product.  (48) NO  is  labile with a  short half life (< 4  seconds  in 
biological solutions) and is rapidly oxidized to nitrite and then nitrate by oxygenated 
haemoglobin, before being excreted into the urine.  Several  co-factors are required 
for  NO  biosynthesis.  These  include  nicotinamide  adenine  dinucleotide  phosphate 
(NADPH),  flavin mononucleotide,  flavin adenine  dinucleotide,  tetrahydrobiopterin 
(BH4), and calmodulin. Once synthesized the NO diffuses across the endothelial cell 
membrane and enters the vascular smooth muscle cells where it activates guanylate 
cyclase, leading to an increase in intracellular cyclic guanosine- 3’,5-monophosphate 
(cGMP) concentrations.  (48) As a second messenger, cGMP mediates many of the 
biological  effects  of  NO  including  the  control  of  vascular  tone,  by  regulating 
intracellular calcium homeostasis and thereby,  smooth muscle cell  contractility.  In 
addition to vascular regulation, NO has many other physiological functions including 
as  an  anti-oxidant,  in  modulating  platelet  thrombotic  effects  and  in  modulating 
leukocyte adhesion, hence the central role it plays in the pathology of atherogenesis. 
(49)
261.4.1  Nitric oxide an important mediator of vascular disturbances in cirrhosis- too 
much and yet not enough
NO related vasodilatation  serves as a counterbalance to local  vasoconstrictors  and 
sympathetic nervous activity. Investigators have demonstrated that isolated perfused 
normal rat livers respond to increases in blood flow and subsequent shear stress by 
developing a flow-dependent increase  in NO  synthesis to counteract the  increased 
perfusion pressure. (50) The enzymatic origin of this NO production was found to be 
hepatic  endothelial  cell  derived  eNOS.(51)  Moreover,  preferential  inducible  nitric 
oxide synthase inhibition was shown to be ineffective in endotoxaemic conditions of 
increased shear stress,  supporting the  importance of eNOS-derived NO production 
for maintaining intra-hepatic vascular tone. (52)
In  cirrhotic  rat  models  with  ascites,  there  is  a  paradoxical  vasoconstriction  in 
response  to  the  eNOS  agonist  acetylcholine,  coupled  with  reduced  hepatic  NO 
production,  suggesting  that  there  is  a  relative  NO  deficiency  in  the  intrahepatic 
microcirculation  contributing  to  increased  intrahepatic  resistance.  (42)  This 
deficiency in NO production has been demonstrated in several experimental models, 
(43, 44) with the suggestion that it is related to the severity of the liver disease as it is 
more  evident  in  cirrhotic  animals  with  ascites.  (42)  Human  studies  in  cirrhotic 
patients  are  limited,  (53)  and  there  is  no  data  to  relate  the  degree  of  eNOS 
dysfunction  with  the  degree  of disease  severity  or  with  underlying  pathological 
factors such as inflammation associated with advanced cirrhosis.
The reduction in NO production in cirrhosis does not appear to be due to decreased 
eNOS expression as this appears to be the same in control and cirrhotic animals. (43, 
44)This finding might implicate posttranslational regulatory mechanisms resulting in 
defective  NO  production  in  cirrhosis.  In  support  of  this  concept,  an  increased
27expression  of  the  eNOS  regulatory  protein  caveolin  1   has  been  described  in 
association with decreased enzyme activity. (54) Several other NOS regulators have 
been identified and may affect NO-cGMP signalling through modification of eNOS 
activity,  albeit  data  in  liver  disease  and  humans  is  lacking.  (55,  56)  Recently, 
interventions  such  as  eNOS  gene  transfer  (57)and  transduction  of the  liver  with 
activated  Akt  (a  serine  protein  kinase  required  for  eNOS  phosphorylation  and 
subsequent activation) have demonstrated reductions of portal pressure in cirrhotic 
rats,  (58)  further  emphasizing  the  importance  of  hepatic  NO  generation  in  the 
regulation of intra-hepatic resistance, whilst also hinting at a potential target for the 
management of elevated portal pressure.  Indeed some novel compounds to deliver 
intra-hepatic  NO  have  been  tested  in  animal  models  to  try  to  ameliorate  portal 
hypertension, (59) but these findings are yet to be substantiated in patients.
1.4.2  The link between inflammation and vascular derangement in alcoholic liver 
disease
Increased  pro-inflammatory  drive,  often  as  a  consequence  of increased  bacterial 
translocation  in  advanced  cirrhosis,(60)  may  interplay  with  numerous  factors  that 
alter vascular tone  such  as  endothelin-1  (61),  cysteinyl-leukotrienes  (62),  and NO 
(48, 63). Of these mediators, NO is believed to be the most important, and TNFa is 
thought to promote vasodilatation and a hyperdynamic circulation in mammals by 
activating NO synthesis. (48) The mechanism reported to be involved is thought to 
relate  to  activation  of  guanosine  triphosphate  (GTP)-cyclohydrolase  I,  which 
generates BH4 production in mesenteric arteries. This increase in BH4 is associated 
with  enhanced  eNOS  activity  and  eNOS-derived  NO  overproduction  in  the 
mesenteric  arterial beds.  (35).  The resultant hypotension elicited by TNFa can be
28reversed via inhibition of NO synthesis, suggesting that L-arginine-derived NO is the 
principal mediator of this observation.(64)
The importance of TNFa in the development of portal hypertension is suggested by 
results  from  studies  on portal  vein  ligated  rats  treated with  anti-  TNFa therapies, 
where a blunting of the hyperdynamic circulation and a reduction of portal pressure 
has been demonstrated albeit, the mechanism by which TNFa evokes these vascular 
effects has not been elucidated. (65, 66) These anti-cytokine treatments are believed 
to  act  largely  through  the  modulation  of intrahepatic  resistance,  and  a  regulatory 
effect on eNOS activity is therefore, an attractive hypothesis (figure 1.3).
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Figure  1.3:  This cartoon depicts the hypothesis that alcoholic hepatitis exists as a 
state of increased pro-inflammatory drive (TNFa), where a paradox exists between 
high systemic nitric oxide (NO) promoting vasodilatation with low systemic vascular 
resistance (SVR) and compensatory high cardiac output (CO), whilst low NO in the 
liver increases hepatic vascular resistance (IHR) and thus increases portal pressure.
291.5  The  clinical  need  for  studies  relating  inflammatory  mechanisms  to  the 
pathogenesis of portal hypertension.
Despite  the  high  mortality  associated with  decompensated  alcoholic  cirrhosis  and 
severe alcoholic hepatitis (up to 40% in some series) (67), there are a limited number 
of treatment options  and  a  lack of consensus  amongst physicians  on their use.  In 
general, the management is supportive with the additional use of glucocorticoids in 
severe alcoholic hepatitis (68) although this treatment, despite encouraging results in 
selected subgroups of patients, remains controversial.  (69)  Similarly,  treatments to 
decrease portal pressure such as (3-blocker monotherapy achieve a target reduction of 
>20  %  reduction  in  hepatic  venous  pressure  gradient  (HVPG)  in  only  a  small 
percentage of patients. (70) This intervention is poorly tolerated, and has little impact 
on  the  inflammatory  mechanisms  that  appear  to  promote  increased  intrahepatic 
resistance. Moreover, these treatments are flawed by the fact that whilst decreasing 
portal pressure, they also decrease mean arterial pressure and thus, further compound 
failing perfusion pressure through sensitive organs such as the liver and kidney. (46) 
There is therefore, a significant clinical need to understand the pathophysiology of 
circulatory  dysfunction  in  alcoholic  cirrhosis  and  relate  this  to  the  apparent 
inflammatory mechanisms that exist in animal models, in the hope that this will help 
in the design of more targeted therapies.
301.6 Hypothesis:
In alcoholic liver disease patients,  a marked pro-inflammatory response, for which 
TNFa is important, regulates vascular resistance by modulating the activity of eNOS 
in systemic and regional vascular beds.
1.7 Aims:
1.  To  define  the  relationship  between  inflammatory  mediators  and  the 
expression  of  severity  of  disease  and  vascular  dysfunction  in  alcoholic 
cirrhosis, and assess responses to anti-inflammatory intervention
2.  To explore the relationship between nitric oxide generation and inflammation 
in cirrhosis
3.  To study novel regulators of nitric oxide synthase and explore their biological 
significance in alcoholic cirrhosis
31Chapter 2 
Methods2.1 Patient Studies
2.1.1 General and ethical consideration:
Patients were recruited from University College London Hospitals (unless otherwise 
stated for a specific  study) with an appropriate alcohol history, and clinical  or/and 
histological  evidence  of  alcoholic  cirrhosis.  All  patients  or  their  relatives  gave 
written informed consent or assent, respectively, in accordance with the Declaration 
of  Helsinki  of  the  World  Medical  Association,  1951.  Several  concurrent 
interventional studies within The Liver Failure group including use of MARS, anti- 
TNF therapies, Probiotics and L-omithine-L-aspartate had local ethics (UCLH/UCL) 
approval for collection and storage of data, plasma and liver biopsy samples obtained 
during routine clinical acquisition, which were used for the studies described below. 
In general, baseline haemodynamic studies (described below) were conducted at the 
time of a trans-jugular liver biopsy or/and assessment of portal pressure, as clinically 
indicated. All patients were managed with standard of care in addition to any specific 
intervention  for  a  defined  study,  and  routine  daily  observations  including  blood 
pressure, heart rate, temperature and urine output. In addition, three times per week 
if not daily estimation of urea and electrolytes, liver function tests and blood count 
were conducted.
Any healthy controls studied also gave full informed consent to participate, including 
the  taking  of  blood  samples  and  subsequent  storage  for  further  scientific 
investigation.
332.1.2  Haemodynamic studies
2.1.2.1  Hepatic venous pressure gradient assessment
All haemodynamic studies were performed following an overnight fast and a 1-hour 
period during which the patient had been resting supine.  Patients were  sedated for 
the  procedure  using  midazolam  (mean  dose  of  3  mg;  Phoenix  Pharma  Ltd., 
Gloucester, UK), as has been shown to be appropriate during HVPG measurements 
owing to lack of effect on HVPG measures whilst improving patient tolerability to 
the procedure.(71) None of the patients in whom haemodynamic measurements were 
made were on beta- blockers. A 5Fr Berenstein occlusion balloon catheter (Boston 
Scientific, Cork, Ireland) was introduced via the right internal jugular route into the 
right hepatic vein under fluoroscopic screening (Toshiba Spot Film Device Model: 
SA-900U;  Tochigi-ken,  Japan).  Wedged  hepatic  venous  pressures  (WHVP)  were 
assessed in triplicate in at least 2 radicals after inflation of the balloon and injection 
of  2mls  of  contrast  medium  (Iohexol  [Omnipaque]  Amersham  Health,  Little 
Chalfont,  UK).  Careful  attention  to  fluoroscopic  examination  ensured  wedged 
positions  obtained  were  without  drainage  by  local  venous  shunts.  Free  hepatic 
venous  pressures  (FHVP)  were  measured  on  deflation  of the  balloon.  Pressure 
measurements  were  recorded  via  pressure  transducer  sets  (Medex  Medical, 
Rossendale, Lancashire, UK) on a Hewlett Packard monitor (Model 86S, HP, Palo 
Alto,  CA,  USA).  Hepatic venous pressure gradient (HVPG) was  calculated as the 
difference between WHVP and FHVP. In certain studies, where described, 24 hour 
HVPG measurements were made by keeping the hepatic venous catheter in place for 
a repeat reading.
342.1.2.2 Cardiovascular Haemodynamics
Heart rate,  oxygen  saturation  and ECG were recorded continuously  and the  mean 
arterial pressure (MAP) (1/3 [systolic -  diastolic] + diastolic pressure) was measured 
prior to catheterization and every 5 minutes thereafter (Hewlett-Packard, Model 86S, 
HP,  Palo Alto, CA, USA).  The pulmonary artery was catheterized via the internal 
jugular sheath using a Swan-Ganz catheter (Edward Lifesciences,  Irvine,  CA) and 
cardiac  output  (CO)  calculated  by  thermodilution  and  displayed  electronically 
(Vigilance  monitor,  Critical  Care  Edwards  Lifesciences,  Irvine,  CA).  Each 
measurement  was  performed  in  triplicate  and  an  electronic  mean  calculated. 
Systemic vascular resistance (SVR) was also calculated when CO, MAP, and central 
venous pressure (CVP) were known, using the formula:
SVR = 80x (MAP - CVP) -  CO.
2.1.2.3 Hepatic bloodflow
Hepatic blood flow (HBF) was determined using a primed (12 mg) followed by a 
continuous  infusion  (1  mg/min)  of indocyanine  green  (ICG)  (Akom  Inc.,  Buffalo 
Grove, IL, USA). The infusion was started 1  hour prior to sampling to ensure steady 
state  concentrations.  HBF was measured by simultaneous  sampling of arterial  and 
hepatic  venous  blood.  ICG  levels  were  determined  spectrophotometrically  at  an 
absorbance  wavelength  of  805  nanometres,  on  an  Agilent  8453  diode-array 
spectrophotometer (Agilent UK) with detection capabilities in the ultra-violet range. 
Plasma flow rate of the liver was calculated on the method of indicator dilution and 
Fick’s principle.(72, 73), and was converted to blood flow using the haematocrit.
2.1.2.4 Renal bloodflow
Renal blood flow (RBF) was determined using a primed infusion (bolus of 0.5g), and 
a  continuous  infusion  (0.5g/hour)  of para-aminohippuric  acid  [PAH]  (Apotheek
35Academisch Ziekenhuis, Maastricht, NL). As with HBF, sampling commenced after 
steady  state  was  reached.  RBF  was  determined  by  measurement  of PAH  in  the 
arterial  and renal venous blood by spectrophotometric analysis  (as  above)  and the 
flow rate calculated by the method of indicator dilution and Fick’s principle.
2.2  Neutrophil oxidative burst and phagocytosis determination
Neutrophils were either investigated in a whole blood assay (as described below) or 
after isolation by a one-step gradient centrifugation.
2.2.1 Neutrophil Isolation
Whole  blood  (4ml)  was  layered  over  5  ml  of Polymorphprep  (Axis-Shield,  Oslo, 
Norway)  and  spun  for  30  min  at  400g  at  room  temperature.  Neutrophils  were 
harvested  from  the  second  interface  and  washed  with  phosphate  buffered  saline 
(Sigma  Aldrich,  St.  Louis,  MO,  USA).  Neutrophils  were  counted  in  a  Thoma- 
haemocytometer and re-suspended in phosphate buffered saline at a density of 5  x 
105  in 50 pi. 50 pi of cell suspension and 50 pi of plasma were used for one assay. 
Viability was tested by Trypan-Blue exclusion and was over 98%.
2.2.2 Neutrophil activation (oxidative burst)
The Phagoburst® kit (Orpegen Pharma, Heidelberg, Germany) was used to determine 
the  percentage  of  neutrophils  that  produce  reactive  oxidants  with  or  without 
stimulation  according  to  the  manufacturer’s  instructions.  In  brief,  100  pi  of 
heparinized whole blood or 50  pi  of isolated neutrophils  and 50  pi  of plasma (as 
indicated) were  incubated for 20 minutes with 20  pi  of opsonized E.coli (2  x  107  
bacteria),  N-formylmethionyl-leucyl-phenylalanine  (fMLP;  5pM),  phorbol-12-
36myristate-13-acetate  (8.1  pM)  or without  stimulus  at  37°C.  Formation  of reactive 
oxidants was monitored by oxidation of dihydrorhodamine  123 to rhodamine which 
gives green fluorescence. To identify neutrophils, cells were stained with anti-CD 16- 
PE  antibody  (Immuntools,  Friesoythe,  Germany)  and  analysed  by  fluorescence 
activated cell  sorting (FACS;  Becton Dickinson FACScan,  San Jose,  USA), using 
Cellquest™  software.  Neutrophils  were  gated  on  forward  and  side  scatter 
characteristics (Figure 2.1 A) and subsequently the percentage of CD 16-positive cells 
producing reactive oxygen metabolites (green fluorescence) was calculated (Figure
2.1  C, E, and G).  Samples were analyzed in duplicate or triplicate.  The inter-assay 
coefficient  of variation  (CV)  for resting  burst  was  5.4%  and  for  stimulated burst 
4.2%. The intra-assay CV for resting burst was 4.7% and 2.4% for stimulated burst.
2.2.3  Neutrophil phagocytic capacity
The  Phagotest®  (Orpegen  Pharma,  Heidelberg,  Germany)  was  used  to  measure 
phagocytosis  by using  FITC-labelled  opsonized E.  coli bacteria.  100  pi  of whole 
blood  or  50  pi  of isolated  neutrophils  and  50  pi  of plasma  (as  indicated),  were 
incubated  with  20  pi  of bacteria  (2  x  107)  at  37°C  for 20  min,  while  a  negative 
control sample remained on ice. Phagocytosis was stopped by placing the samples on 
ice and adding quenching solution that allowed discrimination between attachment 
and  internalization.  Erythrocytes  were  lyzed  and  DNA  staining  solution  allowed 
exclusion of aggregation artefacts  in the  form of bacteria or cells.  The  cells  were 
spun at 250g for 5 minutes and further re-suspended in 50pl of washing solution, and 
incubated  with  lOpl  anti-CD-16  antibody  (IOTest®,  Beckman  Coulter)  for  30- 
40mins  at  room  temperature  and  analyzed  by  flow  cytometry.  Neutrophils  were 
gated on forward and side scatter (Figure 2.1 A) characteristics and subsequently the
37percentage  of  CD 16  positive  cells-  FITC  positive  cells,  corresponding  to  the 
percentage  of  neutrophils  undergoing  phagocytosis  and  the  geometric  mean  of 
fluorescence intensity (GMFI), corresponding to the number of bacteria engulfed by 
one  cell,  was  analyzed.  Figure  2.1  B,  D,  F,  and H.  To  avoid misinterpretation  of 
results due to batch-to-batch variability of bacteria, results were normalized to the 
mean  of at  least  3  healthy  control  samples  for  each  new  batch  of bacteria  used. 
Samples  were  analyzed  in  duplicate  or triplicate.  The  inter-assay  CV  was  10.1% 
(reflecting  the  potential  differences  between  batches  of  bacteria  used  as  stated 
above), the intra-assay CV was 1.6%.
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Figure  2.1:  (A)  Neutrophils  gated 
according to their forward and side 
scatter  (B)  Analysis  of 
phagocytosis:  On a sample without 
bacteria,  markers  are  set  such  that 
99% of the gated neutrophils appear 
within  the  first  maker  (C)  FACS- 
plot from a healthy control subject; 
percentage  of double  positive  cells 
(CD 16  positive  cells  producing 
reactive  oxygen  metabolites 
determined by green fluorescence in 
FL-1)  are  measured.  (D) 
Corresponding  FACS-plot  of  a 
healthy  control  with normal  GMFI 
(E)  FACS-plot  from a patient with 
low  resting  burst,  (F) 
Corresponding  FACS-plot  of  a 
patient with low GMFI, (G) FACS- 
plot from a patient with high resting 
oxidative  burst  (H)  Corresponding 
FACS-plot  of a  patient  with  very 
low GMFI
392.3  Animal model studies
All  animal  experiments  were  performed  under  a  Home  Office  directed  animal 
project license and adhered to the Animals Scientific Procedures Act 1986.
2.3.1  Bile duct ligation in rats
The bile duct ligated (BDL) rat is a model of rapid liver fibrosis that translates as a 
chronic model of cirrhosis. (74)
Surgery was performed under anaesthesia (diazepam  1  mg/kg intra-peritoneal (I.P), 
followed  by  Hypnorm®  150pl/kg  intramuscular  (I.M),  Janssen  Pharmaceutica, 
Belgium). All rats underwent bile duct ligation to induce biliary cirrhosis, or a Sham 
operation. A midline abdominal incision was made under anaesthesia. The common 
bile duct (CBD) was isolated, triply ligated (to ensure definitive ligation) using 3-0 
silk  sutures  and  sectioned  between  the  2  distal  ligatures.  Sham-operated  rats 
underwent laparotomy and isolation of the CBD without ligature or section, leaving 
the biliary system intact.
Twenty-eight days after operation, the rats were randomized into groups, with BDL 
or  Sham-operated rats  as the  respective  controls  and test animals  for counterparts 
that  were  injected  with  bacterial  lipopolysaccharide  (LPS  -   from  Salmonella 
typhimurium, 0.5 mg/kg I.P made up to 0.5mls in saline) or saline. As per protocol, 
the rats were  allowed free  access to  food and water for a period of 3  hours post­
intervention  in  a  temperature  controlled  environment  and  then  sacrificed  by 
exsanguination  under terminal  anaesthesia  (Hypnorm  200pL/kg  I.M),  20  minutes 
after diazepam (lmg/kg I.P).  Blood was withdrawn from the descending aorta and 
immediately  put  into  heparin/EDTA  containing  tubes  until  full  exsanguination,
40centrifuged, and the plasma collected and stored at -80°C until assayed. Liver tissue 
was snap frozen for further analysis.
2.3.2  Galactosamine treated rats
Sprague  Dawley rats  (male,  250-300g)  were  administered a single  IP  injection of 
galactosamine (lg/kg,  Sigma, Poole UK) in saline, to induce acute liver failure, or 
saline only as a control. After 24 hours animals were given a further IP injection of 
either  saline  or  bacterial  lipopolysaccharide  (LPS  1  mg/kg,  from  Klebsiella 
pnuemoniae, Sigma, Poole UK) in saline, or saline only control, and returned to their 
cages.  After  three  hours,  3  groups  of  five  animals  (sham,  galactosamine, 
galactosamine  plus  LPS)  were  anaesthetised  (Hypnorm,  250pl  IP,  Janssen 
Pharmaceutica, Belgium) and blood was withdrawn from the descending aorta into 
heparin  containing  tubes  until  full  exsanguination,  centrifuged,  and  the  plasma 
collected and stored at - 80°C until the point of assay. Tissue samples were collected 
and flash-frozen in liquid nitrogen and stored at -80°C until use.
2.4  Laboratory analytical methods
2.4.1  Cytokine/chemokine analysis
Capture antibodies (BioSource AS, Belgium) for TNFa,  IL-6, IL-8 and soluble TNF 
receptors I and II (TNF-R1, TNF-R2) were coated at 1   pg/ml onto 96 well Maxisorb 
(NUNC,  Denmark)  ELISA  plates  overnight  at  4°C.  The  plates  were  washed  3x 
before being blocked with bovine serum albumin (300jli1; 5g/L) (Fraction V, Sigma- 
Aldrich, Poole, UK) for 2hours at room temperature. Standard (7.5 -  lOOOpg/ml) or 
sample  in  lOOpl  together  with  biotin-conjugated  detection  antibody  (100  pi;  0.4 
pg/ml)  (BioSource  AS,  Belgium)  were  co-incubated  at  room  temperature  for  a
41further  2hours.  In  order  to  accurately  quantify  TNF-R1,  TNF-R2  serial  dilution 
(from  1/32  and down)  of sera  samples was necessary.  After washing,  streptavidin 
(lOOpl;  125ng/ml) (BioSource AS, Belgium) was added to each well for 20min at 
room temperature.  The plates were again washed before  incubation with substrate 
(lOOpl,  300pg/ml  o-phenylenediamine  HC1;  Sigma-Aldrich,  Poole  UK).  The 
reaction was stopped with 50pl 1.8M sulphuric acid and the optical density measured 
at 450nm referenced against 630nm. Individual standard curves were established and 
a  lower  limit  for  TNFa  detection  set  at  5pg/ml.  Each  standard  and  sample  was 
measured in duplicate.  After a  single batch analysis,  the  intra-assay coefficient of 
variation was 5.4%.
2.4.2  Measures of oxidant stress
2.4.2.1  Malondialdehyde  (MDA)  measurement:  The  use  of a  thiobarbituric  acid 
(TBA) test to define the presence of lipid peroxidation aldehydes such as MDA, is an 
accepted test of oxidative stress in disease.(75) Patient plasma (0.5 ml ) was added to 
a reaction mixture (1.0 ml) formed by equal parts of 15% trichloroacetic acid, 0.25 N 
HC1, and 0.375% TBA, plus 2.5 mM butylated hydroxytoluene (BHT) and 0.1 ml of 
8.1% sodium dodecyl sulfate (SDS), followed by 30 min heating at 95°C; pH value 
of the  analytical reaction mixture was about 0.9.  BHT was used to  prevent lipid 
peroxidation  during  heating.  After  cooling,  the  chromogen  was  extracted  with  n- 
butanol and read spectrophotometrically at 532  against a “blank” reaction mixture 
lacking plasma but subjected to the entire procedure and extracted with ^-butanol. 
To correct for background absorption, absorbance values at 572 nm were subtracted 
from those  at  532  nm,  the  latter representing the  absorption maximum of the  2:1 
TBA:MDA adduct.
422.4.2.2  Measurement of  F2-isoprostanes in plasma: Free 8-Isoprostane F2alpha was 
assayed  with  a  commercial  enzyme  immuno-absorbance  (EIA)  kit  (Cayman 
Chemical,  Ann Arbor,  MI)  according to manufacturers  instructions.(76,  77)  200pl 
plasma  was  deproteinised  with  600pl  ethanol  containing  8KBq  3H-PGE2  as  an 
internal  standard  to  account  for  losses.  After  centrifugation  the  supernatant  was 
reduced to  near dryness,  2ml  acetic  acid was  added and the  mixture  applied to  a 
preconditioned (acetic acid washed) C18 SPE cartridge (Waters Corp, Milford, MA). 
The column was washed with 5ml water, dried with oxygen-free nitrogen and eluted 
with 5ml HPLC grade hexane, before the prostanoid fraction was eluted with 5ml 
ethylacetate  containing  1%  methanol.  The  eluant  was  reduced  to  dryness, 
reconstituted in 450ul of EIA buffer,  lOOpl being used to determine recovery of 3H- 
PGE2  and  50pl  added  to  the  EIA  plate  with  50pl  isoprostane  tracer  and  50pl 
antibody and incubated for  18h at room temperature.  The plate was washed before 
the  addition  of 200pl  of Ellman’s  reagent.  The  optical  density  of each  well  was 
measured at 420nm and isoprostane levels were determined by reference to authentic 
standards  and  corrected  for  losses  calculated  from  radioactive  prostaglandin 
recovery.
2.4.3  Nitric oxide measurement
2.4.3.1  NOx: (nitrate/nitrite) production
A method for simultaneous detection of nitrate and nitrite in plasma with a modified 
Greiss reaction,  as described by Miranda et al  (78) was used.  All  chemicals were 
obtained from Sigma-Aldrich (Poole, Dorset, UK) and were of the highest laboratory 
grade. A saturated solution of vanadium (III) chloride (400mg) was prepared in  1M 
hydrochloric  acid (50  mis).  Greiss  Reagent A was  prepared  from N-(l-Naphthyl)
43ethylenediamine  dihydrochloride  (0.1%  w/v)  in  ddFLO.  Greiss  Reagent  B  was 
prepared from sulfanilamide (2% w/v) in 5% hydrochloric acid. All three solutions 
were stored in the dark.
100  p/L  of plasma  was  diluted  1   in  4  with  phosphate  buffered  saline.  This  was 
placed in a Whatman  12 kDa molecular weight cut off filter (Vectaspin, Whatman, 
Maidstone  UK)  and  spun  at  13,000  rpm  for  30  minutes  at  4  °C  to  centrifugally 
remove  proteins  as  described  by  Giovannoni  et  al.(79)  For  the  measurement  of 
nitrate, 50 p/L of the filtrate was pipetted out into a 96 well plate (Maxisorb, NUNC, 
Denmark). To this were added 50 p/L of vanadium (III) chloride solution, 50 p/L of 
Greiss Reagent A, N-( 1  -Naphthyl)ethylenediamine dihydrochloride (NEDD), and 50 
p/L  of Greiss Reagent B,  sulfanilamide (SULF), whereby nitrate was  catalytically 
converted to  nitrite by vanadium  (III)  chloride.  Nitrite  was  measured in  a  similar 
manner except that  samples  were  only  exposed to  Griess  reagents  A  and B.  The 
nitrite and nitrate in the filtrate were determined against a standard curve measured 
at 550nm on a Sunrise 96 well plate reader with accompanying Magellan 3 software 
(Tecan  Sunrise,  Salzburg  Austria).  Linear  regression  of the  mean  values  of the 
absorbance at 540 nm for each standard set minus the blank values was utilized to 
determine the nitrite or total NOx concentrations in samples. These values were then 
subtracted to give the nitrate concentration. Each sample was analysed in duplicate.
2.4.3.2  Measurement of  nitrite in plasma
A  method  for  sensitive  and  specific  measurement  of nitrite  in  plasma  using  a 
chemiluminescence  assay  (80)  was  used.  I3',  synthesised  by  the  addition  of 
potassium iodide  and  iodide  to  acetic  acid  and water,  will  reduce  nitrite  (but not 
nitrate) to NO gas. The released NO gas is carried from the solution in a stream of
44nitrogen gas into the chemiluminescent NO analyser which can detect from 0.3 to 1  
pM NO gas. The instrumental setup is illustrated in Figure 2.2.
All chemicals were obtained from Sigma-Aldrich (Poole, Dorset, UK) and were of 
the highest laboratory grade. A stock solution of 180 ml of I3' reagent was prepared 
from 2g potassium iodide and  1.3g of iodine dissolved in 40 ml ddF^O.  140 ml of 
acetic acid was then added and mixed thoroughly for 30 minutes. Nitrogen gas was 
bubbled through the 9ml I3' reagent in a glass purge vessel. The vessel is linked to a 
trap  containing  15  ml  of  1   M  sodium  hydroxide  and  is  then  connected  to  the 
chemiluminescent NO  analyser (Sievers,  Model  280,  Boulder,  Colorado,  USA)  as 
shown in Figure 2.2. The system was then allowed to reach a steady baseline.
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Figure 2.2 A schematic diagram of the chemiluminescence instrumental setup
100  p/L  of plasma  was  diluted  1   in  4  with  phosphate  buffered  saline.  This  was 
placed in a Whatman  12 kD molecular weight cut off filter (Vectaspin,  Whatman, 
Maidstone  UK)  and  spun  at  13,000  rpm  for  30  minutes  at  4  °C  to  centrifugally 
remove proteins as described by Giovanni et al.(79) 10 pL of the filtered plasma was
45then injected via a syringe into the purge vessel. The NO released then passes into 
the NO analyser to produce a mV peak which was then measured and recorded. The 
mV peaks were allowed to return to baseline prior to subsequent injections.
2.4.33 Tissue eNOS activity determination
The method used was a variation on the widely reported 3H-arginine to 3H-citrulline 
assay,(81, 82) modified for use with liver tissue. Briefly, snap frozen liver tissue was 
homogenised in ice-cold HEPES buffer (20mM, pH 7.4) containing EDTA (ImM); 
sucrose  (250mM);  valine  (60mM);  protease  inhibitor cocktail  (at  lml/20g  tissue); 
and  PMSF  (3.4mg/ml).  This  was  centrifuged  (lOOOg,  lOmin,  4°C)  and  the 
supernatant retained and measured for protein content using the Biurret method.(83) 
For NOS  activity determination,  5pi  of supernatant was  incubated with 40pl  of a 
reaction  medium  [Tris-HCL  buffer  (30mM,  pH  7.4);  NADPH  (1.25mM);  3H- 
arginine (lOpCi/ml, Amersham, UK); norvaline (5mM); and either CaCl2 (400pM) 
or EGTA (600pM)]  at 30°C  for 30 minutes,  and the reaction stopped with  1ml  of 
ice-cold citrate buffer (50mM pH5) containing EDTA (ImM). The arginine:citrulline 
ratio  was  determined  by  separating  the  amino  acid  components  using  thin  layer 
chromatography on silica plates (Kieselgel 60, Merck, Darmstadt, Germany). Non- 
tritiated amino acids were added to aid spot detection, and the components separated 
using a running mixture of CHCl3:Me0 H:NH40H:H20 (ratio of 10:45:20:10).  The 
individual spots were removed and the scintillation activity measured (Ultima Gold 
scintillant, Perkin Elmer, Boston, MA), using a Tri-Carb 2100TR, liquid scintillation 
analyser  (Packard  Biosciences,  Berks,  UK.).  Activity  was  expressed  as  pmoles 
citrulline  made/ mg protein/ hr.  All  chemicals  and reagents  were  supplied by the 
Sigma Chemical Company (Poole, UK) unless otherwise stated.
46As previous studies on hepatic tissue from decompensated alcoholic cirrhotic liver 
patients  had  suggested  that  eNOS  is  the  only  significant  calcium  dependent, 
constitutive, isoform of NOS expressed in these patients’ livers,(84) the difference in 
the measured NOS activities between the calcium present / calcium chelated (EGTA 
present) assays described above, was interpreted as representing eNOS activity.
2.4.4 eNOS protein expression
Immunohistochemistry was carried out using standard antigen-retrieval techniques.- 
Immunohistochemical  staining  was  performed  on  4pm  thick  formaldehyde-fixed/ 
paraffin-embedded,  mounted  hepatic  tissue  sections,  counter-stained  with 
haematoxylin.  After  10  minutes  heating  at  70°C,  slides  were  de-parafinized  with 
xylene, then re-hydrated with decreasing grades of ethanol and finally with water. 
Optimum antigen retrieval was achieved by microwaving slides in citrate buffer for 
20  minutes.  Specific  mouse  anti-human  monoclonal  antibodies  for  eNOS 
(Transduction  Laboratories/Pharmingen,  San  Jose,  CA)  were  applied  and  normal 
mouse serum used as a negative control.
2.4.5 ADMA measurement
Plasma ADMA was measured at The Wellchild Laboratory,  Guys Hospital,  Kings 
College  London  by  Dr  RN  Dalton,  using  fragmentation  specific  stable  isotope 
dilution  electrospray  mass  spectrometry-mass  spectrometry.  Samples  (50pl)  were 
deproteinized  with  acetonitrile  containing  2H6-ADMA,  chromatographed 
(acetonitrile:water,  1:1,  with 0.025%  formic  acid)  on  a Teicoplanin guard column 
10mm x 2.1mm ID (Chirobiotic T, ASTEC Ltd, Congleton, UK), and analysed using 
a SCIEX API4000 (Applied Biosystems, Warrington, UK) in positive ion multiple
47reaction monitoring mode.  The acquisition time was 2.5min with an inject-to-inject 
time of <3min.  Intra-assay imprecision for ADMA was 2.1% at a concentration of 
0.37  pmol/1.  Inter-assay  imprecision  for  ADMA  was  7.4%,  5.8%,  and  5.1%  at 
concentrations of 0.39, 1.15, and 3.96 pmol/1, respectively.
Tissue homogenates were prepared as for the NOS activity assay described in section 
2.4.3.3.  The  supernatants  from these  preparations  were  extracted  and  assayed  for 
ADMA  using  the  same  methodology  as  for plasma  samples,  outlined  above,  but 
using lOjj.1 of each homogenate sample.
2.4.6  DDAH and PRMT Western blot analysis
Human  liver  biopsy  specimens  were  assessed  for  quantification  of DDAH  and 
PRMT.  Homogenized frozen liver tissue was re-suspended in lOOpL of lysis buffer 
(PBS, pH 6.6, containing 0.1% SDS, 0.5% sodium deoxycholate and  1% Nonidet). 
After protein  concentration  determination,  30ug  of protein was  separated by  SDS 
polyacrylamide gel (12%) and transferred to a nitrocellulose membrane, which was 
blocked with  5%  non-fat dry milk  in  PBS  containing  0.1%  Tween  for one  hour. 
Samples  were  incubated  overnight  at  4°C  with  the  primary  antibody  (mouse 
monoclonal  DDAH  II  or  rabbit  polyclonal  PRMT-1  antibody,  1:1000),  before 
washing  and  further  incubation  with  anti-mouse  or  anti-rabbit  horseradish 
peroxidase-conjugated secondary antibody (DDAH II and PRMT-1, respectively) at 
a  dilution  of  1:3000.  The  membranes  were  developed  with  enhanced 
chemiluminescence substrate plus (ECL plus, Amersham, UK).  Blots were imaged 
and quantified using Genesnap/Gene tools  (Syngene,  SLS, UK).  Membranes were 
then stripped at 55°C and re-probed using an a-tubulin mouse monoclonal primary 
antibody  followed  by  secondary  anti-mouse  horseradish  peroxidase-conjugated
48secondary antibody and developed as above, in order to quantify the expression of 
DDAH and PRMT by correcting it for the a-tubulin content.
2.4.7  NOSTRIN study methods
2.4.7.1  Quantitative real-time PCR
mRNA estimation of  NOSTRIN, NOSIP, Caveolin 1 and eNOS:  This work was done 
in collaboration with Prof Werner Muller-Esterl’s group in The Institute Biochemie 
II laboratories, Goethe University, Frankfurt.
mRNA  and protein was  isolated from liver tissue using the  TRI-Reagent (Sigma, 
Taufkirchen, Germany) following the manufacturer’s instructions. From the mRNA, 
cDNA was synthesised using the iScript™ cDNA Synthesis Kit (Bio-Rad Hercules, 
CA,  USA)  according  to  manufacturer’s  recommendations.  Quantitative  real-time 
reverse transcriptase polymerase chain reaction (qRT-PCR) assays were developed 
using the TaqMan technology on an iCycler detection system (Bio-Rad). Assay mix 
of primers  and  TaqMan  MGB  probes  (FAM™  dye-labelled)  for  eNOS,  caveolin, 
NOSTRINp and control ubiquitin C (UbC) spanning exon-exon junctions to exclude 
detection of genomic DNA were from Applied Biosystems (Foster City, CA, USA). 
To detect NOSTRINa,  an “assay-on-design” (Applied Biosystems) with the probe 
spanning the junction of exon-2 to exon-3 of the NOSTRIN sequence was used. The 
whole cDNA of each liver sample was split up into six equal aliquots and analysed 
for target genes and endogenous control. Duplicate cycle threshold (Ct) values were 
normalised against the internal control UbC and analysed using the ACj method. The 
relative  expression  levels  of NOSTRINa  and NOSTRINp  RNAs  were  calculated 
from the normalised mean Cj values.
492.4.7.2 NOSTRIN Immunohistochemistry
Paraffin-embedded sections were pre-treated with xylene and then micro-waved in 
citrate  buffer  for  20  minutes,  to  optimize  antigen  retrieval.  Specific  murine 
monoclonal  antibodies  to  human  eNOS,  caveolin-1  (Transduction  Laboratories, 
Lexington,  USA)  and  human  NOSTRIN  (raised  against  GST-NOSTRIN242-506  by 
Nanotools,  Teningen,  Germany)  were  applied.  As  a  control,  the  antibodies  were 
blocked with GST-NOSTRIN prior to the staining.
2.4.7.3 Western blots
Protein fractions of whole liver samples were isolated with TRI-Reagent according 
to  the  manufacturer’s  instructions.  These  fractions  as  well  as  whole  cells  were 
dissolved in Laemmli buffer (63 mM Tris*HCl, pH 6.8, 2.5% SDS, 5% glycerol, 5% 
p-mercaptoethanol,  0.005%  bromophenol  blue),  subjected  to  SDS-PAGE  and 
transferred to PVDF membranes, which were then probed with mouse monoclonal 
anti  human  Lamp-1  (Transduction  Laboratories,  Lexington,  USA)  and  human 
NOSTRIN.
2.5  Statistical Analysis
Data are represented  as  median  and range  or mean ±  standard  error of the mean 
(SEM).  Unpaired t-tests  have  been used to  define  differences  between means  of 
normally distributed,  equal variance  data,  using a commercially available package 
(Graph Pad Prism, version 3.0; Graph Pad Software, Inc., SanDiego, CA, USA). For 
statistical evaluation of data that was not normally distributed,  an appropriate non- 
parametric test such as a Mann Whitney test, has been used. Results were considered 
significant if p<0.05.
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The role of inflammation in alcoholic cirrhosis
513.1 The effects of inflammation on structure and function
The  initial  elements  of study  were  to  determine  the  fundamental  differences  that 
inflammation  imparts  onto  patients  with  pre-existing  alcoholic  liver  disease  and 
animal models of liver injury, with reference to liver structure, systemic measurable 
indicators  of  biochemical  function  and  inflammatory  parameters.  Markers  of 
oxidative stress were also studied and an assessment of function made with reference 
to disease presentation and outcome.
3.1.1 Structural changes in cirrhosis with inflammation
3.1.1.1 Histological presentation with human alcoholic liver disease
As can be seen within the haematoxylin and eosin preparations at low magnification 
during  light microscopy,  shown  in  Figure  3.1,  in  normal  liver there  are plates  of 
hepatocytes  radiating  out  from  a  central  vein  forming  the  basic  unit  of a  hepatic 
lobule (Figure 3.1  a). With the development of alcoholic liver disease, there is often 
an increasing deposition of fat initially within the cytoplasm of hepatocytes as seen 
in Figure 3.1b. Further progression in about  15% patients leads to the development 
of cirrhosis as denoted by fibrous bands and loss of the normal architectural pattern 
as seen in Figure 3.1c. This pattern of injury can be readily distinguished from the 
effects  of a  superimposed  alcoholic  hepatitis  where  the  additional  inflammatory 
insult  leads  to  the  deposition  of Mallory’s  hyaline  (a  collection  of cytoplasmic 
microfilament  inclusions)  within  swollen  “ballooned”  degenerating  hepatocytes 
(Figure 3. Id). Other characteristic features of alcoholic hepatitis include the ingress 
of  polymorphonuclear  cells,  necrosis  of  hepatocytes  predominantly  around  the 
central vein and perivenular and pericellular fibrosis. A number of these features are 
shown in Figure 3.1e.
52Figure 3.1a: Normal liver
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53Figure 3.1 Histological examples of normal human liver and alcoholic liver disease 
patients  of varying  severity:  a)  normal  liver  architecture;  b)  liver  section  from  a 
patient with early alcoholic liver disease with evidence of fatty infiltration, no peri­
cellular fibrosis and relatively normal hepatocytes; c) an example of a section from a 
cirrhotic liver biopsy with clear distortion of the architecture by fibrous bands;  d) 
high magnification of ‘Mallory’s hyaline’ in a biopsy from a patient with alcoholic 
hepatitis  demonstrating  this  phenomenon  consisting  of collection  of cytoplasmic 
inclusion;  e)  biopsy  from  a  patient  with  acute  alcoholic  hepatitis  with  the  key 
features of balloon degeneration of hepatocytes, peri-cellular fibrosis and an acute 
inflammatory infiltrate of polymorphonuclear cells.
3.1.1.2  Histological presentation in the bile duct ligated rat
As seen in patients with alcoholic cirrhosis, BDL rats undergo significant loss of the 
normal cellular architecture (Figure 3.2a) seen in sham animals,  with increasing fat 
deposition and loss of defined portal tracts, as seen in Figure 3.2b.  This distortion 
and loss  of liver architecture  is  further pronounced by the  addition  of LPS,  as  an 
inflammatory stimulus to BDL animals, with greater parenchymal loss. Figure 3.2c.
543.2a: Sham Rat  3.2b: BDL Rat
3.2c: BDL+LPS Rat
Figure  3.2  a-c:  Histological  specimens  from  rat  liver  showing:  a)  normal 
architecture  of liver  sinusoids  and normal  hepatocytes;  b)  following bile  duct 
ligation with considerable loss of architecture, deposition of fat and with varying 
morphology of parenchymal cells; c) the effects of BDL with superadded LPS 
resulting in even greater architectural disruption.
553.1.2  Serological changes
3.1.2.1: Routine laboratory measures in Alcoholic liver disease patients 
For this study, patients were included if they had evidence of acute decompensation 
of alcoholic liver disease (increasing ascites, pedal oedema or progressive jaundice), 
clinical and radiological evidence of cirrhosis, and a current history of alcohol abuse. 
Patients  were  excluded  if  they  were  <18  or  >75  years  and  had  evidence  of: 
additional/another  aetiology  of liver  disease;  severe  cardiac  dysfunction  or  renal 
failure  (creatinine  >150pmol/L);  hepatic/extra-hepatic  malignancy;  hepatic 
encephalopathy  >Grade  2  (precluding  informed  consent),  and  if  there  was 
microbiological evidence (serial cultures of blood, urine, stool and sputum dependent 
on clinical indication) of infection after 72 hours of broad-spectrum antimicrobials, 
or abnormal chest radiography. Alcoholic hepatitis was defined histologically taking 
into account steatosis, neutrophil infiltration, ballooning of hepatocytes, peri-cellular 
fibrosis and the formation of Mallory’s hyaline.
A  total  of 52  alcoholic  liver  disease  patients  were  studied  sequentially,  27  with 
alcoholic hepatitis (denoted as AH+C+) and 25 with alcoholic cirrhosis without any 
histological  features  of  alcoholic  hepatitis  (denoted  AH-C+).  The  definition  of 
alcoholic hepatitis utilised a grading  system which  in addition to  identification of 
Mallory’s hyaline assessed the degree of hepatocyte ballooning and the numbers of 
acute  inflammatory  cells  according  to:-  Grade  0-1:  ballooned  hepatocytes 
comprising  <5%  of parenchyma and no neutrophils,  ranging up  to  grade  5  where 
ballooned  hepatocytes  comprised  >50%  of  parenchyma  and  there  were  many 
inflammatory  cells.  Applying  this  system,  patients  with  grade  2  and  above  were 
deemed to have histological AH+C+ superimposed on their cirrhosis.  Indeed most 
patients were grade 3-5.
56The white blood cell count (WBC) was significantly elevated in AH+C+ patients as 
compared to patients with cirrhosis alone:  13.7 ±1.5 versus 6.4 ± 0.5, p<0.00001. 
Similarly, the C reactive protein (CRP) was significantly greater in AH±C+ patients 
being 50 ± 7.7 mg/L versus  16.6 ±3.2 mg/L in AH-C± patients. Measures of liver 
function  demonstrated  significantly  elevated  plasma  bilirubin  levels  in  AH±C± 
patients compared with AH-C± patients: 249 ± 38.5 pmol/L vs. 56.4 ± 13.1pmol/L, 
p<0.001.  The  serum  aminotransferases  did  not  differ  significantly  between  the 
patient groups; serum ALT 60 ± 15 U/L in AH±C± patients, vs. 47 ± 9 U/L AH-C± 
patients,  p=0.46.  Similarly,  plasma  albumin  was  not  statistically  significantly 
different  between  the  groups  albeit  AH±C±  patients  did  have  lower  mean  levels 
(28.4 ± 1.7 vs. 31.7 ± 1.1 g/L; p= 0.14).  The prothrombin time, however, as a further 
marker of liver synthetic function was significantly higher in AH±C± compared with 
AH-C±  patients  (18  ±  1   vs.  13.4  ±  0.6  seconds,  p<0.001).  In  addition  to  these 
findings  pertaining  to  the  liver,  the  mean plasma  creatinine  as  a  marker  of renal 
function, was also significantly elevated in AH±C± patients compared to those with 
AH-C± (92.5  ±  11  vs.  59.8  ±  5  pmol/L, p= 0.01),  albeit this remained within the 
normal hospital reference range of 66-112 prnol/L. It is important to note, however, 
a mass spectrometry method was used to measure creatinine, whilst normal hospital 
laboratory  measures  are  via  a  modified  Jaffe  assay,  which  is  open  to 
misinterpretation in the context of hyper-bilirubinaemia. (85)
3.1.2.2: Routine laboratory measures in BDL and Sham rats
Four groups  of animals  were  studied namely  Sham operated  (Sham),  Sham±LPS, 
BDL  and BDL±LPS.  Bilirubin,  creatinine,  albumin  and plasma  aminotransferases 
were measured using standard kits on a Cobas Integra analyser (Roche Diagnostics
57Ltd, West Sussex, UK). The serum aminotransferases were not significantly different 
between Sham animals with and without LPS, or the BDL animals. However, BDL 
animals also given LPS did have a higher plasma ALT compared with BDL alone 
animals  (168 ± 54 vs.  98 ±  15  U/L, p<0.05;  Figure 3.3).  Furthermore, the plasma 
bilirubin was significantly elevated to the same degree in both BDL and BDL+ LPS 
animals  (180 ±  18  pmol/L)  compared  to  Sham  and  Sham +LPS  animals, p<0.01. 
However  no  differences  were  noted  between  any  of the  4  groups  in  relation  to 
plasma creatinine, which remained within the normal range.
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Figure 3.3 shows the marked increase in plasma ALT (* p<0.05) in BDL animals 
treated with LPS, which is not seen following LPS injection in sham animals without 
liver disease.
3.1.3  Plasma Cytokines in patients with alcoholic liver disease
Amongst the alcoholic patients studied, as anticipated from the increased white cell
count and CRP, AH+C+ patients also had significantly elevated plasma cytokines.
58The plasma TNFa was markedly higher in AH+C+ patients than was observed in 
AH-C+ patients (46 ± 20 versus 4 ± 0.5 pg/ml, p<0.01). Similarly, IL-6 levels were 
much  higher in AH+C+ patients  (55.7 ±19 versus 9.3  ± 2, p< 0.01) as shown  in 
table 3.1, suggesting a potential to evoke further inflammatory signals and promote 
neutrophil  recruitment.  Plasma levels  of TNF R  1   and  TNF  R2  were  found to be 
almost double the plasma level of that found in AH-C+ patients (TNFR1:  885 ± 93 
vs. 455 ± 74 ng/ml, p<0.001; TNFR2:  1798 ± 128 vs. 759 ± 136 ng/ml, p<0.001), as 
shown in Figure 3.4. No consistent and significant differences were noted between 
AH+C+ patients and AH-C+ patients in relation to IL-8 and IL-10 plasma levels.
** P<0.001
Figure 3.4. Plasma concentrations of TNF receptor 1  (Rl) and TNF receptor 2 (R2) 
in patients with alcoholic cirrhosis with (AH+C+) and without additional alcoholic 
hepatitis (AH-C+).
593.1.4 Markers of  Systemic Inflammatory Response Syndrome (SIRS)
The  SIRS  score(86) has been defined to reflect the effects of inflammatory events 
resulting in injury to numerous organs. In these studies SIRS was graded according 
to the criteria:  temperature >38°C;  a heart rate > 90 beats/minute; tachypnoea >20 
breaths/minute; white blood cell count of >12 x 109/L or < 4 x 109/L or the presence 
of more than  10% immature neutrophils; with each component assigned  1   point. In 
AH+C+ patients, the SIRS score was significantly elevated with a mean of 1.6 + 0.4, 
compared with AH-C+ patients  in whom the mean was 0.3  ±0.1, p<0.0001.  The 
severity  of the  SIRS  components  was  in  keeping  with  the  high  levels  of serum 
cytokines  and  systemic  markers  of  inflammation  such  as  CRP,  and  had  less 
variability as compared with plasma cytokine levels.
3.1.5 Effects of inflammation on markers of oxidative stress 
Malondialdehyde (MDA), as a marker of lipid peroxidation, and Prostaglandin F2a 
were used to gauge the severity of oxidative stress in patients with cirrhosis and in 
those  with  the  additional  inflammatory  state  of alcoholic  hepatitis.  Patients  with 
AH+C+  had  higher  plasma  levels  of  MDA  generation  compared  with  AH-C+ 
patients (6.65 ± 0.83 vs. 4.48 ± 0.56 pMol/L; p=0.04). Despite statistical significance 
there  was  a  considerable  variability  in  the  MDA  levels  between  patients.  MDA 
values from healthy volunteers were noted to be 3.3 ± 0.21 pMol/L.
By contrast, there was a highly significant difference between elevated Prostaglandin 
F2a levels in patients with AH+C+ compared to cirrhosis alone (404 ± 38 vs. 220 ± 
17 pg/ml; p<0.001), although all liver disease subjects exceeded the ‘normal range’. 
Normal  range  for  Prostaglandin  F2a  using  this  assay  as  supplied  by  the 
manufacturers’ data sheet (Cayman Chemical, Ann Arbor, MI), was (40-100 pg/ml).
603,1.6  Functional effects of  inflammation super-imposed on cirrhosis:
3.1.6.1 Severity of  presentation of liver disease
AH+C+  patients  had  more  marked  expression  of their  liver  disease  at  clinical 
presentation compared to patients  with cirrhosis  alone,  as  evidenced by  increased 
incidence  of hepatic  encephalopathy and more resistant ascites  reflected in higher 
Child-Pugh scores(87) (11.5 ± 0.3 vs. 8.4 + 0.4; p<0.001), and higher MELD scores, 
(88) (15 ± 2.3 vs. 0.26 + 1.4; p<0.001). These patients also had a severe presentation 
of AH as defined by a discriminant function (89) of greater than 32, as reflected by 
the  higher  bilirubin  and  prothrombin  times,  with  the  mean  discriminant  function 
score  of 46±6.  Moreover,  AH+C+  patients  had  a  greater  propensity  to  develop 
culture positive infections during the in-patient episode (65% versus 28%, p=0.004).
3.1.6.2 Patient outcome
There were thirteen in-patient deaths in the fifty-two studied patients, twelve with 
AH+C+ and one with only cirrhosis. Of the AH+C+ deaths, eight developed renal 
failure, four of whom who also had concomitant sepsis. Patients who developed 
culture  positive  infections  were  also  more  likely  to  develop  organ  failure 
(p=0.001) and had a higher incidence of mortality (p=0.002). However, there was 
no  direct  association  between  development  of  organ  failure  and  subsequent 
mortality and SIRS score or plasma level of pro-inflammatory cytokines.
In  the  cirrhotic  only  group,  one  in-patient  died  from  renal  failure  despite 
supportive therapy, whilst the remaining 24 patients were successfully discharged 
from hospital.
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Neutrophil dysfunction and contribution to the effects 
of inflammation in cirrhosis
624.1 Introduction
In patients with severe alcoholic hepatitis, infection complicates the course of illness 
and is associated with significant morbidity and mortality.  (90-92) Neutrophils are 
an  essential  component  of the  innate  immune  response  and  key  players  in  the 
pathogenesis  of alcoholic  hepatitis.  (93)  Data  on  neutrophil  function  in  alcoholic 
hepatitis  is  paradoxical  with  some  studies  suggesting  neutrophil  “priming”, 
indicating a readiness  to respond to bacterial  challenge  as  measured by hydrogen 
peroxide  overproduction,  decreased  L-selectin  expression  (94)  and  high  levels  of 
neutrophil  elastase  (95).  In  contrast,  other  studies  show  decreased  neutrophil 
phagocytic capacity correlating with disease severity. (96) Endotoxin is known to be 
elevated in patients with alcoholic hepatitis (97) and has the capability to both prime 
(98, 99) and also activate neutrophils. (100, 101)
Clarification  of  this  controversy  has  important  clinical  implications.-  Current 
strategies  to treat alcoholic hepatitis  include  administration  of immunosuppressive 
agents  such  as  corticosteroids  and  more  recently,  anti-TNF  strategies  are  being 
evaluated, that may further potentiate susceptibility to infection.  Results of studies 
using these drugs in alcoholic hepatitis patients are conflicting, (102,  103) and whilst 
there is some data showing benefit with anti-TNF strategies,(104,  105) one trial has 
shown increased risk of infection and mortality resulting in early trial termination. 
(106)
In  order  to  reconcile  the  apparent  paradox,  this  study  was  conducted  to  assess 
whether neutrophils exist in either a ‘primed’ or a fully ‘activated state in different 
alcoholic cirrhosis patients. The study determined the effect that activation status had 
on  susceptibility  to  infection  and  clinical  outcome,  using  the  hypothesis  that  full
63activation  would  impair  neutrophil  responses  to  on-going  bacterial  challenge, 
rendering patients more susceptible to infection.
4.2 Patient selection
Patients admitted with alcoholic cirrhosis were enrolled into the study at the time of 
portal pressure  assessment and liver biopsy, performed to  evaluate the  severity of 
disease and presence or absence of alcoholic hepatitis.  Included patients had been 
admitted with  acute  decompensation  of alcoholic  cirrhosis  manifest by  increasing 
jaundice, with no clinical or microbiological evidence (chest X-ray, routine cultures 
of  urine,  blood,  sputum  and  ascites)  of  infection.  Prophylactic  antibiotics 
(cefotaxime) were prescribed following initial  cultures  if there was  a suspicion of 
infection,  and  stopped  if  subsequent  cultures  proved  negative.  Patients  were 
excluded if they were <18 or >75 years, and had evidence of: organ failure (inotrope 
requirement, creatinine >150pmol/L, hepatic encephalopathy >grade 2, requirement 
for  mechanical  ventilation),  hyponatraemia,  hepatic/extra-hepatic  malignancy,  <3 
days  post  gastrointestinal  bleeding  or  if  they  received  any  immunomodulatory 
therapy  prior to  entry  in  the  study.  Blood  from  20  age  and  sex  matched  healthy 
volunteers  with  no  history  of liver  disease  was  studied  to  serve  as  controls  for 
comparison of neutrophil function. Patients were classified histologically into those 
with cirrhosis and superimposed inflammatory alcoholic hepatitis (cirrhosis+AH), as 
described in Chapter 3, section 3.1.2.1.
4.3 Study design
Following  correction  of any  electrolyte  disturbances  or  hypovolaemia,  peripheral 
venous  blood  was  aseptically  collected  into  pyrogen-free  tubes  (BD  Vacutainer 
Lithium-Heparin,  60U  per  tube,  BD,  Plymouth,  UK)  and  used  for  routine
64biochemistry and neutrophil function.  For experiments with cells, blood was kept at 
room  temperature  (maximum  1   hour);  for  harvesting  plasma,  blood  was  placed 
immediately  on  ice.  After  centrifugation  at  4°C,  plasma  was  aliquoted  under 
pyrogen-free conditions into non-pyrogenic cryotubes (Coming Inc., Coming, USA) 
and stored at -80°C until further analysis. Whole blood or isolated neutrophils mixed 
with plasma were used to perform the Phagoburst® or the Phagotest® as described in 
the  methods  in  chapter  2,  section  2.2.2  and  2.2.3.  For  all  experiments  strict 
precautions were taken to avoid endotoxin contamination by working aseptically and 
using  endotoxin-free  equipment.  In  addition  to  routine  laboratory  data  collection, 
discriminant function (89) and MELD (Model of End Stage Liver Disease) (88) and 
Pugh  score  (87) were calculated.  The patients were followed prospectively over a 
period of 90 days. The occurrence of organ dysfunction and mortality were recorded
4.4  Results
4.4.1  Oxidative burst and phagocytosis in patients with alcoholic cirrhosis 
A  total  of 63  patients  with  alcoholic  cirrhosis  (41  of whom have  been  described 
above in chapter 3,  section 3.1.2.1) were  screened for neutrophil activation status, 
and the patients were subsequently classified according to histological criteria into 
those with features of alcoholic hepatitis (graded through a modified NASH scoring 
system)  (107) and those with cirrhosis alone.  Twenty-three patients were found to 
have  alcoholic  hepatitis  and  as  previously  noted,  they  had  features  of  a  pro- 
inflammatory state with elevated CRP, white blood cell count and pro-inflammatory 
cytokines.
The  effects  on  neutrophil  function  were  determined  by  the  capacity  to  under  go 
phagocytosis and from the quantification of neutrophil oxidative burst. In circulating
65un-stimulated  patient  neutrophils,  oxidative  burst  was  increased  significantly 
compared with healthy controls. Neutrophils from all studied patients had a 5.6 times 
higher resting oxidative burst (p<0.001) compared to healthy controls (mean control 
oxidative  burst  8.9%±2.7).  Neutrophils  from patients  with  alcoholic  hepatitis  had 
significantly higher resting oxidative burst compared to patients with cirrhosis alone 
(72 ± 7 vs. 37 ± 5, p<0.001) or controls (p<0.001), as shown in Figure.4.1. 
Stimulation  with  N-formylmethionyl-leucyl-phenylalanine  (fMLP),  a  synthetic 
peptide that triggers minimal oxidative burst in unstimulated neutrophils, continued 
to  show  a  significantly  greater  oxidative  burst  in  alcoholic  hepatitis  patients 
compared with cirrhosis (75 ± 8 vs. 61  ± 7, p=0.01) and also compared to controls 
(75  ±  8  vs.  19  ±  3.5,  p=0.001),  suggesting  prior  priming  of  these  patients’ 
neutrophils.  However,  following  stimulation with E.  coli,  the  absolute  increase  in 
oxidative burst from resting levels (bacterial  stimulated burst minus resting burst) 
was  significantly  reduced  in  alcoholic  hepatitis  patients  compared  with  cirrhosis 
alone (26 ± 7 vs.  60 ± 5, p<0.0001) or controls (control increase in burst:  81  ± 4, 
p<0.001),  as  shown  in the  dark grey bars  in  Figure  4.1.  Phagocytic  capacity was 
measured by the geometric mean of fluorescence intensity (GMFI), which indicates 
the  number  of  bacteria  engulfed  by  one  cell.  Neutrophils  from  patients  with 
cirrhosis+AH  engulfed  significantly  less  bacteria than those  from control  subjects 
(59 ± 13 vs. 99 ± 6, p<0.05, as depicted in Figure 4.1).
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Figure 4.1  The bars represent the percentage of cells undergoing resting oxidative 
burst in untreated neutrophils (white) and after stimulation with fMLP (light grey) or 
challenge with E.coli (dark grey) in samples from control subjects (n=13), patients 
with  alcoholic  cirrhosis  (n=40)  and  alcoholic  hepatitis  superadded  on  cirrhosis 
(cirrhosis+AH) (n=23). The last column bar (black) depicts the phagocytic capacity 
(relative GMFI) in the study groups.
4.4.2  Association  of resting oxidative burst and phagocytosis  with  organ failure 
and survival
Seventeen patients (26%) developed organ failure, whilst  14 (22%) died within 90 
days (30-day mortality  13%) of admission. Renal failure occurred in  15  (8 8%) and 
was associated with ventilation and circulatory failure in 4.  Resting oxidative burst 
was found to be predictive of 90-day mortality (AUROC 0.77, p<0.005,) and organ 
failure (AUROC 0.76, p<0.001), as illustrated in Figure 4.2 A. A cut-off of resting 
burst  >55%  from  the  ROC  curve  (almost  entirely  consisting  of  patients  with 
alcoholic hepatitis) had a sensitivity of 77% and a specificity of 69% for predicting 
death. Phagocytic function was also predictive of death (AUROC 0.80, p<0.05) and
67organ  failure  (AUROC  0.91,  p<0.0001),  as  shown  in Figure  4.3  B.  A phagocytic 
capacity <42% of normal amongst studied patients had a sensitivity of 86% and a 
specificity of 70% to predict mortality.
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Figure  4.2  (A)  Area  under  the  receiver  operator  curve  (AUROC)  shows  the 
predictive utility of measurement of oxidative burst in determining survival. (B): A 
resting burst  of greater  than  55% had the  most  optimal  values  of sensitivity  and 
specificity  derived  as  the  best  average  from  the  AUROC  analysis  to  group  the 
patients, and was used to construct a Kaplan-Meier survival curve; log-rank analysis 
showed a significantly higher mortality (p<0.01) in the group of patients with high 
burst (>55%)
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Figure  4.3  (A)  AUROC  analysis  also  revealed  that  the  phagocytic  capacity  was 
predictive in determining survival. (B) A phagocytic capacity of less than 42%, had 
the optimal sensitivity and specificity on AUROC analysis and was used to construct 
a  Kaplan  Meier  survival  curve;  log-rank  analysis  showed  a  significantly  higher 
mortality  (p<0.001)  in  the  group  of patients  with  decreased  phagocytic  capacity 
(<42%).
4.4.3  Association of resting oxidative burst and phagocytosis with development of 
infection
Although none of the included patients had proven infection at the time of assay for 
neutrophil function, in 38 (60%) patients, infection was clinically suspected during 
the  course  of the hospital  admission.  In  19  of 38  patients  (50%),  culture positive 
infection  was  verified  within  30  days  of  admission,  although  our  hospital 
management protocol necessitated the use of broad spectrum antibiotics as soon as
69an  infection  was  suspected.  In  8,  more  than  one  organism  was  found.  The 
documented culture positive infections are summarized in Table 4.1 
As  shown  in  the  table,  the  following  species  were  cultured:  Enterococcus  (n=9), 
coagulase-negative  Staphylococcus  (n~8),  Candida  sp.  (n=3),  E.  coli  (n=2), 
methicillin-  resistant  Staphylococcus  aureus  (n=2),  Staphylococcus  aureus  (n=2), 
Propionibacterium sp. (n=l). It is evident from the table that after stratifying patients 
by resting burst, those with a high resting burst (>55%), which tended to be patients 
with alcoholic hepatitis, developed more culture positive infections when compared 
with  low resting burst patients  (48% versus  15%,  p<0.005).  Moreover,  only  high 
burst patients developed infections with more than one organism and also developed 
these infections earlier during their hospital stay as compared to low burst patients (7 
versus  16 days, p=0.005). Additionally, 53% of patients with a phagocytic capacity 
<42% developed culture positive infection as compared to  13% of patients with a 
phagocytic capacity >42% (p<0.05). Those patients who developed culture positive 
infections were more likely to develop organ failure (p=0.001), and to die (p<0.0001, 
Figure 4.4).
70Table 4.1 Documented culture positive infections in patients studied during 30 days
High Burst Low Burst
First Positive Culture Second Positive Culture First Positive Culture
Patient
Number Day Organism Day Organism Patient
Number Day Organism
1 4 EC 29 MRSA 2 16 EC
4 14 EC 19 CNS 14 23 E. coli
5 9 CNS 34 EC 17 9 MRSA
7 4 EC 10 CNS 23 15 Staph, aureus
12 2 C. albicans 33 15 Propionibacterium
13 10 Staph, aureus
15 8 CNS
20 5 EC 5 CNS
35 6 EC
36 4 CNS 4 EC
45 2 CNS 3 CNS
48 20 E. coli
61 6 C. albicans
62 7 C. albicans  . 9 EC
EC: Enterococcus
MRSA: methicillin-resistant Staphylococcus aureus 
CNS: coagulase-negative Staphylococcus 
Staph: Staphylococcus 
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Figure 4.4.  (A) Analysis for time to  infection (Kaplan-Meier and log-rank) shows 
patients with high resting burst (>55%) have a significantly higher risk (p<0.005) to 
developing culture positive infections within 30 days.  (B) Using Kaplan-Meier and 
log-rank  analysis  to  determine  differences  in  survival  between  patients  with  and 
without culture positive infections, those with infections have a significantly higher 
90-day mortality (p<0.001).
4.4.4  Effect ofpatients* plasma and normal plasma on neutrophil oxidative burst
Plasma from patients with a high resting burst (>55%; n=6) induced a high resting 
burst in normal neutrophils (p=0.005) whereas plasma of patients with a low resting 
burst (<55%; n=6) failed to do so, as shown in Figure 4.5 A. This result suggested 
presence  of  a  transmissible  factor  in  patient’s  plasma  promoting  neutrophil 
activation.  When isolated neutrophils from patients with known high resting burst 
were  incubated  with  normal  plasma,  the  resting  burst  decreased  significantly  as 
compared to isolated neutrophils incubated with the patients’  own plasma (p=0.02) 
as shown in Figure 4.5 B.
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Figure 4.5 (A) Resting oxidative burst in whole blood (WB) of controls, in whole 
blood of patients, and in normal neutrophils (NN) incubated with patients’  plasma 
(PP). Plasma from patients with high resting burst (H) induced a high burst in normal 
neutrophils, whereas plasma from patients with low resting burst (L) failed to do so, 
(B)  Elevated  resting  oxidative  burst  in  patients’  neutrophils  (PN)  incubated  with 
their  own  plasma  is  reversed  after  incubation  with  normal  plasma  (NP),  C) 
Incubation of normal neutrophils with plasma from patients with low resting burst 
does  not  change  phagocytosis,  whereas  plasma  from  patients  with  high  burst 
decreases  phagocytosis.  Incubation  of patients’  neutrophils  with  normal  plasma 
restores phagocytic function.
4.4.5  Effect ofpatients* plasma and normal plasma on phagocytosis 
Neutrophils from healthy controls incubated with plasma from patients with a low 
neutrophil resting burst did not differ from control, whereas neutrophils from healthy 
controls incubated with plasma from patients with high resting burst showed a 2 2%
PN+'PP  PN+NP
73decrease in phagocytic capacity (p<0.05, n=6). By comparison, incubating patients’ 
neutrophils  for  60  minutes  with  plasma  from  healthy  controls  showed  a  22% 
increase (p<0.05, n=6) in phagocytosis as compared to patients neutrophils incubated 
with their own plasma (Figure 4.5 C).
4.5  Discussion
4.5.1  The  role of inflammation  in  cirrhosis  and the  contribution  by  neutrophil 
responses
From the data presented in Chapter 3, it is clear that the presence of inflammation in 
human alcoholic cirrhosis in the form of alcoholic hepatitis is distinct histologically, 
with  the  presence  of balloon  degeneration  of parenchymal  cells  and  peri-cellular 
fibrosis in keeping with the marked derangement in biochemical function (increasing 
bilirubin and prothrombin time)  evident in these patients.  Furthermore,  increasing 
plasma creatinine, despite the highly catabolic state of these patients, would suggest 
an increasing propensity to  the development of renal  failure  compared to patients 
with  cirrhosis  alone,  suggesting  that  the  inflammatory  activity  in  the  liver,  may 
impact on function of other organs. The inflammatory process was also noted to be 
evident in systemic parameters, with elevation of the pro-inflammatory cytokines, in 
addition  to  SIRS  components  and  CRP.  Of  interest,  soluble  TNF  receptors  are 
known to be  up-regulated in  severe  alcoholic hepatitis  and their levels  associated 
with an increased risk of mortality, (108,  109) suggesting that signalling through the 
TNFa pathway may be important in the evolution of the disease. By contrast, plasma 
TNFa levels in patients with alcoholic hepatitis are widely variable in the literature, 
ranging from values as low as 5pg/ml to as high as 400 pg/ml (13,  94,  110,  111), 
suggesting that other factors such as concomitant infection, degree of endotoxaemia, 
genetic factors and soluble receptor expression may be important in determining the
74measured levels of TNF. Of interest, in the studies described in this thesis, there was 
also considerable variation in plasma TNFa levels with numerous patients having 
values beneath the detection threshold.
In addition to elevation of these inflammatory parameters, there was also evidence 
for a marked increase in indicators of oxidative stress. The metabolism of ethanol per 
se increases the generation of oxidant stress and has been implicated in the pathology 
of alcoholic  liver  disease,(112)  and  this  is  further  compounded  by  the  effects  of 
endotoxin.(113) Oxidative stress has also been linked with the pathophysiology of 
hepatic encephalopathy, through effects upon mitochondria, oxidation of membrane 
phospholipids  and various  enzymes  involved  in  energy  metabolism.  (114-117)  In 
this group of studied patients, those with alcoholic hepatitis had a higher incidence of 
hepatic encephalopathy compared to those with cirrhosis alone and this was reflected 
in their higher Child-Pugh  scores.  Moreover,  oxidative  stress  also  impacts  on the 
levels  of  numerous  vascular  modulators  including  asymmetric  dimethylarginine 
(118, 119) (as discussed later in this thesis in chapters 8 and 9), which may aggravate 
the state of portal hypertension and the development of organ failure (120)and thus, 
the clinical course of disease in these patients. The consequence of the inflammation 
noted via histological  and plasma factors  is  evident  in the  more  severe  nature  of 
decompensation  at  presentation,  and  by  the  course  of the  disease.  Patients  with 
alcoholic hepatitis had a much higher mortality and expressed a higher incidence of 
organ failure in addition to an increased burden of sepsis.
The BDL animal model was chosen to parallel the nature of injury with cirrhosis, on 
which  additional  inflammatory  injury  can be  superimposed.  The  results  from  the 
BDL  studies  complimented  the  findings  in  patients,  with  animals  in  which  an 
inflammatory LPS stimulus had been given in addition to the primary injury (BDL), 
manifesting a more advanced histological severity of disease,  and higher levels of
75biochemical liver injury. Although this was at slight variance with the results from 
the AH+C+ patients in whom there was no significant increment in aminotransferase 
levels, the BDL +LPS model was thought to support the concept that the effects of 
inflammation  on pre-existent  liver injury were not just  confined to  the  effects  of 
alcohol  induced  disease  but  are  likely  to  be  applicable  to  other  forms  of 
inflammatory liver injury.
Given that an acute  inflammatory infiltrate was a characteristic  of acute  alcoholic 
hepatitis,  and that neutrophils are known to generate superoxide through oxidative 
burst,  the  rationale  for  the  study  of neutrophil  responses  was  to  determine  the 
contribution  of neutrophil  activation to  the perpetuation  of injury  and the  overall 
outcome in the patient, when inflammation is superimposed on cirrhosis. Circulating 
neutrophils have been shown to be primed in alcoholic hepatitis, (94, 95) a process 
involving  functional  and  structural  changes,  resulting  in  enhanced  responses  to  a 
microbial challenge.  (98) The results presented confirm that neutrophils in patients 
with alcoholic  cirrhosis  and alcoholic  hepatitis  are primed as  shown by  increased 
oxidative burst upon stimulation with fMLP as compared to controls. The presence 
of  primed  neutrophils  would  suggest  good  bactericidal  function  but  with  the 
potential for promoting local damage if further activated.
Paradoxically, despite data suggesting neutrophil priming, it is also established that 
patients  with  alcoholic  cirrhosis  and  especially those  with  alcoholic  hepatitis,  are 
prone to  infections,  (121),  have  a higher prevalence of sepsis  (122)  and are more 
likely  to  die  from  sepsis  related  complications.  (102)  This  clinical  finding  is 
supported by several studies showing defects in phagocytosis, bactericidal capacity, 
chemotaxis and neutrophil locomotion. (96) It was therefore considered important to 
be able to distinguish between primed (but not activated) neutrophils and those that 
are fully activated. Activation of neutrophils was defined in this study as neutrophils
76that have a high resting burst. Additionally, presentation of a bacterial challenge to 
activated neutrophils  was  associated with  an  inability  of these  cells  to  generate  a 
further oxidative burst, as compared with primed cells. The neutrophils in this study 
population  of alcoholic  hepatitis  patients  showed  both  neutrophil  activation  and 
impairment of phagocytosis. One can only speculate on the mechanism by which an 
increased resting oxidative burst might be related to a decreased phagocytic capacity. 
Since  both  oxidative  burst  and phagocytosis  are  energy  dependent processes,  the 
induction  of oxidative  burst  may  lead  to  an  energy  depletion  and  reduction  in 
phagocytosis. This is supported by data showing that activation of AMP-kinases in a 
state of low cellular energy contributes to a reduction in host defence mechanisms. 
(123)
The clinical importance of these neutrophil abnormalities identified by a high resting 
oxidative burst of >55% and reduced phagocytic capacity (relative GMFI of <42%), 
are highlighted by the observation of increased risk of infection and the association 
with organ failure and mortality in these patients. In general, these observations were 
limited to patients with alcoholic hepatitis, as opposed to those with low burst who 
were in the main, patients with alcoholic cirrhosis alone. It is notable that the group 
with  high-burst  neutrophil  activity  as  described  in  this  study  had  infection  with 
multiple organisms despite antibiotic therapy, within a relatively short time frame. 
Although  every  possible  attempt  was  made  to  exclude  patients  with  pre-existing 
infection at study entry,  one  cannot fully exclude the possibility of an underlying 
sub-clinical  infection  that  remained  un-detected  by  current  routine  microbiology 
techniques,  which  may  have  precipitated  high  resting  oxidative  burst  in  some 
patients.  It  has  been  shown  that  32%  of cirrhotic  patients  with  culture  negative 
ascites  have  detectable bacterial  DNA  in the blood,  which may  indicate  systemic 
bacterial seeding. (124)
77An important observation made through ex vivo experiments in this study was the 
demonstration that the neutrophil functional defect could be transmitted to normal 
neutrophils  incubated with patient’s  serum.  It  was  also  possible  to  show that the 
neutrophil  dysfunction  in  the  patient  was  reversible  following  incubation  with 
normal serum, suggesting removal of this transmissible factor from patients’ plasma 
by placing the neutrophils in a more ‘healthy’ environment. An attractive candidate 
to  study  further  for  consideration  as  such  a  transferable  serum  factor  might  be 
endotoxin,  as  endotoxin  is  known  to  be  elevated  in  patients  with  alcoholic  liver 
disease.  Endotoxin  is  not  only  a  priming  agent  (98)  but  can  also  fully  activate 
neutrophils  (100,  101),  possibly  through  up-regulating  of  the  NADPH  oxidase 
assembly.  (125)  The  highest  levels  of endotoxin  reported  in  patients  with  liver 
disease are found in portal venous blood, (126,  127) highlighting the importance of 
the  bowel  and  altered  gut  permeability  as  the  possible  source  of endotoxin.(128) 
However, the difficulties with measurement of endotoxin make its identification in 
clinical  samples  a  challenge,  as  is  reflected  in  the  wide  range  of values  in  the 
literature. (99, 126, 127, 129, 130)
This  data on neutrophil  responses  in  cirrhosis  can thus  be  summarized as  in part 
explaining the apparent paradox in neutrophil function with heightened responses in 
the  context  of  inflammation  on  the  one  hand,  which  may  further  contribute  to 
inflammatory injury, and increased susceptibility to infection on the other, which in 
turn impacts on patient survival.
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Does inflammation impact on vascular function
cirrhosis?5.1  Circulatory  differences  between  patients  with  decompensated  alcoholic 
cirrhosis and patients with alcoholic hepatitis
5.1.1 Introduction:
Portal hypertension is a frequent clinical syndrome in patients with advanced liver 
disease defined by an increase in the pressure gradient between the portal vein and 
the hepatic veins. The importance of this syndrome is recognized by the frequency 
and severity of its  complications which include bleeding  from gastro-oesophageal 
varices,  renal  dysfunction,  increasing  ascites,  bacteraemia  and  hepatic 
encephalopathy.  (26)  There  is  some  data  that  suggests  that  in  decompensated 
alcoholic cirrhosis, major changes in portal blood flow including reversal of flow is 
associated with a lower 1  year survival in those patients who have proven alcoholic 
hepatitis. (131) Moreover, Poynard and co-workers suggested that the degree of liver 
cell necrosis and the extent of the neutrophilic infiltrate may relate to the level of 
portal pressure gradient. (132) These studies may intimate that in the context of the 
inflammatory state of alcoholic hepatitis, that there is a change in regulation of either 
portal  blood  flow  or/and  intra-hepatic  resistance,  though  the  specific  role  of 
inflammation  and the potential  mechanisms  involved have not been  explored.  An 
understanding  of  such  mechanisms  is  clearly  paramount  in  treating  the  severe 
complications  of portal  hypertension  in  these  patients,  which  contribute  to  their 
recognized poor survival in many series. (67)
Given the findings  of earlier studies presented in Chapters  3  and 4 demonstrating 
significant differences  in  liver architecture,  biochemistry  and  immune  function  in 
cirrhosis with superadded inflammation, it was considered important at the outset, to 
establish the contribution of inflammation to systemic and hepatic vascular function,
80before considering how this  impacts on patient outcome and progression to organ 
failure.
5,1.2  Methods:
5.1.2.1 Patients
Twenty-three  patients  with  alcoholic  liver  disease  who  were  undergoing  routine 
portal  pressure  evaluation  were  studied.  These  patients  were  a  subset  of  those 
previously described in Chapter 4, section 4.2. The study was conducted to facilitate 
an assessment of the vascular effects of additional inflammation on the background 
of cirrhosis.
5.1.2.2 Measurements
Systemic and hepatic haemodynamic evaluation was performed in accordance with 
the methods described in detail in Chapter 2: HVPG pressure measurement (section 
2.1.2.1),  cardiovascular  haemodynamics  (section  2.1.2.2)  and  hepatic  blood  flow 
(section 2.1.2.3). All the haemodynamic studies were conducted after an overnight 
fast, after the patients had been supine for at least 1  hour.
HVPG was calculated as the difference between WHVP and FHVP. The coefficient 
of variation of the measurements of HVPG within a given patient was 3% (0.42) for 
the study group.
5.1.3  Results
Of the 23 patients with alcoholic liver disease studied, 10 patients were subsequently 
found to have histological features of alcoholic hepatitis and the remaining  13  had 
decompensated alcoholic cirrhosis.
815.1.3.1 The systemic circulation
Patients with alcoholic hepatitis had significantly lower systemic vascular resistance 
(SVR) compared to alcoholic cirrhosis without inflammation (671  ± 79 vs.  1266 ± 
124  dyne*sec/cm5,  p<0.01)  as  shown  in  the  Figure  5.1a.  In  keeping  with  this 
observation,  mean  arterial  blood  pressure  (MAP)  was  also  significantly  lower  in 
alcoholic hepatitis patients (74 ± 2 vs. 86 ± 3 mmHg, p=0.01). It should be noted that 
in-spite of the differences in SVR and MAP, there were no significant differences in 
central filling pressure between the patient groups, as gauged through central venous 
pressure measurement (CVP alcoholic hepatitis vs. alcoholic cirrhosis:  13.2 ± 1.1 vs. 
11.7 ± 0.9 mmHg).  Cardiac output was, however, significantly greater in alcoholic 
hepatitis  patients.  This  finding  is  symptomatic  of a more  deranged hyperdynamic 
state than was observed in decompensated alcoholic cirrhosis alone (9.3 ±  1  vs. 6 ± 
0.6 L/min, p<0.01;  (Figure 5.1b).  The heart rate was significantly greater amongst 
the inflammatory alcoholic hepatitis patients compared to cirrhosis alone (92 ± 3 vs. 
82 ± 3 beats/min, p<0.05), as anticipated from the SIRS component evaluation.
A significant inverse correlation was found for SVR (r = -0.71, p<0.001; Figure 5. 
lc) and MAP (r = -0.47, p=0.02) in relation to SIRS  components.  Similarly, there 
was a strong inverse association between TNF receptors  1  and 2 and SVR and MAP 
(r = -0.5, p<0.01  and r = -0.68, p<0.001), respectively. These findings supported an 
association of inflammation with the observed systemic haemodynamic disturbances. 
There was, however, no significant association between elevated SIRS components 
or cytokine levels and cardiac output (r = 0.31, p= 0.1), which may in part reflect the 
wide range of measured cardiac output readings amongst this patient group.
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Figure 5.1 (a) demonstrates that there is a significant reduction in systemic vascular 
resistance (SVR) in patients with alcoholic cirrhosis in which there is the additional 
inflammatory  injury  of  alcoholic  hepatitis  (p<0.01),  compared  to  patients  with 
cirrhosis alone, (b)  shows a markedly higher mean cardiac output in patients with 
alcoholic hepatitis compared to those patients without  inflammation,  in whom the 
mean value is still greater than 5 litres/min, panel (c) shows the inverse relationship 
between a low SVR and a high SIRS score.
5.1.3.2  The hepatic circulation in alcoholic hepatitis
Patients  with  alcoholic  hepatitis  had  significantly  higher  hepatic  venous  pressure 
gradients  (HVPG)  as  shown  in  Figure  5.2a  compared  to  those  with  alcoholic 
cirrhosis alone (25 ± 2 vs.  16 ± 1  mmHg, p< 0.01). Elevated HVPG was also shown 
to have a positive correlation with higher SIRS score components (r=0.66, p<0.001), 
as shown in Figure 5.2c A significant association was also noted between HVPG and 
plasma TNFa  concentrations  (r=0.67,  p=0.01)  and TNF receptor  1   concentrations
83(r=.0.64,  p=0.01),  as  shown  in  Figure  5.2  (d)  and  (e).  Furthermore,  despite  no 
significant differences in CVP, there was significantly reduced liver blood flow in 
patients with alcoholic hepatitis, in whom a hepatic extraction of greater than  10% 
was measurable (n=5) compared to patients with only cirrhosis (n= 7):  [707 ±154 
vs. 1142 ± 124 mls/min, p<0.05; Figure 5.2b].
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Figure  5.2  (a)  Patients  with  alcoholic  hepatitis  (AH)  have  a  significantly  higher 
mean HVPG compared to patients with alcoholic cirrhosis and no inflammation [25 
± 2 vs.  16 ± 1  mmHg, p< 0.01], (b) patients with alcoholic hepatitis have markedly 
lower hepatic blood flow (HBF-calculated from the clearance of Indocyanine Green) 
compared  to  patients  with  alcoholic  cirrhosis  alone  [707  ±154  vs.  1142  ±  124 
mls/min, p<0.05], (c) elevated portal pressure correlates directly with SIRS score, as 
a  reflection  of severity  of inflammation,  (d)  a  positive  correlation  is  also  noted 
between HVPG and plasma TNFa and TNF receptor 1  levels (e).
Calculated  intrahepatic  resistance  was  estimated  from  the  HVPG  and  was 
significantly greater in alcoholic hepatitis patients as compared to cirrhosis patients 
without inflammation (2871 ± 375 vs. 877 ± 84, p< 0.01  (dyne*sec)/cm5), as shown 
in  Figure  5.3.  Available  mean  liver  blood  flow  was  derived  from  the  measured 
clearance of ICG for the studied patient group.
[Calculated  Intrahepatic  resistance  =  (Wedged  -   Free  Hepatic  venous  pressure)  / 
liver blood flow]
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Figure 5.3  Markedly increased  intrahepatic resistance (IHR)  is noted in patients who
have  additional  inflammatory alcoholic  hepatitis  on the  background  of alcoholic
cirrhosis.
5 1.4 Discussion
The findings of this study do support and extend the observations by Poynard (132) 
and  Duvoux  (131)  confirming  clear haemodynamic  differences  in  decompensated 
alcoholic  cirrhosis  patients  who  have  the  additional  inflammatory  component  of 
alcoholic  hepatitis.  In  this  study,  these  differences  have  been  more  formally 
characterized  demonstrating  a  markedly  lower  systemic  vascular  resistance  and 
lower  mean  arterial  pressure  in  patients  with  alcoholic  hepatitis,  confirming  an 
exaggerated  hyperdynamic  circulation  in  these  patients.  Furthermore,  the  patients 
with alcoholic hepatitis also have significantly higher portal pressures as defined by 
hepatic venous pressure gradients. A clear association is observed between elevated 
portal pressure gradient and SIRS components, in addition to plasma TNFa and TNF 
receptor 1  concentrations. Conversely, there is an inverse relationship for both lower 
mean  arterial  pressure  and  systemic  vascular  resistance  with  these  systemic 
inflammatory indices. However, it should be noted that the measurable TNFa levels
86were at the  level  of the detection threshold for most patients,  and similarly,  TNF 
receptor  1   levels  were  low  for many  patients  with  an  HVPG  <20  mmHg.  Thus, 
although statistically correlations were noted, these really are most applicable to the 
patients  with  the  greatest  severity  of  portal  hypertension.  Notwithstanding  the 
limitations with these cytokine assays and the relative underpowered nature of the 
patients  studied,  the  data  observed  would  support  the  assertion  that  increased 
inflammatory  drive  aggravates  the  systemic  hyperdynamic  circulatory  state  in 
cirrhosis,  whilst  also  promoting  a  compromised  hepatic  circulation.  This  is 
evidenced  by  the  markedly  decreased  hepatic  blood  flow  in  the  inflammatory 
patients, with a consequent elevation of intra-hepatic resistance.
It is interesting that patients with alcoholic hepatitis are often described as having an 
audible  hepatic  bruit,  believed  to  be  the  consequence  of  intrahepatic  arterial 
dilatation and regions of hypervascularity. This may be the consequence of a hepatic 
arterial buffer response to diversion of portal venous blood early in the  course of 
rising portal pressure. However, the relationships defined in this study would suggest 
that the severity of portal hypertension in severe alcoholic hepatitis is more complex 
than simply a greater distortion of liver architecture re-routing hepatic blood flow 
through shunts, or any direct contribution by an increased number of inflammatory 
cells.  (132)  It  is  more  likely  that  the  increased  pro-inflammatory  cytokines 
previously described in these patients (133) to which activated peripheral neutrophils 
may contribute,  drive key vascular regulators that are  involved with  local hepatic 
vascular tonic control at the level of the resistance vessels. This may cause regional 
or a more global hepatic hypoperfusion, in the context of splanchnic vasodilatation.
It was of interest that no direct association was found in this study between systemic 
inflammatory components and cardiac output, since the increase in cardiac output is 
a  recognized  response  in  cirrhosis  to  arterial  underfilling  as  a  consequence  of
87increased  splanchnic  vasodilatation.  (30)  A  possible  explanation  may  be  that  an 
increase in cardiac output serves to maintain mean arterial pressure in compensated 
cirrhosis  and  during  early  decompensation.  However,  in  the  context  of sepsis  or 
severe inflammation, as noted in alcoholic hepatitis, loss of cardiac reserve and un­
masking of an underlying dilated cardiomyopathy (related to alcohol or/and cirrhosis 
(134) results in a steady decrease in cardiac output, and a consequent disassociation 
from the relationship with reduced systemic vascular resistance. (135) These changes 
may themselves precipitate a progression to multi-organ failure.
88Chapter 6
Can anti-inflammatory intervention modulate 
vascular dysfunction in alcoholic cirrhosis?
896.1 Introduction:
Given  that  patients  with  inflammation  superimposed  on  cirrhosis  have  a  more 
deranged  hyperdynamic  circulation  and yet  also  a  reduced  hepatic  perfusion  and 
elevated  portal  pressure,  it  was  considered  important  to  determine  whether  the 
blockade of inflammatory pathways or their modulation resulted in a resolution of 
these haemodynamic differences. This would help to confirm the direct contribution 
of inflammation to these circulatory abnormalities in cirrhosis and suggest potential 
avenues for novel therapy. Moreover, such study would provide an insight into what 
factors alter the course and progression to organ failure, which might also contribute 
to the design of further studies to address mechanisms to account for any changes in 
vascular function observed.
6.2 Treatment with an anti-TNFa monoclonal antibody (Infliximab)
6.2.1  Background
TNFa,  a  pro-inflammatory  cytokine,  is  believed  to  exert  vascular  effects  by 
increasing vascular permeability and causing vasodilatation, thought to be mediated 
through  nitric  oxide  dependant  pathways.  (48)  TNFa  has  been  reported  to  be 
elevated in alcoholic liver disease, and in particular, high levels of TNFa are found 
in alcoholic hepatitis (AH). (133) In a pilot study, the administration of the chimeric 
anti-TNFa  antibody  Infliximab  (Schering-Plough  Corporation,  Kenilworth,  NJ, 
USA)  to  patients  with  severe  AH  was  shown  to  be  safe  and  resulted  in  an 
improvement in liver function and a reduction in inflammatory mediators. (105)
An important role  for TNFa  in  the  pathogenesis  of portal hypertension  has been 
suggested by studies on portal vein ligated rats treated using anti-TNFa therapies, 
which demonstrated a blunting of the hyperdynamic circulation and a reduction of
90portal pressure. (65, 66) We hypothesized that in view of the reported role of TNFa 
in the pathogenesis of AH, administration of an anti-TNFa antibody to AH patients 
would result in a reduction in portal pressure and an improvement in the systemic 
haemodynamic  derangement.  This  would  also  confirm  the  role  of TNFa  in  the 
inflammatory  mechanisms  that  might  be  related  to  the  development  of  portal 
hypertension.
This  study  evaluated  the  acute  and  short-term  effect  of  a  single  infusion  of 
Infliximab, on the portal, cardiovascular and renal haemodynamics in patients with 
severe AH.
6.2.2  Study Design
Patients:  Ten  patients  (8  males,  mean  age  53  +  8  years)  with  severe  AH  were 
recruited  into  this  study,  following  approval  by  the  local  ethics  committee. 
Following admission, patients were observed for 72 hours prior to inclusion. Patients 
were  included  if they  had  severe  AH  defined  by  a  compatible  clinical  history 
(alcohol consumption of >80g alcohol/day for men and >60g/day for women up until 
the time of admission), a discriminant function of >32 (89), histological evidence of 
AH  (balloon  degeneration  of hepatocytes;  Mallory  bodies;  neutrophilic  infiltrates 
and apoptotic acidophilic bodies), and a deterioration in liver function tests over the 
observation period, despite supportive medical management. Patients were excluded 
if they  were  <18  or  >75  years  and  had  any  of the  following:  renal  dysfunction 
(plasma creatinine>130  pmol/L),  severe cardiovascular or cerebrovascular disease, 
active or latent tuberculosis, hepatic or extra-hepatic malignancy and treatment with 
vasoactive agents or corticosteroids therapy.
Haemodynamic  assessment was performed prior to  entry  into the  study,  24  hours 
after  administration  of Infliximab  (Schering-Plough  Corporation,  Kenilworth,  NJ,
91USA) and on the day prior to discharge. The study was terminated either on day 28 
or the day of discharge, whichever occurred earlier. Day -2: Baseline haemodynamic 
assessment was performed in nine patients at the time of undergoing a transjugular 
liver biopsy.  In  the  tenth  patient,  a  biopsy  had  been  performed  prior  to  hospital 
transfer  and  it  was  therefore,  difficult  to  justify  a  baseline  haemodynamic 
assessment. Day 0: 48 hours following the biopsy and histological confirmation of 
AH,  Infliximab  was  administered  intravenously  (Schering-Plough  Corporation, 
Kenilworth, NJ, USA) over a 2-hour period, at a dose of 5mg/Kg body weight. Day 
1:  Repeat  haemodynamic  assessment  was  performed  the  next  morning,  24  hours 
after the Infliximab infusion, in 8 patients through an indwelling 9 French internal 
jugular  sheath  (William  Cook  Europe,  Bjaeverskov,  Denmark),  negating  further 
venepuncture.  1  patient declined a repeat haemodynamic study at this time. Prior to 
the day of discharge or day 28: A further haemodynamic assessment was performed 
at a mean of 19±4 days in 5 of the patients who consented to the third phase of the 
study.
Sampling: Blood was collected before the study began and then daily for one week 
after infusion; thereafter, two times per week until day 28 for routine haematology, 
biochemistry and CRP. During each haemodynamic assessment, blood was collected 
from an artery, hepatic and renal veins in pre-cooled heparinised tubes. Plasma was 
separated by centrifugation (3000rpm,  lOminutes at 4°C) and stored at -80°  C for 
subsequent  analysis.  A  24-hour urine  collection  enabled  determination  of sodium 
excretion.
926.2.3 Measurements
The  methods  applied  for  haemodynamic  evaluation  of hepatic  venous  pressure 
gradient, systemic haemodynamics and regional blood flow have been described in 
Chapter 2, sections 2.1.2.1-2.1.2.4.
Plasma cytokines were assayed by standard ELISA techniques (Chapter 2,  section 
2.4.1)  and  levels  of NOx  (nitrate/nitrite)  through  a  modified  Greiss  reaction  as 
described in Chapter 2, section 2.4.3.1.
Standard biochemical parameters (bilirubin, ALT etc) were obtained from hospital 
records.  The  study  was  terminated  either  on  day  28  or  the  day  of  discharge, 
whichever occurred earlier.
6.2.4 Results
The  10 patients were deeply jaundiced at the time  of entry  into the  study,  with a 
mean bilirubin of 335.9 (±41.6) pmol/L and an alanine aminotransferase (ALT) of 
46  (±3.5) U/L.  All had ascites and 6 had mild hepatic  encephalopathy.  The mean 
discriminant  function  was  68.9  (±8.9).  Treatment  with  Infliximab  resulted  in 
beneficial biochemical effects on liver function as manifest by a significant reduction 
in prothrombin time (p<0.05) after 1  week and also a significant improvement in the 
serum bilirubin  levels  (p<0.05)  by the  time  of discharge,  as  shown  in  Table  6.1. 
There  was  a  corresponding  reduction  in  discriminant  function  score  at  1   week 
(p<0.01), which was sustained at 28 days (62.9 ± 9 at day 0; 53.6 ± 9 at day 7; 42.3 ± 
5 at day 28; p<0.05).
93Table 6.1 Changes in liver function and SIRS components prior to and after 
treatment with Infliximab
Baseline Day 1 Day 7 Day 14 Day 28
(Day-2)
Prothrombin Time 20.7 ± 20.1 ± 18.8 ± 18.3 ± 1.2 17.8 ±
[10-13] (seconds) 1.7 1.8 1.6 * * 0 q**
Bilirubin [3-17] 335.9 ± 285.5 ± 267.6 ± 219.2 + 141.1 ±
(pmol/L) 41.6 48.2 43.4 40.4 * 17.7*
C-reactive protein 86.8 ± 53.1 ± 48.7 ± 39.2 ± 5.6 32.7 ±4.f
[0-5] (mg/L) 13.7 9.2  ** 10.3 ** *** ***
White blood cell 17.5 + 13.5 ± 13.8± 1.6 13.5 ± 1.2 12.3 ± IT
count [3-10] x 109/L 2.7 1.6  ** ** ** ***
Temperature °C 37.7 ± 37 ± 0.2 37 ± 0.3 36.8 ± 0.2 36.8 ±o.:
0.3 * * *
Heart Rate 93.8 ± 85.3 ± 85.7 ± 79 ±3.2 73.5 ± l.f
(beats/min) 3.7 3.1 * 2.9 * ** ***
Respiratory Rate /min 22.3 ± 18.7 ± 18.5 ± 17.1 ±0.8 17.7 ±1.1
1.5 1.1 2.1
* p<0.05, ** p<0.01, *** p<0.001 compared with baseline values, [normal range]
The  biochemical  changes  observed  occurred  in  the  light  of  a  reduction  in 
inflammation, as evidenced by a reduction and sustained improvement in the SIRS 
score  (2.5  ±  0.4  at  day  0  to  0.5  ±  0.27  at  day  28;  p<0.001).  There  was  also  a 
substantial reduction in CRP 24 hours after treatment with Infliximab (86.8 ± 14.4 to
53.1  ± 9.2 mg/L; p<0.001, Table.6.1).
Clinical evidence of improvement was sustained during the study period in all but 
one  patient  who  died  at  28  days  from  an  aspiration  pneumonia  and  subsequent
94septicaemia.  Aside  from  this  particular  patient,  no  other  individual  required  any 
vasoactive  agents,  admission  to  the  intensive  care  unit  or  antibiotic  therapy  or 
developed  any  signs  of progressive  hepatic  encephalopathy.  In  3  patients,  the 
occurrence of ascites required paracentesis.
6.2.4.1 Haemodynamic changes
6.2.4.1.1  Portal  haemodynamics:  HVPG  was  reduced  by  more  than  30%  of the 
baseline value in 7 of the 8 patients who had a repeat assessment within 24 hours of 
the treatment with Infliximab. Overall, the mean HVPG was reduced by 38.9 % from 
a mean of 23.4 ± 2.8 mmHg at baseline to  14.3 ±1.9 mmHg on day  1   (p<0.001) 
Moreover, the mean HVPG on the day prior to discharge (a mean time interval of 19 
± 4 days) was 12.8 ± 1.9 mmHg (p<0.001). Figure 6.1.
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Figure  6.1.  Infliximab  causes  a  significant  reduction  (>30%)  in  portal  pressure 
following  a  single  i.v.  administration  (5mg/Kg)  in 7  out of 8  patients  who had  a 
repeat  pressure  measurement  within  24hours.  This  effect  on  portal  pressure  was 
sustained throughout the patients’ admission, a mean interval of 19 days.
956.2.4.1.2  Cardiovascular Haemodynamics:  In  all  10  patients,  MAP  was  increased 
significantly from its baseline value of 71.6 ± 1.7 mmHg to 77 ± 1.9 mmHg on Day 
1   (p<0.001), and remained elevated on the day prior to discharge (mean 81.1  ±3.2 
mmHg,  p<0.001),  as  shown  in  Figure6.2a  This  was  associated with  a  significant 
increase in SVR from 477.7 ± 72 (baseline) to 786.2 +  124 dyne*sec/cm5  prior to 
discharge, p<0.01,  [Figure 6.2b]. There was a corresponding 22% reduction in CO 
(p<0.05) by the end of the  study (10.9 ±  1   to  8.4 ±  0.8  L/min),  [Figure  6.2c],  in 
addition to a significant reduction in heart rate (93.8 + 3.7 to 85.3 + 3.1  at day  1: 
p<0.05;  and  73.5  ±  1.6  on  the  day  prior  to  discharge:  p<0.001).  No  significant 
changes in central venous pressure were observed following Infliximab therapy.
Figure 6.2 (a) There is a significant increase in mean arterial pressure (MAP) and 
(b)  systemic  vascular  resistance  following  treatment  with  a  single  infusion  of 
Infliximab  (5mg/Kg).  In  the  case  of MAP,  this  improvement  occurred within  24 
hours and improved significantly further by the time of discharge
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Figure  6.2c  There  is  a  general 
reduction in cardiac output (CO) 
following treatment of alcoholic 
hepatitis  patients  with 
Infliximab.  However,  it  can  be 
seen that in 2 patients  (denoted 
by  dotted  lines)  that  the  CO 
increased  back  to  baseline 
values,  despite  manifesting  a 
reduction in portal pressure
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6.2.4.1.3  Hepatic Blood Flow: Although HBF was measured in all of the patients, 
data was  analysed  in  the  6  patients  who  had a hepatic  extraction  of Indocyanine 
green (ICG) greater than 10% [mean % ICG extraction: baseline 11.9 ± 0.9%; Day 1  
12.5 ± 0.7 %]. A significant increase in HBF was observed in the 6 patients in whom 
it was measurable, from 506.2 ± 42.9 ml/min at baseline to 591.8 ± 55.2 ml/min on 
day  1,  as  shown Figure  6.3.  This was  associated with a decrease  in  intrahepatic 
resistance, evident 24 hours after a single infusion of Infliximab.
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Figure  6.3  There  is  a  marked 
increase  in  hepatic  blood  flow 
within  24  hours  following  a 
single  infusion  of  Infliximab, 
and  this  increased  still  further 
by  the  time  of discharge  from 
hospital.  These  changes 
occurred  in  the  presence  of 
lowered  portal  pressure 
following  Infliximab  therapy. 
The effects were coupled with a 
lowering  of  intrahepatic 
resistance after  1   day as shown 
in the lower panel of the figure.
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6.2.4.1.4  Renal  Blood  Flow  and  Renal  Function:  Following  treatment  with 
Infliximab, no patient was found to develop renal impairment. There was in fact, a 
significant increase in RBF from the baseline value of 424.3 ±65.1 ml/min to 506.3 
± 85.7 ml/min at the time of discharge (p<0.01).Figure 6.4a. This increase in RBF 
was mirrored by an increase in urinary sodium excretion from 10.3 ± 2.5 mmol/L on 
day 0 to  19  ±  5.1  mmol/L  on day  1,  as  shown  Figure  6.4b  This  improvement in 
sodium excretion was sustained at the time of discharge (23.3 ± 4.3 mmol/L and was 
statistically  significant  (p<0.01).  By  contrast,  although  the  urine  output  increased 
from 895.8 (±140) ml pre treatment to  1122 ±  109 ml at the time of discharge, this 
failed to reach statistical significance (p=0.21).
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Figure 6.4 (a) Intravenous Infliximab administration (5mg/Kg) caused a significant 
increase in renal blood flow prior to discharge (mean of 19 days);(b) change in renal 
blood flow was associated with an increase in urinary sodium excretion, which also 
reached statistical significance prior to discharge.
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This study is the first to measure changes in portal and systemic haemodynamic in 
alcoholic hepatitis patients following treatment with Infliximab, and demonstrates an 
early, significant reduction in HVPG (mean of 38%; p<0.001), which was sustained 
over  several  weeks  and was  coupled with  a  significant  increase  in hepatic  blood 
flow.  This  observation  further highlights the  critical  role  played by  inflammation 
driven  through  TNFa  in  the  development  of portal  hypertension  in  AH,  and  the 
possible  effects  this  may  have  on  intrahepatic  resistance.  In  addition,  the  results 
show  a  significant  improvement  in  systemic  haemodynamic;  as  evidenced  by  a 
reduction  in  cardiac  output  with  a  concomitant  increase  in  systemic  vascular 
resistance and MAP, which may help to explain the increase in renal blood flow and 
sodium excretion.
These results confirm those of a previous observation,  (105) that treatment of AH 
patients with Infliximab is well-tolerated with 9 of the patients studied surviving, and 
demonstrating  significant  improvements  in  their  prothrombin  time  and  serum 
bilirubin  levels,  and  consequently  a  decreased  discriminant  function  (p<0.01). 
Improvement in CRP  and white  cell  count 24  hours  after Infliximab  therapy was 
associated  with  a  reduction  in  SIRS  components,  and  circulating  IL-6  and  IL-8, 
highlighting an important role for TNFa in sustaining the inflammatory response in 
these patients.  This  is  further supported by data  in our earlier collaborative  study 
showing  a  decrease  in  intrahepatic  IL-8  mRNA  synthesis  28  days  following 
Infliximab administration to AH patients. (105) The lack of significant reduction in 
TNFa  levels  in  the  patients  in  whom  it  was  measured  following  Infliximab 
administration, has been previously noted (105,  136) and may reflect the relatively 
small  numbers  of patients  included  in  this  study  and/or  the  complex  interaction 
between TNFa and its bound and free receptors.  Soluble TNF receptors have been
99shown to be up-regulated in severe AH (108) whilst TNF levels in patients with AH 
are widely variable in the literature. They range from values as low as 5pg/ml to as 
high  as  400  pg/ml  (13,  94,  110,  111),  suggesting  that  other  factors  such  as 
concomitant infection, degree of endotoxaemia, genetic factors and soluble receptor 
expression may be important in determining the measured levels of TNF.
The significant reduction in HVPG following treatment with Infliximab found in the 
present  study  is  likely  to  be  due  to  a  combination  of an  alteration  in  both  the 
“forward”  and  “backward”  components  of portal  hypertension.  The  changes  in 
forward component, which regulates splanchnic inflow largely through a reduction 
in cardiac output and increase in systemic vascular resistance, have been documented 
in studies in animal models. (57, 66,  137) However, as shown in Figure 6.2c, in this 
study  there  was  an  increase  in  cardiac  output  in  2  patients  despite  a  sustained 
reduction in their HVPG. This would appear to suggest that in addition to regulating 
splanchnic inflow, there is an equally important role for TNFa in the modulation of 
factors  that regulate  intrahepatic  resistance  that  is,  the  “backward  component”  of 
portal hypertension.
This notion is further supported by the observation of a reduction in HVPG despite 
an increase in hepatic blood flow. Additionally, no significant change in HVPG was 
found  in  studies  in  portal  hypertensive  patients  with  cirrhosis  demonstrating  a 
reduction in cardiac output and a significant increase in systemic vascular resistance 
and MAP  after systemic  inhibition of nitric  oxide  synthase with the inhibitor Ng- 
monomethyl-L-arginine (L-NMMA).(138,  139) This would suggest that modulation 
of  systemic  regulators  of the  forward  component  alone  may  be  insufficient  to 
significantly reduce HVPG.
The  intrahepatic  resistance  is  thought  to  have  a  “fixed”  component  relating  to 
fibrosis and a change in cellular architecture and size, and a “variable” component
100that can be modified by many factors including the activity of hepatic stellate cells 
(HSC).  Following  liver  injury,  HSCs  undergo  trans-differentiation  to  a 
myofibroblastic phenotype, significantly impairing segmental blood flow, whilst also 
proliferating and increasing production of the extracellular matrix. TNFa has been 
shown to be instrumental in activation of rat hepatic stellate cells and also increases 
the  synthesis  of extracellular  matrix  proteins  (45),  albeit  human  data  is  limited. 
Moreover, spontaneous apoptosis in activated HSCs is significantly down regulated 
by TNFa, thus prolonging the survival of activated HSC in chronic liver disease and 
maintaining increased intrahepatic resistance.  (140)  It is possible that in  alcoholic 
hepatitis, where there is an overproduction of TNFa,(141) a prolonged activation of 
HSC may give rise to significant elevation of HVPG through increased intrahepatic 
resistance. It is interesting, therefore, to propose that the mechanism of reduction in 
intrahepatic  resistance  after  administration  of  anti-TNF  may  result  either  from 
apoptosis  of HSCs, their deactivation or from remodelling of extracellular matrix. 
However, there is no evidence to suggest massive HSC apoptosis can occur within 
24  hours  of Infliximab  administration  to  account  for  the  observed  reduction  in 
HVPG, or data to show that HSC activation can be reversed.  Similarly there is no 
human data to support rapid remodelling of extracellular matrix, albeit this has been 
described within 24 hours using cultured HSC. (140)
An  alternative  explanation  for  the  decrease  in  intrahepatic  resistance  following 
Infliximab administration, stems from research demonstrating decreased intrahepatic 
endothelial nitric oxide synthase (eNOS) activity in cirrhosis. (43, 53) Although the 
mechanisms  for the  local intrahepatic  deficiency of NO  and the  differential tissue 
regulation  of  NO  production  remain  ill-defined,  there  is  evidence  from 
cardiovascular  research  studies  suggesting  that  methylarginine  derivatives  are 
important  in  regulating  NOS  activity  following  endothelial  injury.  (142,  143)  Of
101interest,  asymmetrical  dimethylarginine  (an  endogenous  endothelial  nitric  oxide 
synthase inhibitor) is in turn regulated by dimethylarginine dimethylaminohydrolase, 
an enzyme whose activity can be modified by TNFa. (119) One may thus speculate 
that administration of Infliximab may reduce the intrahepatic concentration of eNOS 
inhibitors,  resulting  in  a  compartmentalised  increase  in  intrahepatic  NO.  The 
potential role of ADM  A is explored later in this thesis.
Another important finding in this study was the early improvement in hepatic blood 
flow and renal blood flow following Infliximab treatment.  These findings coupled 
with the fact that there was no significant difference in central venous pressure or 
free  hepatic  venous  pressure  before  and  after treatment,  discounts  a  reduction  in 
central  volume  as  a  possible  explanation  for  the  observed  reduction  in  HVPG. 
Furthermore,  most  treatments  aimed  at  lowering  portal  pressure  and  splanchnic 
vasodilatation  cause  deleterious  effects  on  renal  perfusion,  largely  through  a 
reduction in MAP. The significant acute and sustained increase in MAP reported in 
this study is likely to have played an important role in the increase in renal blood 
flow  and  sodium excretion  observed.  This  improvement  in  renal  blood  flow may 
explain why none of the patients  studied developed hepatorenal  syndrome despite 
their severe presentations. A similar observation was also reported by Akriviadis et 
al  in  their placebo  controlled trial  of AH patients  treated with  Pentoxifylline,  an 
inhibitor  of  TNFa  synthesis.(144)  This  study  found  a  significant  reduction  in 
hepatorenal  syndrome  related  deaths  (12%  versus  43%)  in  the  treatment  arm 
compared with placebo, reflecting the importance of maintaining renal perfusion. A 
further possible explanation for the improvement in renal perfusion and function that 
was observed is that the reduction in HVPG may result in a favourable change in the 
“hepatorenal axis”, (145) independent of the improvement in MAP. This assertion is 
supported by the data from this  study  showing an improvement in natriuresis  and
102urine output, in addition to a significant increase in renal blood flow, concurrent with 
improvement in liver function and systemic haemodynamics.
Following the observations made in this study and its subsequent publication, there 
was a randomized controlled trial of Infliximab given 3 times at a dose of lOmg/Kg 
with concomitant corticosteroids versus corticosteroids alone, published by Naveau 
et al (106). In this French study, there were significantly increased deaths related to 
infection  and  a  demonstration  of reduced  neutrophil  responses  in  the  combined 
treatment  group,  which  led  to  a  moratorium  on  the  use  of Infliximab  applied  to 
alcoholic  hepatitis.  However,  there  were  many  controversial  elements  to  the 
protocol  used  in  the  Naveau  study  as  noted  by  the  use  of  multiple  high  dose 
Infliximab infusions in addition to high dose prednisolone, which place it at variance 
to the published data from other small  studies.  (146)  A potential  criticism of the 
study data presented here is that it did not have a control arm to compare with the 
effects of Infliximab. However, by way of justification, the inherent design of this 
study was to allow one to establish whether TNFa had a role in the development 
portal  hypertension,  and  it  did  not  aim  to  assess  Infliximab  treatment  efficacy. 
Clearly, it would be difficult to justify intensive repeat haemodynamic assessments 
and  a  transjugular  liver  biopsy  in  patients  not  receiving  any  active  therapy  and 
thereby, there could be no ‘placebo’. It is also important to note that the significant 
reduction  in  HVPG  and  MAP  occurred  within  24  hours  of the  administration  of 
Infliximab, and was sustained thereafter until discharge.  This would suggest that it 
would  be  highly  unlikely  for  the  improvements  in  HVPG  and  systemic 
haemodynamics to have occurred as part of the natural course of AH. Indeed, early 
work  by  Maddrey  et  al  (89)  reported  HVPG  data  in  AH  patients  treated  with 
corticosteroids or placebo, and showed no significant difference in HVPG between 
the  treatment  groups  over the  28-to-32-day  study period.  Moreover,  the  observed
103improvement  in  haemodynamics  coincided  with  the  significant  reduction  in 
inflammatory indices 24 hours after Infliximab therapy, supporting a hypothesis that 
reducing a TNFa driven inflammatory cytokine cascade, restores the imbalance in 
vascular  mediators  that  promotes  a  hyperdynamic  state  and  perpetuates  further 
elevation in portal pressure.
6.3  Treatment  with  Albumin  dialysis  using  The  Molecular  Adsorbents 
Recirculating System (MARS)
6.3.1  Introduction
AH often precipitates decompensation in patients with alcoholic  cirrhosis  and this 
may  lead to  associated  organ  failure.  It has  also  been  suggested that  histological 
necrosis and an acute inflammatory infiltrate contributes to the worsening of portal 
hypertension in these patients (132). Our previous study on the effects of anti-TNF 
therapy and those  of others(147)  suggest that the  inflammatory mediators  of AH, 
especially pro-inflammatory cytokines such as TNFa, are especially important, and 
modulation of these factors may result in an amelioration of portal pressure.  This 
implies that portal hypertension in the  setting of acute AH may possibly be more 
labile  and  amenable  to  therapeutic  interventions  compared  to  that  in  alcoholic 
cirrhosis without evidence of hepatic inflammation. Moreover, an increased risk of 
variceal bleeding due to AH would have potentially more serious consequences with 
respect to outcome due to the associated decompensation. Albumin dialysis using the 
Molecular  Adsorbents  Recirculating  System  (MARS;  Teraklin  AG,  Rostock, 
Germany) has been used mainly in the treatment of liver failure (148), and our group 
had previously shown its potential benefit in patients with severe acute AH.  (149) 
Interestingly, a preliminary report has described an acute reduction of portal pressure
104in four patients with acute-on-chronic liver failure (ACLF) after the first session of 
MARS, which increased before the second session but again underwent reduction, 
albeit less steep, after the second session (150). A noteworthy point is the fact that all 
four  patients  had  evidence  of  hepatic  inflammation  (AH-3,  non-alcoholic 
steatohepatitis-1).  The aim of this  study, was thus to evaluate the acute effects  of 
albumin  dialysis,  using MARS,  on portal  haemodynamics  in patients  with  severe 
acute  AH.  Patients  treated with haemofiltration  alone  were  investigated using the 
same  protocol  to  establish  whether  changes  observed  were  specific  to  albumin 
dialysis or just an effect of extracorporeal therapy.
6.3.2  Methods
6.3.2.1  Patient selection
Inclusion criteria: (i) Patients were included with severe AH, which was defined by 
a  history  of  alcohol  abuse,  clinical  and  laboratory  stigmata  of  acute  AH  and 
supported  by  histological  evidence,  (ii)  Acute-on-Chronic  Liver  Failure  (ACLF), 
defined  as  acute  deterioration  in  liver  function  over  2-4  weeks  due  to  a  defined 
precipitant  leading  to  severe,  progressive  clinical  deterioration  despite  supportive 
care  (over  72  hours)  with  (a)  increasing jaundice  (bilirubin>85pmol/L),  and  (b) 
either hyperbilirubinaemia>300pM and/or encephalopathy (>grade 2)  (151)  and/or 
renal failure, (iii) Clinically significant portal hypertension: (HVPG >12mmHg). 
Exclusion  criteria:  Patients  were  excluded  if they  were  <18  or  >75  years  old, 
adequate  consent  could  not  be  obtained,  were  already  enrolled  in  another  study 
protocol, had uncontrolled variceal bleeding or uncontrolled infection over the past 
48  hours,  had  known  hepatic/extrahepatic  malignancy,  were  pregnant,  had  co­
existing HIV infection or severe cardio-respiratory disease. Concomitant or previous 
corticosteroid therapy was not an exclusion criterion.
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Eleven patients were finally included and received a 6-hour session of extracorporeal 
therapy.  Eight  patients  received  MARS  treatment  in  conjunction  with 
haemofiltration. Three others did not consent to MARS but agreed to haemodynamic 
assessment  and  haemofiltration,  and  received  a  6-hour  session  of  veno-venous 
haemofiltration  alone.  HVPG  changes  at  6  and  24  hours  were  the  primary  end­
points.
6.3.2.3  Monitoring:  The  patients  were  evaluated clinically  and biochemically  and 
The  Child  Pugh  score  (87)  and  discriminant  function  (89)  were  calculated.  The 
severity of encephalopathy was assessed using the West Haven criteria (151). Mean 
arterial  pressure,  electrocardiogram,  heart  rate  and  temperature,  were  monitored 
continuously  during  treatment.  The  patients  were  actively  warmed  to  a  core 
temperature of 37°C if temperature dropped during treatment. Intravascular volume 
was maintained using crystalloids,  colloids or red cells  as  appropriate to maintain 
central venous pressure between 8  and  10cm H2O.  Blood glucose was maintained 
between 5-7mmol/L with infusion of 50% dextrose.
6.3.2.4 Extracorporeal therapy:  The MARS  system consists of a blood circuit,  an 
albumin  circuit,  and  a  renal  circuit,  in  our  studies  using  continuous  veno-venous 
haemofiltration (Hospal BSM 22c, Hospal, Lyon, France). Blood is dialysed across 
an albumin-impermeable high-flux dialysis membrane (MARS Flux; Teraklin AG). 
The albumin circuit contains 600 ml of 20% human albumin, which passes through 
the  dialysate  compartment  of  the  blood  dialyser.  It  subsequently  undergoes 
haemofiltration  and  passage  through  activated  charcoal  and  anion  exchange  resin 
columns to remove acquired toxins.  Heparin was used as required (if patient’s INR 
<1.4) to prevent clotting in the extracorporeal circuit. The blood and albumin circuit
106were  run  at  150  ml/min,  with  1   L/hour  fluid  exchange,  maintaining  equal  fluid 
balance. Each MARS session was continued for 6-8 hours duration.
6.3.2.5 Haemofiltration: Continuous veno-venous haemofiltration (Hospal BSM 22c) 
was performed with similar rates of blood flow (150 ml/min) and fluid exchange (1 
L/hour) as that used for MARS.
6.3.2.6  Haemodynamic  measurements:  Haemodynamic  studies  were  performed  at 
the time  of trans-jugular liver biopsy prior to the  extracorporeal  session,  and this 
followed an overnight fast and a  1-hour period during which the patient had been 
resting supine.  The methodology applied for measurement of HVPG and systemic 
haemodynamics  was  as  described  previously  (chapter  2,  section  2.1.2.1-2.1.2.3). 
Patients were sedated for the procedure using midazolam (median dose of 3  [range 
2-5] mg; Phoenix Pharma Ltd., Gloucester, UK).
6.3.3  Results
Eleven patients with severe alcoholic hepatitis (median DF >68) were studied who 
had been assigned to treatment with MARS (n=8) or standard medical therapy (n=3), 
which included haemofiltration, as part of a larger trial on assessment of the efficacy 
of  MARS  [Teraklin  AG,  Rostock,  Germany].  Patients  in  the  2  groups  were 
comparable with respect to liver disease severity (discriminant function and MELD 
score) but patients in the treatment arm had a significant reduction in bilirubin within 
24 hours (p<0.001) and a trend towards a lower serum creatinine.  Of interest, there 
were no significant differences in CRP, white blood cell count or liver function in 
between  the  groups  after  MARS  treatment.  None  of the  patients  received  any 
immuno-modulatory treatments as all had contra-indications (sepsis, recent GI bleed 
and/or renal failure).
6.3.3.1  Hepatic Haemodynamics: All included patients had a median HVPG of 16 
(13-22) mmHg.  Following MARS therapy,  HVPG reduced significantly (p< 0.01)
107after 6 hours (the end of a treatment session), and remained at this level by 24 hours. 
The reduction in HVPG was greater than 20% reduction from baseline levels in 7/8 
patients receiving MARS, both at 6 and 24 hours, as shown in Figure 6.5.
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Figure 6.5.  Hepatic  venous pressure  gradients  (HVPG)  before  and  after a  6-hour 
session of extracorporeal treatment with MARS. All but one MARS-treated patient 
showed a significant (>20%) reduction of HVPG (both at 6 and 24 hours).
No  significant  change  in  HVPG  was  observed  in  the  patients  receiving 
haemofiltration  and  supportive  management  alone.  Six  of the  patients  reached  a 
target level of <12 mmHg at 6 hours.  In two patients with repeated measurements 
during the  session,  a reduction in HVPG was apparent within the first 2 hours  of 
commencement of treatment.
Patients  treated with the  extracorporeal  MARS  system had an  overall  increase  in 
hepatic blood flow (as compared to no significant change in the patients treated with 
haemofiltration). This translated into a significant decrease in intra-hepatic resistance 
(p<0.05) in patients treated with MARS, as compared to a small increase in patients 
treated with haemofiltration alone, as seen in Figure 6.6.
108*  p<0.05;  n.s.- not statistically significant
Figure 6.6. MARS therapy induces a significant decrease (p<0.05) in intrahepatic 
resistance (IHR) within 24 hours compared to patients on haemofiltration alone, in 
whom there is no significant change from baseline.
6.3.3.2  Systemic haemodynamics
MAP increased over the treatment period of 6 hours and this was sustained at 24 h 
(p<0.05),  as  shown in Table  6.2.  Cardiac  output showed a similar rapid sustained 
improvement. (p<0.05)  The improvement in cardiac output, correlated well with a 
reduction  of HVPG  following  MARS  treatment  (r=0.7,  p<0.05).  None  of these 
haemodynamic  parameters  improved  with  haemofiltration  and  supportive  therapy 
over the 24-hour study period.
109Table  6.2:  Changes  in  haemodynamics  6  hours  and  post  24  hours  following 
intervention with MARS.
MARS group (n=8) Haemofiltration group (n=3)
Baseline 6 hours 24 hours Baseline 24 hours
HVPG 
(mm Hg)
17
(13-22)
11
(9-15)**
12
(9-15)***
16
(15-17)
14
(14-19)
MAP 
(mm Hg)
72
(45-79)
80
(58-99)
76
(64-93)*
71
(65-91)
67
(65-78)
CO
(l/min)+
8.4
(6.9-17.0)
7.8 
(6.1-9.4)*
6.8 
(5.5-8.9)**
10.3
(9.3-11.3)
9.5
(7.8-11.1)
+  n=4 in MARS group
P-value vs. baseline: * p<0.05; ** p<0.01; *** p<0.001 
6.3.4. Discussion
The results of this small study demonstrate an acute reduction in portal pressure with 
albumin dialysis using MARS which was sustained for up to 18 hours after stopping 
the  treatment.  Although the  exact mechanism  of this  portal  hypotensive  effect  of 
MARS remains unclear, the reduction in portal pressure is, at least in part, the result 
of effect on the forward component of portal hypertension (i.e. cardiac output), with 
a  further  contribution  through  lowering  of  intrahepatic  resistance.  The  clinical 
importance  of this  observation  stems  from  the  fact  that portal  pressure  reduction 
occurred  to  an  extent  which  is  deemed  to  reduce  the  risk  of  variceal 
bleeding/rebleeding,  rapidly  within  a  few  hours  of institution  of MARS.  Portal 
pressures greater than 12mmHg underlie the development of varices and a reduction 
to values <12mmHg (152) or by >20% of the baseline (29) are known to prevent 
rebleeding (153) In this study, within 6 hours HVPG fell by >20% in 7/8 patients, 
and  reached  12  mm  Hg  in  6/8.  It  is  very  unusual  for  most  conventional  portal 
pressure reducing  strategies  to  achieve  such a rapid response.  This reduction was 
sustained for at least 18 hours after stopping treatment.
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not simply due to a reduction of intravascular volume as a simple consequence of 
extracorporeal therapy. This is borne out by the facts that (i) central venous pressure 
was maintained between 8-10 cm H2O, under the study protocol, (ii) negative fluid 
balance was avoided, maintaining  1   litre/hr equal exchange in both the MARS and 
haemofiltration  groups,  and  (iii)  no  significant  change  of  haematocrit,  serum 
albumin, creatinine or electrolytes occurred in either group following extracorporeal 
therapy, (iv) Finally, and most importantly, the volume of the extravascular circuit 
was very similar in both groups, and both systems (MARS and haemofiltration) were 
run  at the  same pump  speeds with similar fluid exchange rates,  in  spite  of which 
systemic  and  portal  haemodynamics  improved  with  MARS  but  not  with 
haemofiltration.
Given  the  severity  of presentation  in  these  patients,  as  had  been  noted  in  our 
previous studies, the hepatic extraction of ICG in several patients was less than 10% 
and there-by unsatisfactory for calculation of hepatic blood flow. Not withstanding 
this,  hepatic  blood  flow  data  was  available  in  6  patients  and  a  corresponding 
calculation of intrahepatic resistance (IHR),  did show a  significant reduction after 
MARS treatment, which was not evident in patients on haemofiltration alone. This 
would  support  a  role  for  modulation  of a  vascular  mediator  such  as  NO  in  part 
explaining  the  observed  reduction  in  HVPG,  through  its  effects  on  intra-hepatic 
resistance..
The  lack  of response  seen  with  haemofiltration  suggests  that  the  portal  pressure 
changes  were  mediated  by  the  possible  removal/alteration  of an  albumin-bound 
substance.  The  exact  underlying  pathophysiological  mechanism  may  relate  to 
removal  of  inflammatory  mediators,  alteration  of NO  metabolism,  reduction  of 
oxidative  stress  or modulation  of the  renin-angiotensin-aldosterone  axis.  Previous
111studies from our group suggest that while alteration of NO metabolism or reduction 
of oxidative  stress are a possibility,  systemic inflammatory markers  (leukocytosis, 
CRP) remain unchanged following MARS dialysis.(154)This might support a notion 
for  the  removal  of a putative  factor  from the  peripheral  blood  that  mediates  the 
hepatic haemodynamic  changes observed in this  study.  Of interest,  a recent study 
published on the effects of 2 different extracorporeal systems including MARS, has 
also  demonstrated  an  improvement  in  systemic  haemodynamic  parameters,  and 
altered  levels  of metabolites  of nitric  oxide,  in  addition  to  favourable  changes  in 
rennin activity and sympathetic drive. (155)
112Chapter 7
Is there a link between hepatic inflammation and 
circulatory dysfunction through altered regulation of
nitric oxide synthase?
1137.1 Introduction:
Taking the preceding data together, further experiments were conducted in order to 
try to elucidate whether the significant modulator of hepatic vascular tone controlled 
by  inflammatory  signals  was  nitric  oxide,  and  how  this  may  be  altered  by 
inflammation on the background of pre-existing liver disease.
7.1.1 Nitric oxide generation during hepatic inflammation
NO is believed to play an important role  in both the normal regulation of hepatic 
microvascular resistance via its relaxing influence on the perisinusoidal stellate cells 
(156), and also in the context of endothelial dysfunction in experimental cirrhosis. 
(42-44) Increasing evidence points to a decrease in intrahepatic NO generation in the 
context  of  cirrhosis  (43,  53)  Reduced  hepatic  eNOS  activity,  with  a  resultant 
decrease in NO release, is likely to result in loss of the counteracting influence to 
potent  vasoconstrictors  such  as  endothelin-1  and  angiotensin  II,  (41,  156)  and 
thereby bring about an increase in the sinusoidal resistance.  This is highlighted by 
studies  demonstrating a paradoxical  vasoconstrictor response to acetylcholine as a 
loss of endothelium-dependent vasodilatation through nitric oxide. (42)
An increase in splanchnic/systemic endotoxin load, which in liver disease is believed 
to parallel the degree of hepatic decompensation, (129) has been suggested to be the 
trigger  for  activating  NOS  activity  with  subsequent  excess  NO  production  (32) 
However, others have suggested that in states of increased endotoxaemia, endothelial 
nitric oxide synthase (eNOS) generated by regional vascular endothelial cells may be 
down-regulated.  (157).  This  apparent  paradox  may  relate  to  the  effects  of post- 
translational modification of NOS or through the actions of endogenous regulators, 
as the hepatic mRNA and protein expression of this enzyme have been found to be 
similar  in  control  and  cirrhotic  animal  models.  (44,  158)  However,  general  data
114from  human  studies  is  limited  and  the  role  for  inflammation  in  promoting  these 
changes  to  eNOS  functional  activity,  perhaps  driven  through  increased  levels  of 
endotoxin, is poorly characterized.
Given the findings presented in this thesis on the vascular derangements in alcoholic 
hepatitis to this point,  and the clear reversible nature of the intra-hepatic vascular 
defect with modulation of inflammation, the link between hepatic inflammation and 
circulatory  dysfunction  through  altered  regulation  of  nitric  oxide  synthase  was 
investigated.
7.2  Studies  in  patients  with  alcoholic  cirrhosis  to  assess  NO  generation, NOS 
protein and mRNA expression
7.2.1 Patient selection
Plasma  samples  were  drawn  from  24  patients  presenting  with  decompensated 
alcoholic cirrhosis, (increasing ascites, pedal oedema or progressive jaundice), with 
clinical and radiological evidence of cirrhosis, and a current history of alcohol abuse. 
Patients  were  excluded  if  they  were  <18  or  >75  years  and  had  evidence  of: 
additional/another  aetiology  of liver  disease;  severe  cardiac  dysfunction  or  renal 
failure  (creatinine  >150pmol/L);  hepatic/extra-hepatic  malignancy;  hepatic 
encephalopathy  >Grade  2  (precluding  informed  consent),  and  if  there  was 
microbiological  evidence  of  infection  after  72  hours  of  broad-spectrum 
antimicrobials.  Patients  were  studied  at  transjugular  liver  biopsy  (days  1-3  of 
admission), performed to assess  severity of liver dysfunction in those with ascites 
or/and coagulopathy. Classification to AH superimposed on cirrhosis (AH+C+) was 
made on subsequent histological examination using the criteria described in section
3.1.1.1 of chapter 3.
115Blood samples were drawn from a peripheral artery and from the hepatic vein into 
pre-cooled tubes  and the plasma obtained by  centrifugation  stored  at -80°C,  until 
subsequent  analysis  for nitrite  and nitrate.  Liver tissue  obtained with  appropriate 
approved ethical consent at the time of transjugular biopsy, was divided such that 
some of the sample was fixed in formalin for routine histological assessment, and the 
remainder  snap  frozen  until  subsequent  assessment  for  tissue  NOS  activity.  For 
comparison to ‘normal’ tissue, clear hepatic resection margin tissue from 3 patients 
with colorectal hepatic metastases and no evidence of liver disease were used.
7.2.2  Results:
The patients studied form a subset of those described in greater detail in Chapter 3 
section  3.1.2.1.  Ten  patients  had  histological  evidence  of  alcoholic  hepatitis 
superimposed  on  cirrhosis,  whilst  14  had  cirrhosis  without  evidence  of 
inflammation.
7.2.2.1 Generation of  nitrite  from arterial and hepatic venous samples
There were no statistically significant differences between measurements of nitrite in 
arterial samples compared to samples taken from the hepatic vein for either group of 
patients:  Alcoholic hepatitis:  artery (0.65 ±0.17  pM) and hepatic vein (0.61  ±0.1 
pM); p=0.8 and alcoholic cirrhosis: artery (0.61 ± 0.07 pM) and hepatic vein (0.56 ± 
0.11  pM);  p=0.7.  In  addition,  there  was  no  statistically  significant  difference 
between artery or hepatic venous nitrite values when comparing patients with and 
without additional inflammation (alcoholic hepatitis).
7.2.2.2 Hepatic tissue NOS activity measures
In contrast to measurements of nitrite, assessment of hepatic tissue NOS generated 
NO  in  a  sub-group  of patients  using  the  method  outlined  in  Chapter  2,  section
1162.4.3.3,  demonstrated  a  significantly  reduced  total  NOS  activity  in  patients  with 
inflammatory alcoholic hepatitis [n=6] compared to alcoholic cirrhosis patients [n=6] 
(38.5  ±  12.6  vs.  91.4  ±  31.8  nmoles  citrulline/h/mg  liver  tissue,  p=0.04).  eNOS
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activity  was  calculated  following  Ca  chelation  with  EGTA  (total  NOS  activity 
minus Ca2+-independent activity), and also demonstrated significantly lower activity 
in AH patients (23 ± 6.4 vs. 46 ± 13 nmoles citrulline/h/mg liver tissue, p=0.04). The 
total and eNOS contribution to activity of alcoholic cirrhosis patients was slightly 
reduced compared to normal control tissues in which total NOS activity was  133 ± 
53 nmoles citrulline/h/mg liver tissue. Given the limited availability of normal tissue, 
any reliable statistical comparisons were constrained. The HVPG was shown to have 
a  significant  inverse  association  with  hepatic  tissue  eNOS  activity  (R=  -  0.64; 
p=0.01),  (Figure  7.1)  highlighting  the  importance  of reduced  NO  generation  to 
elevated portal pressure.
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Figure  7.1  This  graph  demonstrates  the  significant  inverse  correlation  between 
hepatic venous pressure gradient and hepatic tissue eNOS activity in patients with 
alcoholic liver disease.
7.2.2.3  Immunohistochemistry of  NOS expression
Liver biopsy specimens assessed for tissue NOS activity were also studied for eNOS 
protein  expression.  Immunostaining  of these  tissue  specimens  with  anti  human 
eNOS  demonstrated  eNOS  expression  in  both  alcoholic  hepatitis  and  alcoholic
117cirrhosis  biopsies  (Figure  7.2),  albeit the  method was  semi-quantitative  and thus, 
would not allow a clear difference to be defined between the 2 alcoholic liver disease
groups
Figure  7.2.  The  figure  above  shows  immunostaining  of paraffin-embedded  liver 
biopsy  sections  from  an  alcoholic  hepatitis  patient  (a)  and  an  alcoholic  cirrhosis 
patient  (b)  using  monoclonal  anti-human  eNOS  (positive  staining  denoted by  the 
position of the arrows).
7.2.2.4  mRNA quantification of eNOS
Using  quantitative  RT-PCR,  the  transjugular  liver  tissue  specimens  from  the 
decompensated  alcoholic  cirrhosis  patients  described  above  were  evaluated  for 
eNOS  mRNA  quantification.  eNOS  mRNA  in  the  liver  samples  of inflammatory 
alcoholic  hepatitis  patients  were  significantly  increased  (as  denoted  by  markedly 
lower cycle threshold [Ct] values) compared to cirrhosis alone patients (7.2+0.4 vs. 
9.8±0.4,  p=0.001)  and  specimens  from  resection  margins  of ‘normal’  liver  [n=3] 
(11±1.8,  p=0.02).  No  significant  difference  was  found  between  eNOS  mRNA 
expression  levels  in  cirrhotic  livers  without  inflammation  and  normal  livers 
(p=0.25), as shown in Figure 7.3, below.
118Figure  7.3  There  is  significantly 
higher eNOS  mRNA expression in 
patients  with  cirrhosis  with 
superadded  inflammatory  alcoholic 
hepatitis  (AH+C)  compared  with 
alcoholic  cirrhosis  alone  and 
samples  of  histologically  normal 
livers.  The values  of expression of 
mRNA  are  denoted  as  relative 
expression  1/Cycle  Threshold 
(1/Ct)  for  normal  liver,  alcoholic 
cirrhosis  and  alcoholic  cirrhosis 
with  superimposed  alcoholic 
hepatitis  (AH+C).Thus,  the  greater 
the  expression,  the  smaller  the  Ct 
value
7.3  Studies in  an  acute liver failure  animal  model-  Comparison  of Sham  and 
Galactosamine Liver tissue NOS activity
7.3.1  Introduction
Galactosamine injection into rodent models is a well-established method of evoking 
acute hepatic necrosis, and this is believed to be the consequence of impaired RNA 
and protein synthesis.  (159) Furthermore,  if a further insult by injection of LPS  is 
applied, their follows a marked inflammatory response as evidenced by very high 
serum  aminotransferases  and histological  evidence  of central  necrosis.  (160)  It  is 
also of interest that cultured hepatocytes from these animals show a marked decrease 
in generation of nitric oxide. (161)
Having observed a marked decrease in eNOS activity in patients with alcoholic liver 
disease,  we  wished  to  confirm  these  findings  in  a  model  with  a  known  hepatic 
inflammatory insult, which is independent of the effects of alcohol, and to which a
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119defined  further  challenge  with  LPS  could  discern  the  effects  of  superadded 
inflammation.
7.3.2  Method
Rats were treated with galactosamine injection, with or without subsequent injection 
with LPS, as described in Chapter 2, section 2.3.2.
Hepatic tissue nitric  oxide  synthase  generated nitric  oxide was  assessed using the 
methodology  applied  to  human  liver  tissue  homogenates  as  described  in  section
2.4.3.3 of Chapter 2.
7.3.3 Results
Liver  specimens  acquired  from  5  rats  treated  with  galactosamine  alone,  were 
compared with 5 specimens from rats that had received galactosamine followed by 
LPS after 24 hours. Five sham rats were used as a normal control for inflammatory 
activity.
The  galactosamine treated animals had a reduced total NOS  activity compared to 
sham rats (7.9 ± 0.9 vs. 12.3 ± 2.7 activity/ mg protein, p<0.05). Furthermore, adding 
further  liver  injury  by  the  administration  of LPS  had  the  effect  of an  increased 
incidence  of  early  deterioration  (within  3  hours)  in  the  animal’s  condition, 
warranting termination of the experiment. Under these conditions, there was an even 
greater  reduction  in  NOS  activity:  (4.7  ±  1   vs.  12.3  ±  2.7  activity/  mg  protein; 
p<0.01). Figure 7.4.
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Figure 7.4. Hepatic tissue NOS activity in sham, galactosamine treated rats and rats 
given  LPS  in  addition  to  galactosamine.  The  addition  of LPS  to  galactosamine 
treated animals resulted in a greater than 50% reduction in NOS activity compared to 
sham treated animals.
7.3.4  Discussion
These  results  do  not  show  significant  differences  between  measurement  of nitric 
oxide metabolites in patients with alcoholic hepatitis and those with cirrhosis alone, 
nor when comparing between regional samples (artery compared to hepatic vein). It 
is  important  to  note  that  measurement  of plasma  nitrate/nitrite  in  hepatic  venous 
samples does not simply reflect the local hepatic generation of NO metabolites but 
also any spill-over from the splanchnic territory, through a contribution from portal 
venous  blood.  In  addition,  these  assays  are  considerably  dependent  on  local 
conditions  including  state  of  hypoxia,  underlying  nitrogen  balance  (nutritional 
status) and renal function, which can affect their sensitivities. As such, it was clear 
that a more  ‘reliable’  NOS  activity assay was needed which would reflect hepatic 
tissue NO generation.
121Following  on  from  a  period  of  method  development,  and  using  a  modified 
Strategene assay, it was possible to demonstrate a significant reduction in total and 
eNOS activity in hepatic tissue from alcoholic hepatitis patients compared to those 
with alcoholic cirrhosis alone. These results also demonstrated an inverse correlation 
between  hepatic  venous  pressure  gradient  and  eNOS  activity,  supporting  the 
assertion that a deficient intra-hepatic NO generation is likely to be important in the 
development of increasing intra-hepatic resistance. The human NOS activity findings 
were also mirrored by data generated in the galactosamine rodent model,  showing 
that the liver insult alone decreased NOS activity compared to sham,  and that this 
was further exaggerated by the addition of LPS.  However,  this  further deleterious 
reduction  in  hepatic  eNOS  activity  in  the  context  of hepatic  inflammation  may 
appear secondary to changes impacting directly on enzyme activity, or as result of 
the effect of inflammation acting on eNOS transcription or protein translation.
The above data shows that eNOS mRNA is increased in alcoholic hepatitis patients, 
whilst  protein  expression  assessed  semi-quantitatively  through  immuno- 
histochemistry  shows  no  difference  in protein expression compared with cirrhosis 
alone.  These findings have also been substantiated by studies  in rodent models of 
cirrhotic  bile  duct  ligation  showing  increased  mRNA  and  preserved  protein 
expression in the diseased state.  (158) This implies that the reduced eNOS activity 
noted in patients as well as in the animal model was likely to be due to an effect 
directly  on  enzyme  function,  raising  the  possibility  of  action  of  inhibitors  or 
dysfunctional molecular architecture influencing eNOS activity.
122Chapter 8
Is there evidence for altered levels of asymmetric 
dimethylarginine in liver failure and is this related to 
the severity of inflammation ?
1238.1 Introduction:
The  previous  demonstration  of  a  reduction  in  eNOS  activity  in  patients  with 
alcoholic  hepatitis  in  spite  of an  increased  expression  of eNOS  mRNA  and  the 
apparent preservation of eNOS protein expression, raised the possibility of potential 
inhibitory regulators of NOS activity. From the cardiovascular literature, there has 
been  increasing  importance  attributed  to  the  role  of asymmetric  dimethylarginine 
(ADMA)  as  a  regulator  of  vascular  tone,  and  a  potential  risk  factor  for  the 
development of hypertension, cardiovascular morbidity and poor outcome in patients 
with chronic renal disease. (118,  162-164) Although at the time of the study, there 
was  no  supportive  ADMA-related  physiology  or  pathophysiology  liver  literature 
available, some data has subsequently been published (165-168) The possibility that 
deterioration in vascular function in liver failure, whether this be acute or secondary 
to an acute decompensation of chronic  liver disease,  may be  as  a consequence of 
elevated levels of ADMA, is addressed in the following sections.
8.2 Study of patients with acute liver failure secondary to paracetomol overdose
8.2.1  Background
In patients with acute liver failure (ALF) and fulfilling criteria for poor prognosis, 
rapid  progression  to  multiorgan  failure  is  common  and  without  urgent  liver 
transplantation,  their mortality rates are nearly 90%.  (169) The pathophysiological 
basis of the evolution of multiorgan failure in these patients is not clear. ADMA, an 
endogenous NO synthase (NOS) inhibitor,  is synthesized by the action of protein- 
arginine-methyltransferases  on  arginine  residues  of  nuclear  proteins.  ADMA  is 
released following proteolysis, and most of this free circulating ADMA undergoes 
metabolism  by  dimethylarginine  dimethylaminohydrolases  (DDAH),  an  enzyme 
widely distributed in numerous tissues,  including the liver.  (170) Indeed,  the liver
124has been shown to be an important site of ADMA elimination through the action of 
DDAH,  (167)  and  only  a  small  amount  of free  ADMA  is  excreted  in  the  urine. 
Recent data from patients with sepsis related multi-organ failure  and concomitant 
hepatic  dysfunction  demonstrate  high  circulating  levels  of  ADMA,  which 
independently predict outcome. (171) Interventions such as tight glycaemic control 
associated with improved survival  in  sepsis  related multi-organ  failure have been 
linked with a reduction in circulating levels of ADMA. (172)
Levels of ADMA in patients with liver dysfunction vary widely, and the reasons for 
this are as yet, unclear. (166, 168) Studies from the cardiovascular literature suggest 
that inflammation in cell systems is associated with altered metabolism of ADMA 
through  reduction  in  DDAH  activity.  (119)  The  impact  of raised ADMA  levels 
during inflammation may be further compounded by reduced availability of arginine 
if there is concomitant sepsis. (173)
There  is  an  increasing  body  of literature  supporting  the  view  that  the  systemic 
inflammatory response, be it generation through hepatic inflammation or/and sepsis, 
is  important  in  determining  the  outcome  of ALF  patients.  (174-177)  Given  the 
inflammatory  environment  of ALF,  a  resultant  high  ADMA  may  contribute  to 
vascular dysregulation and organ dysfunction. The aim of this study in patients with 
ALF  was  to  test  the  hypothesis  that  a  cytokine  driven  inflammatory  response  is 
important in modulating ADMA levels.
1258.2.2 Methods
Relatives of patients gave informed written assent in accordance with the 
Declaration of Helsinki of the World Medical Association, 1989, and the study 
approved by the local ethics committee.
8.2.2.1 Patients: Ten patients with severe ALF secondary to paracetamol overdose 
[age  31  (21-46);  7  female  patients]  presenting  or transferred to  Edinburgh  Royal 
Infirmary, were included.  All patients had equivalent severity of liver disease and 
renal  dysfunction  and fulfilled Kings  College criteria  for poor prognosis.  Patients 
were managed using a standardised protocol of care and 8 of the 10 were treated for 
raised  intracranial  pressure.  All  patients  underwent  continuous  veno-venous 
haemofiltration.  Patients were  enrolled  into the  study within the  first 48  hours  of 
admission to the intensive care unit with grade-IV HE, and all required mechanical 
ventilation. The patients were followed until liver transplantation or death.
8.2.2.2 Sampling and Assays: Blood was collected from an artery, and in 4 patients 
who  had  a  transjugular  liver  biopsy,  also  from  the  hepatic  vein.  In  patients 
undergoing  liver transplantation,  arterial blood was  sampled  immediately prior to 
and up to 4 hours post transplantation. In a single patient, arterial blood was sampled 
repeatedly  during  the  different  phases  of the  transplant  operation.  Sampling  was 
performed  in  pre-cooled  heparinized/  EDTA  coated  tubes  (Becton  Dickenson, 
Drogheda,  Ireland).  Routine  haematology,  biochemistry  (including  liver  function 
tests)  and  C-reactive  protein  were  measured  in  all  patients.  Additional  plasma 
samples  were  separated  by  centrifugation  and  plasma  stored  at  -80°  C  for 
subsequent  analysis  of  cytokines,  chemokines  and  ADMA  analysis.  For 
comparative  age  matched  [36  (31-48);  5  female]  healthy  control  ADMA  levels,
126venous blood was drawn from an ante-cubital vein in  10  laboratory  staff with no 
known liver disease or vascular pathology.
8.2.2.3  Cytokines/chemokines:  TNFa,  IL-6  and  IL-lp  were  measured  using 
standard commercial assay kits (BioSource, Nivelles, Belgium) as described in the 
methods in Chapter 2, section 2.4.1. The lower limit of detection was estimated to be 
5pg/ml and the intra-assay coefficient of variation was 4.5-5.5 %.
8.2.2.4 ADMA:  Plasma ADMA was measured using fragmentation  specific  stable 
isotope dilution electrospray mass spectrometry-mass spectrometry, as described in 
detail in Chapter 2, section 2.4.5.
8.2.3  Results
The  clinical  characteristics  and  subsequent  management  in  the  10  studied  ALF 
patients  are  summarised  in  Table  8.1  below.  All  the  patients  fulfilled  the  Kings 
College  Criteria  for  liver  transplantation  and  required  multiple  organ  support, 
including  mechanical  ventilation  for  severe  encephalopathy  and  veno-venous 
haemofiltration for renal failure. Most patients required inotropic support and 8 of 
the patients required treatment with mannitol and fluid removal for the management 
of intracranial  hypertension.  All  patients  received  broad  spectrum  antibiotics  as 
prophylaxis, but despite this measure, culture positive infection was observed in 6 
patients  {Staphylococcus  aureus  in  4,  Klebsiella  pneumonia  in  1   and  Candida 
albicans  septicaemia  in  1).  Two  patients  developed  uncontrolled  intracranial 
hypertension  during  follow  up  that  remained  unresponsive  to  medical  therapy 
(Patients 9 and  10, depicted in Figure 8.4).  Six patients underwent orthotopic liver 
transplantation (OLT) whilst the other 4 died (2 awaiting an organ for transplantation 
and  2  with  contraindications  for  transplantation  on  psychosocial  grounds  and 
remained unlisted for OLT).
127Table 8.1 (Overleaf)
Clinical characteristics and biochemical data for the 10 studied patients. 
Abbreviations:
POD-paracetamol overdose,  *  after resuscitation, KCH-Kings College Hospital.
128Patient
1
Patient
2
Patient
3
Patient
4
Patient
5
Patient
6
Patient
7
Patient
8
Patient
9
Patient
10
Age (years) 31 28 21 28 46 29 32 30 19 33
Sex F F M M F F F F M F
Aetiology of 
acute liver 
failure
POD POD POD POD POD POD POD POD POD POD
Candidate 
for OLT
No No No Yes Yes Yes Yes No Yes Yes
Other
substances
abuse
EtOH EtOH EtOH No No No No No No No
Highest 
recorded 
prothrombin 
time (sec)
112 >100 >120 112 >100 >100 110 >100 >100 121
Alanine
amino
transferase
(IU/L)
10290 8628 4584 7986 2461 10460 7640 8970 7561 8756
Bilirubin
(pmol/L)
82 99 145 41 128 64 51 104 56 65
Time delay 
between poisoning 
and hospital 
admission
52 hr 38 hr 72 hr not
known
64 hr 58 hr 90 hr 72 hr 8 llu- not
known
Creatinine
(pmol/1)
356 231 276 313 221 243 198 171 239 353
*Arterial 
hydrogen ion 
concentration 
(nmol/L)
46 89 46 41 54 56 78 56 59 61
SIRS score 2 2 1 2 3 3 3 4 4 4
CRP (ug/ml) 54 46 67 55 72 76 81 71 102 78
Mechanical
Ventilation
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Continuous
venovenous
haemofiltration
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Inotropic
support
Yes Yes No Yes Yes No Yes Yes Yes Yes
Fulfil KCH 
criteria for OLT
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Liver
Transplantation
No No No Yes No Yes Yes Yes Yes Yes
1298.2.3.1 ADMA levels
ADMA levels on admission of the patients to intensive care were markedly elevated 
compared to levels in normal controls (patients: mean ± SEM:  1.75 ± 0.3  pmol/L, 
controls:  0.37  ±  0.02  pmol/L;  p<0.001).  There  was  no  significant  change  in  the 
levels of ADMA during the course of the illness (ADMA level:  1.8 ± 0.3 pmol/L at 
time of transplantation or death), compared with 1st measurement; p=0.4. In the four 
patients  that  had  hepatic  vein  catheterisation,  no  net-uptake  of  ADMA  was 
detectable across the liver, as shown in Figure 8.1. However, as can be seen from the 
data in the figure, ADMA levels in both artery and hepatic vein from these 4 patients 
were  significantly  higher  than  the  plasma  ADMA  value  noted  in  age  matched 
controls.
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Figure 8.1 The relative concentrations of ADMA are shown for the 4 patients who 
underwent hepatic venous catheterisation. It is evident that there was no net hepatic 
uptake  of ADMA  in  these  patients  with  ALF.  ADMA  levels  in  both  artery  and 
hepatic vein from patients were however, significantly higher than noted in plasma 
values from age matched controls [Control ADMA: 0.37 ± 0.02 pmol/L].
130Within 1  hour post liver transplantation, there was a significant reduction of ADMA 
levels to values which were only marginally higher than control levels (Figure 8.2).
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Figure 8.2 The ADMA concentrations are shown between control groups and in the 
6  ALF  patients  immediately  before  and  1   hour  post  liver  transplantation.  The 
patients  have  significantly  higher  ADMA  levels  compared  to  controls  pre­
transplantation, but these decrease rapidly to control levels within 1  hour post liver 
transplantation.
During the transplant operation, there was a slight increase in ADMA levels during 
the  anhepatic  phase.  However,  as  soon  as  the  liver  was  reperfused  following 
reconnection with the portal vein, there was an immediate and marked reduction in 
ADMA concentration. This effect on reduction in ADMA level with reperfusion was 
further  enhanced  following  return  of  hepatic  artery  perfusion.  ADMA  levels 
continued to progressively decrease until the time of final sampling, which was up to 
4 hours following reperfusion of the transplanted liver, as shown below. (Figure 8.3)
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Figure 8.3 Changes in plasma ADMA concentration pre-, per- and post-operatively 
are  illustrated.  There  is  a  slight  increase  in  ADMA  concentration  during  the 
anhepatic phase of the transplantation procedure, but following reperfusion with the 
portal vein and subsequently the hepatic artery, there is a significant and progressive 
reduction in ADMA, up to 4 hours post-reperfusion.
8.2.3.2  Inflammatory markers
The  pro-inflammatory  cytokine  concentrations  in  the  patients  were  significantly 
higher  than  in  controls,  in  whom  levels  were  below  detection  threshold.  Patient 
cytokine levels were as follows: TNFa: 28.9 ± 5 pg/ml, IL-lp: 32 ± 6 pg/ml and IL- 
6: 93 ± 8 pg/ml. An important observation was that ADMA levels correlated strongly 
with  the  levels  of  the  pro-inflammatory  cytokines:  TNFa  (Figure  8.4:  r=0.76; 
pO.OOl);  IL-lp  (r=0.6;  p<0.01)  and  IL-6  (r=0.56;  p<0.01).  Patients  9  and  10 
depicted  in  the  figure  were  noted  to  have  the  highest  ADMA  and  TNFa 
concentrations,  and  these  two  patients  developed  uncontrollable  intracranial 
hypertension resulting in death in these patients.
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Figure 8.4 There is a significant positive correlation between plasma ADMA levels 
and TNFa concentrations, with r=0.76 and a P value of <0.001. Patients 9 and 10 are 
noted to have the highest ADMA and TNFa concentrations, and these two patients 
developed uncontrollable intracranial hypertension and died.
SIRS  score  (86)  was  variable  between  the  patients,  ranging  from  2  to  4  and  in 
general,  those  with  higher  values  of SIRS  had  higher  ADMA  levels.  CRP  was 
elevated in all patients but there was no direct correlation between CRP values and 
ADMA levels or SIRS score.
1338.3  Does inflammation superimposed on a model of acute liver injury further 
impact on ADMA? -Study of a rodent model of liver failure
8.3.1 Background
The aim of this study was to investigate the effects of liver injury on the levels of 
ADMA  using  a  rat  model  of acute  toxic  injury by  intraperitoneal  galactosamine 
injection, before and 3 hours after LPS injection. Having shown that inflammation in 
the context of liver injury in humans is associated with elevated ADMA, this study 
would also help determine whether inflammation exerts additional effects on levels 
of dimethylarginines in a model with prior acute liver injury.
8.3.2 Methods
The  methods  for  this  experimental  galactosamine  model  are  described  in  section
2.3.2  of Chapter 2.  Plasma aminotransferases in the animals were measured using 
standard kits on a Cobas Integra analyser (Roche Diagnostics Ltd, west Sussex, UK). 
ADMA  measurements  were  performed using  the  method  described  in  Chapter 2, 
section 2.4.5.
8.3.3 Results
8.3.3.1  Biochemistry and inflammatory indices
Galactosamine  animals  [n=5]  had  markedly  elevated  plasma  aminotransferases 
compared with sham animals: [n=5] (ALT:  1707 + 644 vs. 58 ± 11  IU/ml; p<0.05), 
which  were  further  exaggerated  by  injection  of LPS.  There  were  no  significant 
differences between sham and galactosamine treated animals with and without LPS, 
in regard to plasma bilirubin.  However,  the  galactosamine  animals that were  also 
administered LPS did have significantly higher plasma creatinine levels compared to
134sham animals (44 ± 6 vs. 25 ± 1.6 pmol/L; p< 0.05) or sham animals that were also 
administered LPS (26 ±1.1 pmol/L). Previous studies in the literature had confirmed 
the  severity  of  inflammatory  insult,  largely  driven  through  a  TNFa  mediated 
pathway, in these animals, whilst also showing elevated levels of IL-6 and interferon 
y, (178, 179) and thus, these cytokines were not assayed in these animals.
8.3.3.2  Plasma ADMA
ADMA  levels  were  found  to  be  significantly  higher  in  galactosamine  injected 
animals compared to sham (1.1  ± 0.08 vs. 0.7 ± 0.03  pmol/L; p<0.01, Figure 8.5). 
Furthermore, ADMA levels were found to be  even greater after administration of 
LPS to galactosamine pre-treated animals with mean ADMA levels increasing to 1.6 
±0.3  pmol/L, albeit that there was no statistical difference (p= 0.14) compared to 
values amongst the galactosamine alone animals. The likely explanation for lack of 
statistical  differences  between  the  galactosamine  groups  was  the  considerable 
variation  of levels  within  this  small  group  of animals.  Of interest,  the  levels  of 
ADMA  in  sham  rats  subsequently  administered  LPS,  was  no  different  from  that 
measured in sham animals (0.65 ± 0.05 vs. 0.7 ± 0.03 pmol/L, p=0.4).
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Figure  8.5  Galactosamine  treated  rats  show  markedly  elevated  plasma  ADMA 
concentrations, which was further enhanced by LPS injection
8.3.3.3  Plasma SDMA
Given the high creatinine  levels in the galactosamine + LPS  administered animals 
and evidence in the literature for high symmetric dimethylarginine (SDMA) values 
in  renal  dysfunction,  the  levels  of  this  dimethylarginine  homologue  were  also 
measured.  SDMA  levels were  considerably elevated  in the  galactosamine  animals 
also  administered  LPS  compared  to  sham  animals  (0.6  ±  0.08  vs.  0.33  ±  0.02 
pmol/L;  p<  0.01).  There were no  differences  in  SDMA  levels between  sham and 
galactosamine alone animals (p = 1) and sham animals administered LPS (p= 0.8), as 
seen in Figure 8.6
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Figure  8.6  Galactosamine  treated  rats  show  markedly  elevated  plasma  SDMA 
concentrations  only after administration of LPS  21h after galactosamine  injection, 
which appears to mirror the increase in plasma creatinine observed in these animals. 
There were no significant differences in SDMA levels between galactosamine alone 
and sham and sham-LPS treated animals
83.3.4. Plasma arginine levels
Arginine levels were also measured for each of the animal groups, as arginine is the 
main  substrate  for  NOS  for  which  the  dimethylarginines  act  as  competitive 
inhibitors. Plasma arginine was significantly reduced in galactosamine administered 
animals compared with sham (4 ± 1.2 vs.  175 ± 19 pmol/L; p<0.01). The addition of 
LPS to sham animals did result in a decrease in arginine levels to 98 ± 20, p< 0.05 
compared  with  sham  without  LPS.  However,  though  the  addition  of  LPS  to 
galactosamine  animals,  as  might  have  been  anticipated,  did  cause  a  significant 
reduction  in  plasma  arginine  compared to  sham,  (16  ±  11  vs.  175  ±  19  pmol/L; 
p<0.01), this did not significantly alter plasma arginine concentrations further when
137compared  to  the  negligible  levels  of  plasma  arginine  detected  in  animals 
administered galactosamine alone (p=0.4).
8.3.4  Discussion
In the human study, all the patients described manifest established features of acute 
liver  failure  namely,  a  rapid  development  of multi-organ  failure  with  associated 
changes  in  intra-cranial  pressure,  an  increased propensity to  infection  and  a high 
mortality  in patients  that were  not transplanted.  The  patients  had higher baseline 
values  of ADMA  compared  to  age  matched  controls,  in  keeping  with  previous 
observations in acute and chronic liver failure patients, (165,  168) and these levels 
reduced  significantly  in  those  patients  that were  transplanted.  However,  the  most 
important finding of this study was a good correlation between ADMA levels and 
pro-inflammatory  cytokines,  lending  support  to  the  hypothesis  that  inflammation 
may be important in regulating ADMA metabolism.
It has been suggested that the liver is a major site for ADMA metabolism through the 
action of the enzyme DDAH. (167) However, DDAH activity has been shown to be 
modulated by  the  effects  of oxidative  stress  and  inflammation  in  model  systems. 
(119,  180)  Indeed  under  experimental  conditions  of  cytokine  driven  iNOS  up 
regulation,  there  is  a  relative  inactivation  of DDAH  through  S-nitrosylation  of a 
cysteine  residue  (Cys  249),  leading  to  accumulation  of ADMA  with  consequent 
inhibition  of NOS.  (181)  In  patients  following  liver  transplantation,  increases  in 
ADMA have been noted prior to the onset of acute rejection, a process that manifests 
both  biochemically  and  histologically  as  expressing  increased  indices  of 
inflammation. (168) Other data supporting an association between inflammation and 
ADMA  have  been  described  in  chronic  kidney  disease  patients,  in  whom  renal 
transplantation is associated with a significant improvement in brachial artery flow
138mediated dilatation concomitant with  a decrease  in  CRP  and ADMA;  the  kidney 
being also a significant site of DDAH activity. (182)
The data described in this human study also  shows  that the  failing liver loses  its 
ability  to  extract  ADMA  in  contrast  to  normal  livers,  where  significant  hepatic 
dimethylarginine elimination has been demonstrated. (183) It has been hypothesized 
that the “local” accumulation of ADMA may contribute to the development of multi­
organ  failure,  through  its  inhibitory  action  on  NOS  in  regional  circulatory  beds. 
(184)  This  is  a  realistic  possibility  to  explain  the  observation  of low  systemic 
vascular resistance and relative mean arterial pressure, despite high plasma ADMA 
levels, as has been described in decompensated cirrhosis. (165,  166) It is of interest 
that improvement in organ function following transplantation for ALF is associated 
with a rapid decline in ADMA levels, which this study shows to  occur within the 
first hour after transplantation. This may suggest that the new graft is more capable 
of  efficiently  clearing  ADMA  since  DDAH  activity  is  likely  to  be  preserved. 
Additionally,  the  decrease  in  ADMA  may  also  result  from  a  reduction  in  the 
inflammatory  cytokine  burden post  transplantation,  since  removal  of the  necrotic 
failing liver has been shown to be associated with a sharp and sustained reduction in 
inflammatory cytokines. (185)  These results also suggest that hepatic function and 
perfusion contribute to ADMA regulation as evidenced by an initial small increase in 
ADMA  during  the  anhepatic  phase  of the  transplant  operation,  consistent  with 
complete  absence  of hepatic  DDAH  activity.  Following  restoration  of portal  and 
hepatic arterial flow with new graft placement, there was a significant reduction in 
ADMA levels, in an environment of reduced inflammatory drive.
The  study  in rats  administered galactosamine to  induce  acute  liver injury,  and an 
additional group  in which a further inflammatory insult was  super-imposed in the 
form  of LPS  injection,  allowed  one  to  address  whether  inflammatory  injury  in
139addition to that imposed by the primary insult (galactosamine) further elevates levels 
of dimethylarginines.  The results of this  study did suggest an additional  effect on 
elevation of plasma ADMA by administration of LPS to the galactosamine injured 
model.  However,  when  LPS  was  administered  to  sham  animals,  there  was  no 
significant effect on ADMA levels which may suggest that a ‘priming’ effect of the 
initial liver injury may be required to then manifest the effects of inflammation on 
the metabolism or/and  synthesis  of ADMA (Chapter 9).  Furthermore,  it has been 
suggested that there  is  a difference  in the handling  of dimethylarginines between 
humans and rodents. (186) In a study by Nijveldt and co-workers, injection of LPS 
into normal animals was also found not to precipitate a rise in plasma ADMA. (187) 
The  explanation  put  forward  by  the  authors  was  an  increased  uptake  of  the 
dimethylarginines through the y+ cationic co-transporter system, induced by LPS. 
Another interesting observation following the measurement of plasma arginine levels 
in this animal model study, was that administration of LPS to sham animals resulted 
in significantly reduced levels of plasma arginine. This reduction in plasma arginine 
was even more significant after administration of galactosamine suggesting that any 
NOS  dependent  NO  generation  might  be  further  compromised  by  reduced 
availability of the substrate for this enzyme, after the liver insult. This coupled with 
the observed further elevation in ADMA (the competitive inhibitor for arginine) in 
galactosamine rats and galactosamine animals treated with LPS, would be likely to 
exert even greater deleterious effects on vascular modulation in systems that were 
dependent  on  NO  generation  to  maintain  vascular  tone.  (188,  189)  It  is  also 
important to note that local generation of NO serves numerous functions in addition 
to  maintaining  vascular  tone,  including  as  an  anti-oxidant,  (190)  a  modulator  of 
leukocyte adhesion (191) and an inhibitor of platelet aggregation. (192) Thus, high 
levels  of  ADMA  may  compound  inflammatory  injury  in  vascular  beds  during
140progressive liver failure, through lack of NO availability and control of interaction 
with leukocytes and platelets.
Another important finding from this study was evidence for an association between 
inflammation and the development of organ failure, manifest as elevated creatinine 
in  animals  with  galactosamine  +  LPS  compared  to  galactosamine  alone.  These 
animals were also shown to have high SDMA levels. Association between SDMA 
and markers of renal function including creatinine have recently been identified, with 
SDMA proving to be a reliable marker of renal function. (193) Thus this study might 
suggest  that  SDMA,  despite  having  no  significant  hepatic  metabolism  through 
DDAH  (unlike  the requirement by ADMA),  may  also  be  affected by  superadded 
inflammatory injury in liver failure.  The data from this  study leads directly to the 
question of whether elevated dimethylarginines could have a significant biological 
effect  in  the  progression  of liver  failure  to  multi-organ  injury,  and  whether  they 
could act as markers to assess disease progression, or/and in monitoring the effects 
of treatment responses.
141Chapter 9
Does elevated ADMA in liver disease relate to 
increased portal pressure and is it of biological
importance?
1429.1 Background
Patients presenting with severe AH on the background of cirrhosis manifesting as an 
acute  hepatic  decompensation,  can  be  incorporated  within  the  recently  described 
entity known as  acute-on-chronic  liver failure  (ACLF).  (194)  In ACLF, the  acute 
decompensation in liver function occurs  secondary to precipitating events  such as 
sepsis, upper gastrointestinal bleeding, ischemia or an additional superimposed liver 
injury such as AH. ACLF is characterised by multi-organ failure and a high risk of 
mortality, albeit with the potential for reversibility if the patient’s condition can be 
supported adequately. The severity of portal hypertension is likely to be an important 
determinant of mortality in these patients through association with variceal bleeding, 
progressive renal failure and hepatic encephalopathy.'
A potential link between changes in portal blood flow and poor outcome in severe 
AH has been suggested. (131) Furthermore, elevated portal pressures in patients with 
decompensated  cirrhosis  independently  predict  survival,  (195)  although  the 
pathophysiological  mechanisms  behind  these  haemodynamic  disturbances  are 
incompletely  defined.  As  previously  discussed,  factors  modulating  intrahepatic 
resistance,  an important contributor to the  severity of portal hypertension,  include 
liver  ultra  structural  changes  secondary  to  cirrhosis  in  addition  to  variable 
components such as myo-fibroblastic stellate cell activity and vaso-active mediators 
such as NO. (196) Data from animal studies strongly support the notion that in portal 
hypertension, there is a deficiency of intrahepatic NO resulting from a reduction in 
the activity of eNOS. (42, 44) Hepatic NO delivery in these animal models reduces 
the  severity  of portal  hypertension through  a reduction  in  intrahepatic  resistance. 
(197)
143ADMA, an endogenous NOS inhibitor, is thought to be an important contributor to a 
detrimental reduction in NOS activity in disease, including effects on vascular tone. 
(142) The liver is an important site of ADMA metabolism, both in its production due 
to the high rate of protein turnover and more importantly, its elimination through the 
action  of DDAH  (167).  Recent  data  suggests  that  patients  with  decompensated 
cirrhosis have higher ADMA levels compared to compensated disease, and that these 
levels increase further with evolving liver failure (166, 168). Inflammation may also 
increase  ADMA  levels  and  exacerbate  vascular  dysfunction  by  reducing  NOS 
activity, as evidenced by studies in cultured endothelial cells exposed to TNFa or 
oxidised LDL,  showing a reduction in DDAH activity and an increase in ADMA. 
(119)
To explore the potential biological role of the dimethylarginines further during the 
evolution from liver failure to multi-organ failure, a study was conducted to assess 
patients  with chronic  alcoholic  liver disease  in whom there  was  a progression to 
ACLF following a precipitating event, namely AH. The earlier data presented in this 
thesis  had  already  suggested  that  these  patients  have  significant  systemic  and 
regional haemodynamic disturbances associated with evidence of NO dysfunction, 
and  a  high  incidence  of progression  to  organ  dysfunction.  This  study  assessed 
whether: (i) ADMA and SDMA were increased in AH patients compared to patients 
with alcoholic cirrhosis alone; (ii) there was a relationship between hepatic ADMA 
concentrations and severity of portal hypertension and (iii) dimethylarginines could 
be useful as potential markers of clinical outcome in ACLF.
9.2  Methods
Included  consenting  patients  had  evidence  of acute  decompensation  of alcoholic 
liver disease (increasing ascites, pedal oedema or progressive jaundice), clinical and 
radiological evidence of cirrhosis,  and a current history of alcohol abuse.  Patients
144were excluded if they were <18 or >75 years and had evidence of: additional/another 
aetiology  of liver  disease;  severe  cardiac  dysfunction  or  renal  failure  (creatinine 
>150pmol/L);  hepatic/extra-hepatic malignancy;  hepatic  encephalopathy >Grade 2 
(precluding  informed  consent),  and  if  there  was  microbiological  evidence  of 
infection after 72 hours of broad-spectrum antimicrobials.
Patients were studied at transjugular liver biopsy (days 1-3 of admission), performed 
to  assess  severity  of liver dysfunction  in  those  with  ascites  or/and  coagulopathy. 
Classification to patients with decompensated cirrhosis with superadded AH at risk 
of  ACLF  (AH+C+)  was  made  on  subsequent  histological  examination  using 
previously  defined  criteria,(198)  in  addition  to  a  compatible  alcohol  history  and 
clinical  signs  of  decompensated  cirrhosis.  Patients  received  supportive  therapy 
including nutrition and vitamin supplementation according to local guidelines. Local 
treatment protocols were initiated for development of complications including, sepsis 
(antimicrobials  after  culture);  hepatorenal  syndrome  (terlipressin  0.5-2mg 
intravenously, up to six times daily with 60g salt-poor albumin); organ failure (full 
intensive care support including haemofiltration or/and ventilation, as indicated). No 
patient received immuno-modulatory treatment during the study.
9.2.1 Measurements: Haemodynamic studies were performed after overnight fasting 
and a one hour supine resting period, in sedated patients. HVPG  was measured as 
described previously in section. 2.1.2.1 of Chapter 2.
9.2.2 Sampling and Assays: Blood was collected from an artery and hepatic vein in 
pre-cooled  heparinized/  EDTA  coated  tubes.  Routine  haematology,  liver 
biochemistry  and  CRP  were  measured.  Plasma  creatinine  was  assessed  by  mass 
spectrometry. (85) Additional plasma was separated by centrifugation and stored at - 
80° C  for subsequent analysis of cytokines and ADMA.  Hepatic tissue was either
145formalin-fixed or snap-frozen in liquid nitrogen and stored at -80°C for subsequent 
assessment of ADMA concentration and PRMT 1   and DDAH II protein estimation. 
Blood samples drawn from a “control” group of 12 healthy volunteers (9 male), with 
no  history  of alcohol  excess  nor any past medical history,  were used to  evaluate 
“normal” ranges for ADMA and SDMA.
9.2.2.1 Cytokines/chemokines:  TNFa,  IL-6, IL-8 and soluble TNF receptors I and 
II (TNF-R1, TNF-R2) were measured using standard commercial assays (BioSource, 
Nivelles,  Belgium)  as  described  in  Chapter  2,  section  2.4.1.  The  lower  limit  of 
detection was 5pg/ml and the intra-assay coefficient of variation ranged from 4.5 % 
to 5.5%.
9.2.2.2 ADMA  levels:  Plasma ADMA was  measured using  fragmentation  specific 
stable  isotope  dilution  electrospray  tandem  mass  spectrometry,  as  described  in 
section 2.4.5 of the methods chapter. Within assay imprecision for ADMA was 2.1% 
at  a  concentration  of 0.37jimol/l.  Inter  assay  imprecision  for  ADMA  was  7.4%, 
5.8%, and 5.1% at concentrations of 0.39, 1.15, and 3.96 pmol/1, respectively.
9.2.23 DDAH and PRMT Western blot analysis: Detailed methodology for Western 
blot assessment  of DDAH  II  and  PRMT  1   protein  expression  is  provided  in  the 
Chapter 2, section 2.4.6.
1469.3 Results
9.3,1  Patient clinical chemistry and inflammatory cytokine profile:
In this study, 52 patients were included with a mean Pugh score (87) for the group of 
10±0.3, and an elevated mean HVPG of 19±1  mmHg. The patients were the same 
cohort  previously  studied  in  detail  in  relation  to  characterisation  of  their 
inflammatory status, as described in Chapter 3. Twelve patients were excluded due 
to: viral hepatitis (7), severe renal dysfunction (3), lack of histological evidence of 
cirrhosis (1), and overwhelming sepsis in 1  patient. Using the histological criteria for 
defining  alcoholic  hepatitis  listed  in the  methods  above,  the  52  included patients 
were then divided into those with alcoholic hepatitis and cirrhosis [AH+C+] (n=27), 
and those  with  alcoholic  cirrhosis  alone  [AH-C+]  (n=25).  Table  9.1.  Severity  of 
necro-inflammation in AH+C+ biopsies was graded by applying a scoring  system 
similar to  that  suggested  for non-alcoholic  steatohepatitis,  (107)  with  all  patients 
having moderate-severe grading agreed upon by 2 independent histopathologists. In 
addition  to  histological  criteria,  all  AH+C+  patients  had  acute  severe  alcoholic 
hepatitis as evidenced by a mean discriminant function score of 46±6, and reflected 
in the significantly elevated plasma bilirubin levels and prothrombin times compared 
to AH-C+ patients, Table 9.1. Mean serum creatinine was within normal reference 
ranges for both groups, albeit mean values were higher in AH+C+ patients, p=0.01. 
Twenty  AH+C+  patients  had  moderate/severe  ascites  compared  with  ten  AH-C+ 
patients;  p=0.008.  Twelve  AH+C+  patients  had  grade  2  or  more  hepatic 
encephalopathy compared to four AH-C+ patients; p=0.02.
As has been outlined above in Chapter 3 and can be seen from Table 9.1  from the 
baseline  characteristics,  in  this  cohort  of patients  the  inflammatory  indices  were 
significantly elevated in AH+C+ patients  and they had  significantly higher portal
147pressures. Data for plasma IL-8 and IL-10 are not described despite being measured 
owing to marked variability in measurable levels which were largely below the assay 
detection limit in this cohort of patients.
9. 3.2 Patient Outcome: There were thirteen in-patient deaths in the fifty-two studied 
patients, twelve with AH+C+ and one with only cirrhosis.  Of the AH+C+ deaths, 
eight  developed  renal  failure,  four  of whom  also  had  concomitant  sepsis.  Two 
patients  died  from  uncontrolled  GI  bleeding,  whilst  two  other  patients  failed  to 
recover from spontaneous bacterial peritonitis with gram negative organisms, with 
development  of  multi-organ  failure.  (Table  9.2).  Amongst  the  fifteen  AH+C+ 
survivors successfully discharged from hospital within 28 days, six had evidence of 
infection  during  their  admission,  one  with  renal  failure  responded  to  supportive 
therapy and two had episodes of controlled variceal bleeding. AH+C+ patients who 
died had no significant difference in discriminant function (p=0.3), Pugh (p=0.2) or 
MELD  (p=0.6)  scores  compared with  surviving  AH+C+ patients.  In  the  cirrhotic 
only  (AH-C+)  group,  one  in-patient  died  from  renal  failure  despite  supportive 
therapy. Of the remaining 24 AH-C+ patients successfully discharged from hospital, 
five had an episode of infection during their admission, and there was  1   controlled 
variceal bleed. AH-C+ patients had significantly lower Pugh (p<0.001) and MELD 
(pO.OOl) scores than AH+C+ survivors (n=15).
148Table  9.1:  Baseline  clinical  chemistry  and  inflammatory  characteristics  for  all 
studied patients and their sub-classification into patients with cirrhosis and alcoholic 
hepatitis (AH+C+) and cirrhosis with no inflammation (AH-C+)
All Patients 
(n= 52)
Alcoholic Hepatitis 
(AH+C+, n=27)
Cirrhosis Only 
(AH- C+, n=25)
Age (years) 50 [32-69] 47 [32-69] ns 51 [38-67]
Bilirubin
[3-17]
(pmol/L) 169 + 26 249 ± 39 *** 56 ± 13
Prothrombin (secs)
no-121
15.6 ± 0.7 18 ± 1 ** 13.4 ±0.6
ALT
T8-501
(U/L) 55 + 9 60 ± 15 ns 47 ±9
Creatinine
T66-1121
pmol/L) 76.5 ± 9.7 92.5 ± 11 * 59.8 ± 5
Pugh Score 10 + 0.3 11.5 ±0.3 *** 8.4 ± 0.4
MELD Score 7.4 ± 1.7 15 ±2.3 *** 0.26 ± 1.4
HVPG
[<5]
(mmHg) 19 ± 1 22 ± 1.9 ** 15.5 ± 1.6
CRP
[0-5]
(mg/L) 33.5 ±6.5 50 ±7 *** 17 ± 3
WBC
[3-10]
(x109/L) 10.2+1.4 13.7 ± 1.5 *** 6.4 ± 0.5
SIRS
[0]
0.9 + 0.2 1.6 ±0.4 *** 0.3 ±0.1
TNFa
[0-5]
(pg/ml) 21 ±11 46 ±  20** 4 ±0.5
TNFR1
[0-1.6]
(ng/ml) 726 ± 76 885 ± 93 ** 455 ± 74
TNFR2
[0-3.51
(ng/ml) 1237± 141 1798± 128 *** 759± 136
IL-6
[0-5]
(pg/ml) 29.5 ± 9.6 55.7 ± 19 * 9.3 ±2
*  p<0.01;**  p<0.001;*** p<0.0001;ns- no significant difference
[Normal values]: Reference ranges for normal values in our laboratory
SIRS= Systemic Inflammatory Response Scores (temperature >38°C; a heart rate > 
90 beats/minute;  tachypnoea >20 breaths/minute;  white blood cell count of >12 x 
109/L  or  <  4  x  109/L  or  the  presence  of more  than  10%  immature  neutrophils) 
(86)HVPG= Hepatic Venous Pressure Gradient
149Table 9.2 Outcome characteristics amongst studied patients
Alcoholic 
hepatitis Deaths 
(n=12)
Alcoholic
hepatitis
Discharged
(n=15)
Cirrhosis Only
Discharged
(n=24)
Renal Failure 8 1 0
Gastrointestinal
Bleed
2 2 1
Infection 6 (2 with SBP) 6 5
Pugh score 11.9+  0.5 11.1 ±  0.4 8.4+  0.4  ***
MELD 16.2+  3.9 14.2+  3.1 0.7+  1.7  ***
Discriminant
Function
53+  13 41+6 -
*** p<0.001 :Alcoholic cirrhosis compared with Alcoholic hepatitis patients 
discharged from hospital
9 3.3 ADM  A: Mean plasma ADMA levels were higher in the 52 patients compared 
to  12  healthy  controls  [age:  38(31-55);  9  male]:  0.59±0.03  vs.  0.37+0.01 pmol/L; 
p<0.001.  Furthermore,  AH+C+  patients  had  significantly  higher  ADMA  values 
compared to  the  AH-C+  group:  0.69±0.04  vs.  0.49±0.02pmol/L;  p<0.001.  Figure 
9.1a. Hepatic tissue ADMA levels were also considerably higher in AH+C+ patients 
compared  to  AH-C+  (97±23  vs.  27±13pmol/mg  protein,  P<0.05),  and  correlated 
with  portal  pressure,  r  =0.61,  p<0.05.  Plasma  ADMA  levels  were  significantly 
greater in patients that died during their admission [n=13] compared with survivors 
[n=39] (0.77±0.08 vs. 0.53±0.02|iimol/L; p<0.001); Figure 9.1b. Further sub-analysis 
revealed  significantly  greater ADMA  levels  between  discharged  AH+C+  patients 
and  non-inflamed  AH-C+  patients  (0.62+0.04  vs.  0.49+0.02  pmol/L,  p<0.01). 
Furthermore, ADMA levels were higher in AH+C+ patients that died compared to 
AH+C+ survivors, P<0.05. Figure 9.1c.
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Figure 9.1 panel (a) shows that patients with cirrhosis and superadded alcoholic hepatitis 
(AH+C+) had significantly higher ADMA levels (p<0.001) compared to patients with 
cirrhosis alone (AH- C+). All cirrhotic patients had significantly higher ADMA levels 
compared with normal volunteers (p<0.001). (b) In-patient survivors with decompensated 
cirrhosis  [n=39]  had  significantly  lower  ADMA  levels  than  those  that  died  [n=13]; 
p<0.001. (c) Surviving alcoholic hepatitis patients (AH+C+) had greater ADMA levels 
compared with the cirrhosis alone (AH- C+) survivors  [n=24]; p<0.01. ADMA levels 
were significantly higher in AH+C+ patients that died [n=12]  compared with AH+C+ 
survivors; p<0.05)
1519.3.4  SDMA: Mean plasma SDMA levels for the 52 patients although higher, were 
not significantly greater than in controls:  0.77±0.08 vs.  0.46±0.01pmol/L,  p=0.08. 
However, levels of SDMA were significantly higher in AH+C+ patients compared to 
AH-C+  (1.03±0.1  vs.  0.48±0.03pmol/L;  p<0.001).  SDMA  levels  amongst AH-C+ 
patients were similar to healthy volunteers (p=0.67) [Figure 9.2a]. Levels of SDMA 
were significantly higher in patients that died compared with all survivors, (1.6±0.35 
vs.  0.6±0.05pmol/L;  p<0.001)  [Figure  9.2b].  Further  sub-analysis  of  AH+C+ 
patients demonstrated a significantly greater SDMA in patients that died compared 
with  AH+C+  survivors,  in  whom  the  mean  SDMA  was  0.8±0.1pmol/L;  p<0.05 
[Figure 9.2c]. It is noteworthy that there was also a significant difference in SDMA 
between AH+C+ survivors and non-inflamed AH-C+ survivors in whom the mean 
SDMA level was 0.48±0.03; p<0.01.
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Figure 9.2a Patients with alcoholic hepatitis (AH+C+) had significantly higher 
SDMA levels (p<0.001) compared to cirrhosis alone (AH- C+) patients. There 
were no differences in SDMA levels between AH- C+ patients and healthy 
volunteers.
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Figure 9.2b demonstrates that in-patient survivors with decompensated cirrhosis 
[n=39] had significantly lower SDMA levels than those that died [n=13]; p<0.001
p<0.001
p<0.05
Figure 9.2c demonstrates the greater plasma SDMA levels in alcoholic hepatitis 
(AH+C+) patients that died [n=12] compared to those that survived [n=15]; 
p<0.01. AH+C+ survivors also had higher SDMA values compared with AH-C+ 
(non-inflammatory cirrhotic) survivors (n=24); p<0.01.
1539.3.5  Predictors of  Survival'. Baseline measurements (day 0-3) of ADMA, SDMA, 
Pugh Score, calculated MELD and DF, were used to compare the predictive utility of 
these measures in determining in-patient survival, by area under the curve (AUC) for 
receiver operator curves (ROC). The AUC for each predictive measure for all 
patients, and a separate analysis for AH+C+ patients, is shown in the Table 9.3 
below.
Table 9.3 Comparison of prognostic scores with dimethylarginine levels to predict 
outcome in all studied alcoholic cirrhosis patients and in a subgroup with alcoholic 
hepatitis using receiver operator curves
All Patients Alcoholic Hepatitis (AH±C±)
Scoring system/
Dimethylarginine
level
Cut-off value 
(%Sensitivity; 
Specificity )
AUROC Cut-off value
(%Sensitivity;
Specificity)
AU ROC
Pugh 10.5 (63; 75) 0.81 ±0.07 11.5 (60; 64) 0.65 ±0.11
DF 36  (76; 73) 0.78 ± 0.08 39  (53; 70) 0.55 ±0.13
MELD 10.3  (74; 73) 0.76 ± 0.08 18.9 (60; 40) 0.53 ±0.12
ADMA 0.57 (74; 77) 0.83 ± 0.06 0.65 (73; 75) 0.74 ± 0.09
SDMA 0.7  (77; 85) 0.87 ± 0.06 0.89 (73; 67) 0.82 ± 0.08
DAS 1.23 (77; 92) 0.9  ±0.05 1.52 (73; 83) 0.85 ± 0.07
This table clearly shows that when comparing sensitivities and specificities for each 
scoring  system  and  their  related  AUROC,  ADMA,  SDMA  and  their  summated 
score- DAS  (see below) perform as well  if not better then other currently applied 
scores in AH (MELD,DF, and Pugh).
Also of note, when ADMA was compared with SDMA in AH+C+ patients as shown 
in Figure 9.3, at the cut-off value for SDMA of 0.9 pmol/L derived from its ROC, all 
deaths predicted by using an ADMA cut-off 0.65  pmol/L were not accounted for 
(denoted  by  the  shaded  area),  suggesting  a  potential  benefit  of  utilizing  the 
discriminatory benefit of both these dimethylarginines.
1542i
▲ ■   AH+C+ Survivors 
a  AH+C+ Non-Survivors
A
A
A  *
0  1  2  3  4  5  6  7
SDMA (pmol/L)
Figure 9.3  A plot  of ADMA vs.  SDMA  in alcoholic  hepatitis  (AH+C+)  patients 
demonstrates  that  at  the  cut-off value  for  SDMA  of  0.9  pmol/L  derived  from 
receiver operator curves, a number of deaths as predicted by ADMA using a cut-off 
0.65 pmol/L, are not accounted for as denoted by the shaded area.
A simple mathematical summation of ADMA and SDMA was devised to obtain a 
combined  ‘dimethylarginine score’-DAS  [DAS=ADMA+SDMA]  in order to see if 
this would improve the predictive utility of an individual dimethylarginine level in 
determining  survival.  The  calculated  DAS  was  significantly  higher  in  AH+C+ 
patients compared with AH-C+ (1.9±0.2 vs.  0.96±0.04; p<0.001) Furthermore, the 
DAS value was significantly higher in non-surviving AH+C+ patients compared to 
survivors,  2.5±0.38  vs.  1.4±0.16;  p<0.01.  It  was  interesting  to  note  that  DAS 
improved the specificity, whilst maintaining a high sensitivity of predicting outcome 
in all patients, and appeared at least as good in determining outcome as Pugh, DF or 
MELD scores, Table 9.3.
Repeat  dimethylarginine  measurements  were  made  from  blood  taken  during 
admission in the 12 AH+C+ patients that died compared to values from 18 surviving 
patients, including 6 AH+C+ patients. In patients that died, there was a significant
155percentage increase in DAS (p<0.01), whilst a small decrease in DAS was noted in 
patients who survived and went on to be discharged from hospital, Figure 9.4.
Survivors  Non-survivors
Figure  9.4  The  percentage  increase  in  DAS  [ADMA+SDMA]  value  in  non­
surviving alcoholic hepatitis patients [n=12] compared to values from  18 surviving 
patients, including 6 alcoholic hepatitis patients, in whom there was a net decrease in 
DAS value (p<0.01).
A Kaplan-Meier plot for all studied patients (Figure 9.5) demonstrates a significantly 
decreased in-hospital survival in patients with an admission DAS value >1.23; log 
rank of p<0.0005. Thus patients with a higher DAS score have a significantly 
increased risk of in-hospital mortality.
156Kaplan-Meier analysis for 
all cirrhotic patients
1.0-
0 .8-
DAS
    <  1.23
    >1.23
C O
0.4-
log rank p<0.0005 0 .2-
0 .0-
0 100 200 300
Days
Figure 9.5. A Kaplan-Meier survival analysis comparing in-hospital mortality in all 
studied alcoholic cirrhotic patients, based on admission DAS value < 1.23 or > 1.23 
(p<0.0005).  A  higher  DAS  score  significantly  increases  the  risk  of  in-hospital 
mortality.
Furthermore, a DAS cut-off of 1.52 appeared to be a more useful predictor than all 
other  scoring  systems  when  evaluating  survival  in  AH+C+  patients,  as  shown  in 
Figure 9.6. From closer inspection of the area under the curve of the ROC curves for 
DF, Child-Pugh, MELD and DAS, shown below, it is evident that in the subgroup of 
AH+ C+ patients, the DAS value provides the most reliable predictor of mortality 
(AUROC =0.84), using a DAS cut-off of 1.52.  This provides a sensitivity of 73% 
and a specificity of 83%.
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Figure 9.6. The Receiver Operator Curves (ROC) curves for discriminant function 
(DF),  Child-Pugh, MELD and Dimethylarginine  Score  (DAS)  are  shown with the 
area under the curve (AUROC) listed.  It is evident from these  figures that in this 
group  of alcoholic  hepatitis  patients,  the  DAS  value  provides  the  most  reliable 
predictor  of  mortality  (AUROC  =0.84),  using  a  DAS  cut-off  of  1.52;  with  a 
sensitivity of 73% and a specificity of 83%
9.3.6  DDAH  II  and  PRMT-1  expression:  Representative  Western  blots  for 
dimethylarginine-dimethylaminohydrolase-II  (DDAH-II)  and  protein-arginine- 
methyltransferase-1  (PRMT-1)  expression  in  the  studied  AH+C+  and  AH-C+ 
patients, together with their corresponding a-Tubulin protein blots, to control for gel 
loading are shown in Figure 9.7. A quantification of DDAH II and PRMT-1 densities 
on these Western blots of all assessed patient biopsies is represented by the column 
bars having been corrected for a-Tubulin expression. PRMT-1  data for 7 patients is 
shown  due  to  limited  homogenate  extracted  from  1   AH-C+  patient  that  was 
insufficient  to  allow  for  adequate  gel  loading.  Hepatic  DDAH  II  expression  was
158significantly lower (p<0.01) in the 4 AH+C+ patients in whom it was measured, as 
compared  with  4  AH-C+  patients.  In  contrast,  expression  of  PRMT-1  was 
significantly increased in AH+C+ patient livers’ (p<0.01).
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Figure 9.7 Quantification of DDAH II and PRMT-1 densities on Western blots of 
all  assessed  patient  biopsies  is  represented  in  the  column  bars  for  alcoholic 
hepatitis (AH+C+) and cirrhosis alone (AH-C+) patients, having been corrected 
for  a-Tubulin  expression.  AH+C+  patients  have  significantly  lower  DDAH  II 
expression (p<0.01) and significantly higher PRMT-1 (p<0.01) expression
1599.4 Discussion
This  study  confirms  that  patients  with  alcoholic  cirrhosis  with  superimposed 
histologically  proven  inflammatory  alcoholic  hepatitis  (AH+C+)  and  high  pro- 
inflammatory  cytokines  and  SIRS  components,  have  higher  portal  pressures 
compared  to  patients  with  only  cirrhosis  (AH-C+).  This  study  extends  previous 
observations of increased free circulating ADMA in decompensated cirrhosis (165) 
with the new additional finding of increased plasma and hepatic tissue ADMA in 
inflammatory AH+C+ patients compared to AH-C+, and demonstrates an association 
between increased ADMA and elevated portal pressure. Furthermore, these results 
demonstrate  significantly  lower  ADMA  and  SDMA  levels  in  survivors  of 
decompensated  cirrhosis,  with  SDMA  also  discriminating  between  survivors  and 
non-survivors in the sub-group of inflammatory AH+C+ patients, in whom death is 
associated primarily with progression to renal failure (development of ACLF). When 
current validated scoring systems  (Child-Pugh, DF  and MELD) used to determine 
in-patient mortality in alcoholic hepatitis or following intervention (terlipressin and 
albumin  for  deteriorating  renal  function  or  haemofiltration)  were  applied  to  the 
described cohort of patients, their predictive utility was limited. It is possible that the 
limited numbers of patients studied may have reduced the predictive utility of these 
scores compared with the published literature. However, it is important to note that 
the MELD score is dependant on measured creatinine and INR both of which will 
vary  between  laboratories  and  are  subject  to  significant  error  in  this  group  of 
patients. This is reflected by the variability in the cut-off values for MELD described 
in  the  literature,  for  predicting  outcome  in  AH.  (199-201).  Similarly,  DF  has  a 
limited range of predictive use and it is likely that the clinical variables associated 
with Pugh score in our patients, who were studied by the same observers were more
160internally consistent. Not withstanding this, circulating levels of ADMA, SDMA or 
their sum DAS, demonstrated a greater utility in predicting those patients that were 
at risk of dying.
There  is  general  agreement  in  the  literature  that  increased  intrahepatic 
resistance in cirrhosis is contributed to by reduced local NO availability, secondary 
to decreased hepatic eNOS activity. (42, 44)  ADMA is a competitive, endogenous 
inhibitor of eNOS produced during proteolysis, (142) and it has been suggested that 
the liver is an important site of ADMA metabolism. (167) Elevated ADMA has been 
shown to be associated with endothelial dysfunction in numerous conditions (202), 
and its increased urinary excretion described in patients with chronic active hepatitis. 
(165)  Moreover,  ADMA  has  been  found  to  be  elevated  in  end-stage  cirrhotics 
compared to healthy controls  and  in liver failure patients prior to  orthotopic  liver 
transplantation,  the  levels  falling  significantly,  post  transplantation  (168)  These 
studies imply that with progression of liver disease and portal hypertension ADMA 
rises,  and  following  liver  transplantation,  there  is  a  rapid  decline  suggesting  a 
correction  of  the  derangement  in  ADMA  metabolism  associated  with  reduced 
inflammatory indices. (185) This study demonstrates significantly increased plasma 
and hepatic tissue levels of ADMA in AH+C+ patients compared to AH-C+ patients. 
The  effects  of inflammation  appear  to  be  above  and  beyond  those  expected  for 
decompensated  alcoholic  cirrhosis  alone  (166).  These  data  would  support  the 
hypothesis that following an increase in hepatic inflammatory mediators, there is an 
alteration in hepatic ADMA metabolism or/and generation.
ADMA homeostasis is maintained by its metabolism through the enzyme DDAH, 
which is particularly abundant in the liver and kidney.  (203)  DDAH  activity has 
been shown to be reduced by inflammatory stimuli such as TNFa.(119) It follows
161that when levels of TNFa are markedly increased, as seen in AH+C+ patients, one 
might expect higher liver ADMA levels through impaired metabolism,  and this in 
turn may decrease local hepatic NOS activity. This assertion is supported in part by 
the  observation  of increased hepatic  tissue  ADMA  coupled  with  decreased  liver 
DDAH II protein expression (the most abundant DDAH subtype found in the liver) 
in AH+C+ patients in this study, in whom HVPG was significantly increased.
An  alternative  explanation  for  the  findings  in  this  study  of increased  ADMA  in 
AH+C+  patients  might  be  through  increased  ADMA  production.  ADMA  is 
generated by the action of PRMTs, a family of enzymes that methylate the side-chain 
nitrogen of arginine within proteins(204) with the subsequent catabolic release of the 
resulting methylated arginine residues. Several types of PRMT have been described 
with Type I being responsible for the generation of NG-monomethyl-L-arginine (L- 
NMMA) and ADMA, and Type II, L-NMMA and SDMA. Upon proteolysis, which 
is  increased  in  hyper  metabolic  states  such  as  cirrhosis  and  inflammation,  (205) 
significant amounts of ADMA are generated (206). The rate of ADMA and SDMA 
generation is thus likely to be dependent on the presence and activity of PRMTs and 
the  rate  of protein  breakdown.  In  keeping  with  this,  this  study  demonstrates  an 
increase in expression of PRMT-1  in AH+C+ patients in whom there is increased 
inflammation,  compared to AH-  C+ patients.  This  finding  is  further supported by 
data from studies on human endothelial cells exposed to oxidised LDL-cholesterol, 
in which up-regulated ADMA release is associated with increased PRMT expression 
(118).
Although this study was neither powered nor specifically designed to look at the role 
of the dimethylarginines in determining survival, one of the most important findings 
to emerge from the study was the association of elevated ADMA and SDMA levels
162with in-hospital mortality for the whole group of alcoholic cirrhotic patients (25%) 
and specifically,  in AH+C+ patients,  in whom the mortality was 44%,  in keeping 
with previous published series. (207) Current outcome predictive scores in alcoholic 
hepatitis  focus  on  biochemical  (bilirubin,  prothrombin  time  and  creatinine)  and 
clinical  variables  (degree  of  ascites  and  grade  of  encephalopathy)  but  do  not 
specifically  factor  in  the  changes  in  pro-inflammatory  state  or  haemodynamic 
disturbances associated with this condition. (89, 200)
This study has identified the potential use of dimethylarginine levels as measurable 
biological markers (with minimal inter-assay variability), that may predict early in­
patient mortality with a better sensitivity (73%) and specificity (83%) than currently 
used prognostic  scores.  The  data presented here  also  suggests  a  further temporal 
increase in dimethylarginine levels in those with poor outcome but firm conclusions 
on  the  discriminatory  value  of repeated  measurements  are  limited  by  the  small 
number of patients that have been studied.  It is possible that ADMA levels partly 
reflect the inflammatory state in AH in which vascular dysfunction occurs, including 
within  the  renal  circulatory  bed,  heralding  the  onset  of organ  failure,  and  thus 
progression  to  ACLF.  Increasing  ADMA  has  been  associated  with  a  decreased 
effective  renal  plasma  flow  and  increased  renovascular  resistance,  (208)  which 
would lead to increased retention of SDMA. Indeed, SDMA has recently been shown 
to be elevated in hepatorenal syndrome patients compared to patients with cirrhosis 
without renal failure. (209) A combined dimethylarginine (DAS) score thus factors 
in both inflammation and incipient renal dysfunction (the main cause of mortality in 
the  AH+C+  patient  cohort  described  in  this  study)  and  might  explain  the  better 
predictive utility of the DAS score identified in this study.
163Chapter 10
Other regulators that may account  for a decrease in 
hepatic eNOS activity
16410.1 Introduction
There is an increasing body of literature in cirrhotic animals suggesting a reduction 
in the activity of hepatic endothelial nitric oxide synthase (eNOS), (42, 44) and this 
is  despite  apparently  normal  hepatic  eNOS  protein  expression.(43)  The  resultant 
reduction  in  hepatic  nitric  oxide  (NO)  generation  contributes  to  increased 
intrahepatic  resistance  and  elevated  portal  pressure.  Indeed,  a  reduction  in 
intrahepatic  resistance,  and  thereby  severity  of portal  hypertension,  through  the 
delivery  of NO  to  the  liver  in  model  systems,  either  pharmacologically,  (59)  or 
through gene transfer techniques,(57, 58) highlights the importance of hepatic NO 
generation in the pathophysiology of portal hypertension.
Studies  in relation to  decreased hepatic  eNOS  activity have,  to  date,  focussed on 
inhibitors  of eNOS  activity  such as  caveolin-l(43,  210)  and ADMA  (162),  or on 
processes  affecting  the  post-translational  modification  of eNOS.  (58)  Recently,  a 
more complex subcellular regulation of NO generation has been described through 
interaction of eNOS with specific proteins involved with trafficking within the cell. 
One such protein, eNOS traffic-inducing protein (NOSTRIN), was first identified by 
Prof Muller-Esterl’s lab in a yeast two-hybrid approach.  (56)  Subsequent work by 
this group has  demonstrated an interaction and co-localisation between eNOS  and 
NOSTRIN in cultured vascular endothelial cells and eNOS-expressing cell lines, and 
that NOSTRIN over-expression results in a redistribution of eNOS into intracellular 
vesicle-like  structures  whilst  significantly  inhibiting  NO  release.  (56)  Similarly, 
other eNOS interacting proteins such as NOSIP may be instrumental in displacing 
eNOS  from  plasma  membrane  caveolae  with  a  consequent  inhibition  of  NO 
generation. (55)
165The principal  aim of this  study was to  determine whether the  greater severity  of 
portal hypertension previously described in this thesis in patients with inflammatory 
alcoholic hepatitis  compared to patients with cirrhosis  alone,  was  associated with 
differences in gene expression for the NOS-regulatory proteins caveolin-1, NOSIP, 
and NOSTRIN.
10.2  Methods
10.2.1  Patients:  Patients  were  included  in  this  study  if  they  had  a  clearly
documented history of alcohol consumption of greater than >80 g of alcohol/day for 
men and >60 g/day for women up until the time of admission. Admission to hospital 
was  precipitated  by  decompensation,  defined  by  the  development  of progressive 
jaundice,  derangement  of  coagulation  and  liver  function  tests,  or/and  the 
development  or worsening  of ascites.  All  eligible  patients underwent transjugular 
liver biopsy and portal pressure assessment as clinically indicated, and a sample of 
liver  biopsy  tissue  was  snap  frozen  in  liquid  nitrogen  for  further  evaluation,  in 
accordance with given informed consent and approval by the local ethics committee. 
Patients were excluded if they were <18 or >75 years and had any of the following: 
renal  dysfunction  (plasma  creatinine  >130  pmol/L),  severe  cardiovascular  or 
cerebrovascular  disease,  active  or  latent  infection,  hepatic  or  extra-hepatic 
malignancy  and treatment with vasoactive  agents  or  corticosteroid therapy  in the 
prior month.
Liver  tissue  was  assessed  by  an  independent  histopathologist  for  evidence  of 
alcoholic cirrhosis, and further criteria applied (balloon degeneration of hepatocytes; 
Mallory bodies; neutrophilic infiltrates and apoptotic acidophilic bodies) to define a 
sub-group of patients with alcoholic hepatitis.  (198) Liver tissue was also obtained
166from 6 additional patients undergoing hepatic resection for metastatic disease of a 
colonic  primary  lesion,  who  had no  significant history  of alcohol  intake,  and no 
evidence  of  liver  disease  or  derangement  of  liver  function  tests.  Histological 
inclusion criteria of the 6 selected specimens included a clear resection margin with 
no evidence of cellular atypia and no evidence of cirrhosis.
10.2.2 Hepatic portal venous pressure  measurements:  The  methods  applied  for 
assessment of portal pressure are detailed in section 2.1.2.1 of Chapter 2.
10.2.3 mRNA  and protein  expression  assays:  The  methodology for Quantitative 
real-time PCR and Immunohistochemistry and Western blotting are detailed in the 
Methods in Chapter 2, sections: 2.4.7.1-3.
10.2.4  Cell  culture  and transfection:  Human  hepatocellular  carcinoma  (Hep3B) 
cells were cultured in DMEM/10% FCS with or without 1   pM retinoic acid for up to 
6 days. Chinese hamster ovary (CHO) cells stably expressing eNOS (CHO-eNOS) 
were  cultured  in  DMEM/10%  FCS  containing  200nM  methotrexate.  Transient 
transfections  with  pcDNA-3.1B-NOSTRINa  and  pcDNA-3.1 B-NOSTRINp  were 
performed  with  Nanofectin  (PAA,  Coelbe,  Germany)  according  to  the 
manufacturer’s instructions.  Cells on coverslips were fixed in methanol 20 h post­
transfection,  treated  with  monoclonal  anti-NOSTRIN,  and  analysed  by  confocal 
laser-scanning microscopy.
10.2.5 Co-immunoprecipitation: Human liver was frozen in liquid nitrogen, ground 
and lysed in OG buffer (50 mM Tris HC1, pH 7.4; 2 mM EDTA;  1  mM EGTA; 50 
mM NaF;  150 mM NaCl;  1  mM Na3V04;  lOmM Na4P20 7;  1  mM DTT; 60 mM N- 
octylglycoside;  protease  inhibitor cocktail  (Roche  Diagnostics  GmbH,  Mannheim, 
Germany)).  Co-immunoprecipitation  was  performed  using  polyclonal  rabbit  anti- 
NOSTRIN  (AS532).  Western  blots  of  co-immunoprecipitates  and  lysates  were
167probed  with  mouse  anti-eNOS,  anti-caveolin-1  (Transduction  Laboratories, 
Lexington, USA) and anti-NOSTRIN (see above).
10.3  Results
10.3.1  Characterisation of Caveolin-1 and NOSIP:
Biopsy specimens from 20 decompensated alcoholic cirrhotic patients were included, 
with  10  of these  fulfilling  histological  and clinical  criteria  for  alcoholic  hepatitis 
superimposed  on  cirrhosis.  All  the  alcoholic  hepatitis  patients  had  a  moderate  to 
severe grading of necro-inflammation histologically and as was previously observed, 
these patients  had  significantly higher inflammatory  indices  compared to patients 
with  alcoholic  cirrhosis  alone.  By  quantitative  RT-PCR,  caveolin-1  mRNA 
expression  levels  were  significantly  higher  in  alcoholic  hepatitis  patients’  livers 
compared to  cirrhotic  livers  without inflammation (4.6±0.3  vs.  6.3±0.4,  p=0.007), 
and when compared to normal liver (9.7+2.1, p=0.02). The expression of mRNA is 
denoted as relative expression 1/Cycle Threshold (1/Ct) in Figure 10.1 below. Given 
limitations in available material from a transjugular liver biopsy, it was difficult to 
obtain  quantitative  protein  characterisation  using  techniques  such  as  Western 
blotting for Caveolin-1  expression in the biopsy tissue. However, there is historical 
and accepted evidence in the literature for increased Caveolin-1 expression in human 
cirrhosis (21 l)and in animal models of alcoholic (212) and bile duct ligated cirrhosis 
(43)
Of note, there were no significant differences observed in NOSIP mRNA expression 
levels  between  the  alcoholic  patient  groups  (with  and  without  additional 
inflammatory alcoholic hepatitis) and resection specimens with histologically normal 
liver tissue (p=0.3 and 0.5, respectively).
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Figure  10.1  The  mRNA  expression  (represented  as  1/Cj)  for  Caveolin-1  was 
significantly higher in alcoholic hepatitis (AH+C) patients compared to patients with 
alcoholic cirrhosis alone (p<0.01). No significant difference was noted in Caveolin-1 
mRNA between cirrhosis and histologically normal biopsies.
10.3.2  Characterisation of  NOSTRIN
Quantification  of mRNA  for  NOSTRIN  expression  revealed  significantly  higher 
levels in liver samples of alcoholic hepatitis patients compared to those with only 
alcoholic cirrhosis (2.3±0.3  vs. 3.4+0.2, p=0.009;  Figure  10.2A). Liver samples of 
alcoholic  cirrhosis  patients  also  had  significantly  higher  NOSTRIN  mRNA 
expression levels compared to normal tissue, (6.8+2, p=0.04). Furthermore, a second 
mRNA  species  hybridising  with  NOSTRIN-specific  probes  was  discovered, 
representing a novel isoform of NOSTRIN that lacks exon-2. The shortened isoform 
was designated NOSTRIN(3 whereas the parent full-length NOSTRIN was referred 
to  as  NOSTRINa.  Importantly,  NOSTRINp  mRNA  was  significantly  elevated  in 
alcoholic hepatitis patients as compared to those without inflammation (15.1+0.7 vs.
16919.6±1.7, p=0.04), while it was not detected at all in normal tissue (Figure  10.2.B).
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Figure  10.2 A:  NOSTRINa
mRNA  levels were  significantly 
higher  in  alcoholic  hepatitis 
(AH+C) patients  compared with 
alcoholic  cirrhosis  alone 
(p<0.01);  cirrhotic  specimens 
had  higher  NOSTRINa  mRNA 
levels  compared to  normal  liver 
specimens (p<0.05).
Figure  10.2B:  NOSTRINp
mRNA  levels  were  significantly 
higher  in  alcoholic  hepatitis 
(AH+C)  patients  compared  to 
those  with  cirrhosis  alone 
(p<0.01);  NOSTRINp  mRNA 
was  undetectable  in  normal  liver 
tissue.
Sequence  analysis  of  the  NOSTRINp  cDNA  revealed  that  skipping  of  exon-2 
generates a premature stop codon in exon-3 such that an internal methionine codon 
present in exon-4 is used for alternative transcription  initiation  at the NOSTRINp
170mRNA. This results in a shortened isoform lacking the first 78 amino acid residues 
at the N-terminus of NOSTRIN.
In collaboration with colleagues in Frankfurt, experiments were devised in order to 
determine the potential relevance of NOSTRINa and NOSTRIN(3’s association with 
the  vascular  endothelium  in  relation  to  physiology/patho-physiology.  Firstly,  to 
analyse  for  expression  of NOSTRIN  protein,  Western  blots  were  performed  on 
lysates of human liver tissue specimens with a monoclonal antibody binding to the 
C-terminal portion that is shared by NOSTRINa and p (Figure  10.3A). On Western 
blots, the two NOSTRIN isoforms clearly differed by their size, as demonstrated by 
recombinant  expression  of the  proteins  in  Chinese  Hamster  Ovary  (CHO)  cells. 
NOSTRINa was detected at 58 kDa, and NOSTRINp at 50 kDa (Figure 10.3B), and 
thus they could be easily distinguished from each other.
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Figure 10.3 (A) NOSTRINa displays a characteristic domain structure comprising 
an N-terminal Fes/CIP homology (FCH) domain, two coiled-coil domains (ccl  and 
cc2),  and  a  C-terminal  Src  homology  (SH3)  domain.  NOSTRINp  lacks  the  N- 
terminal  78  amino  acid  residues  and  thus  most  of the  FCH  domain  present  in 
NOSTRINa,  (B) In Western blotting, recombinant expression of NOSTRINa  and 
NOSTRINp in Chinese Hamster Ovary (CHO) cells show molecular masses of 58 
and 50 kDa, respectively.
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171In  the liver samples, NOSTRINa protein expression was readily detectable  at the 
expected  size  in  all  patient  samples  analysed  (Figure.  10.3C).  NOSTRINp  was 
present  in  all  alcoholic  liver  disease  patient  biopsies  but  was  not  found  to  be 
expressed in normal hepatic tissue. Due to the strict size limitation of the available 
trans-jugular biopsy specimens, it was not possible to perform quantitative protein 
analyses. On the Western blots, the protein levels of Lamp-1   (lysosome associated 
membrane protein-1) were used to ensure that roughly equal amounts of total protein 
were analysed (Figure 10.3C).
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Figure  10.3C Western blotting analysis  of human  liver samples  for expression of 
NOSTRINa and NOSTRINp. To estimate total protein loading, Lamp-1  is shown as 
a  marker.  NOSTRINa  was  detected  in  all  liver  samples  analysed,  whereas 
expression  of NOSTRINp. was  restricted to  patients  with  AC  (alcoholic  cirrhosis 
alone  and  no  inflammation)  or  AH+C  (alcoholic  hepatitis),  and  was  not  seen  in 
normal liver tissue (N).
Study of hepatic (Hep3B) cell lines demonstrated endogenous NOSTRINa but not 
NOSTRINp  was  present.  (Figure  10.4A).  Moreover,  NOSTRIN  expression  was 
shown to increase in Hep3B cells with the addition of retinoic acid (RA) in a time- 
dependent manner (Figure 10.4A). After six days of RA treatment, low levels of a 50 
kDa  band  were  detected  by  the  monoclonal  NOSTRIN  antibody,  fitting  the 
molecular weight of NOSTRINp (Figure  10.4B). In line with this finding, elevated
172mRNA levels were  found for both NOSTRIN isoforms  in RA-stimulated vs.  non­
stimulated Hep3B cells using qRT-PCR (Figure 10.4C).
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Figure 10.4. Expression of NOSTRINa and NOSTRINp in cultured hepatocyte-like 
Hep3B cells treated with  1   pM retinoic acid (RA) or mock-treated with DMSO for 
up to six days, and analysed by (A, B) Western blotting and (C) qRT-PCR. Values 
given are normalized to ubiquitin C and shown as relative expression (1/Ct). Both 
experimental  methods  show a clear up-regulation of NOSTRINa  and NOSTRINp 
expression after RA treatment. Note that (B) shows a blot after prolonged exposure.
10.3.3  Interaction partners of  NOSTRIN
Immunohistochemistry  performed  on  human  liver  tissue  sections  demonstrated  a 
close association between NOSTRIN and hepatic vascular endothelium, with a cuff 
of positive staining around vascular structures (Figure  10.5A and B). This staining 
pattern  was  lost  following  pre-absorption  of the  NOSTRIN  antibody  with  GST- 
NOSTRIN.  Importantly,  identical  observations  were  made  with  both  monoclonal 
(Figure 10.5B, a+c) and polyclonal anti-NOSTRIN (Figure 10.5B, b+d). This finding 
suggested that NOSTRIN and eNOS may indeed interact in liver endothelium. To 
confirm this observation, a co-immunoprecipitation was performed on human liver 
lysates  and  probed  with  mouse  anti-eNOS,  anti-NOSTRIN  and  anti-caveolin-1.
173eNOS and caveolin-1 were shown to co-precipitate with NOSTRIN but not with pre- 
immune serum (Figure 10.5C), as has previously been observed in human umbilical 
vein endothelial cells (HUVECs). (56)
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Figure 10.5 NOSTRIN localisation and its interaction partners in liver tissue (A, B) 
These panels show liver tissue with H+E-staining (A) or immunohistochemistry (B); 
Polyclonal  (a + c)  and monoclonal  (b + d)  anti-NOSTRIN was used for staining. 
The figure demonstrates a close association between NOSTRIN and hepatic vascular 
endothelium, with  a cuff of positive  staining  (monoclonal  and polyclonal)  around 
vascular structures. This staining pattern is lost after pre-absorption of the NOSTRIN 
antibody  with  GST-NOSTRIN,  used  as  a  control.  (Bars:  50  pM),  (C)  Co- 
immunoprecipitation was performed using rabbit anti-NOSTRIN (AS532). Western 
blots  of co-immunoprecipitates  and human  liver lysates  were  probed  with  mouse 
anti-eNOS,  anti-NOSTRIN  and  anti-caveolin-1.  eNOS  and  caveolin-1  co- 
immunoprecipitate with NOSTRIN from total liver lysates, but not with pre-immune 
serum.
17410.3.4 Comparison of  NOSTRINa and ft isoforms
To  analyse  NOSTRINp  more  closely,  the  localisation  of  the  recombinantly 
expressed protein was determined using immuno-fluorescent labelling and confocal 
microscopy  in  CHO  cells  expressing  eNOS  (CHO-eNOS)  transfected  with 
NOSTRIN a or NOSTRIN p cDNA, by our collaborators in Frankfurt. NOSTRINa 
localised  to  vesicular  and  tubular  membrane  structures  throughout  the  cytoplasm 
(Figure  10.6A),  whereas NOSTRINp  displayed  a  pre-dominantly nuclear  staining 
(Figure 10.6B).
NOSTRINa NOSTRINp
Figure  10.6  Subcellular  localisation  of  NOSTRINa  and  NOSTRINp:  Chinese 
Hamster  Ovary  (CHO)-eNOS  cells  were  transfected  with  NOSTRINa-  (A)  or 
NOSTRINp-cDNA- (B), fixed with methanol and analysed by immunofluorescence. 
The  two  isoforms  clearly  differ  in  their  subcellular  localisation;  NOSTRINa 
primarily cytoplasmic and NOSTRINp nuclear.
17510.4 Discussion:
The  results  from  these  elements  of study  show  that  expression  of several  eNOS 
regulatory  proteins  become  altered  in  cirrhosis.  Initially,  NOSIP,  an  intracellular 
regulator of eNOS, was tested to evaluate any alterations in its expression pattern but 
no  significant  differences  in  mRNA  expression  levels  were  found  between  the 
cirrhotic  and  non-cirrhotic  patient  groups.  In  contrast,  it  could  be  shown  that 
NOSTRINa (the full-length parent protein) was expressed in normal liver and in a 
hepatocyte cell line (Hep 3B), and through immunohistochemistry on patient liver 
biopsies, found to be associated with vascular structures suggesting interactions with 
vascular  endothelium.  It  was  also  possible  to  demonstrate  that  NOSTRINa 
expression was significantly higher in cirrhotic liver compared with the normal liver 
indicating that NOSTRINa expression was likely to be subject to regulation under 
pathological conditions. Furthermore, alcoholic hepatitis patients demonstrated even 
higher  levels  of NOSTRINa  mRNA  compared  to  patients  with  cirrhosis  alone, 
whilst  also  having  the  lowest  eNOS  activity  and  higher  portal  pressures,  as 
determined by our earlier studies. At present the mechanism by which NOSTRINa is 
up-regulated in cirrhosis and further increased during inflammation remains unclear. 
However,  the  association  between  inflammation  and  increased  expression  of 
NOSTRINa  may  suggest  a  potential  role  for  NOSTRINa  in  regulating  eNOS 
activity  during  hepatic  inflammation,  impacting  on  the  severity  of  portal 
hypertension.  It was also possible to confirm previous observations of a potential 
role for caveolin-1 in regulating the activity of hepatic eNOS, (43) by demonstrating 
increased caveolin-1 expression in patients with cirrhosis.
Full-length NOSTRIN has been demonstrated to physically interact with eNOS via 
its  C-terminal  SH3  domain.  (56)  Over-expression  of NOSTRINa  in  CHO-eNOS
176cells  results  in a  significant  decrease  in eNOS  activity,  in conjunction with  a re­
distribution of eNOS from the plasma membrane to intracellular sites. (56) Further 
studies have revealed that during internalisation of eNOS, NOSTRINa serves as a 
homo-trimeric  platform  to  recruit  proteins  like  dynamin  and  Neuronal  Wiskott- 
Aldrich  Syndrome  Protein  (N-WASP)  which  play  a  crucial  role  in  endocytic 
processes. (213) Moreover, NOSTRINa can directly bind to caveolin-1 independent 
of its interaction with eNOS, and the interaction between NOSTRINa and eNOS is 
significantly increased in the presence of the caveolin-1  scaffolding domain.  (214) 
Thus, enhanced interaction between NOSTRINa, eNOS and caveolin-1 may silence 
eNOS  activity  during  subcellular  transport.  (214)  In  this  study,  an  interaction 
between  eNOS,  NOSTRIN  and  caveolin-1  was  confirmed  in  a  co- 
immunoprecipitation  assay  from  lysed  human  liver  specimens.  Furthermore, 
immunohistochemistry  clearly  demonstrated  association  of  NOSTRIN  with  the 
hepatic vascular endothelium.
The nature of a physiological stimulus regulating the interaction of NOSTRINa with 
its binding partners is currently unknown. There are some indications, however, that 
NOSTRINa may be regulated by changes at the transcriptional level. Treatment of 
murine  F9  cells  with  retinoic  acid  induces  expression  of  a  murine  NOSTRIN 
orthologue.(215)  In the present  study,  it has been shown that exposure  of Hep3B 
cells  to retinoic  acid increases the  expression  of NOSTRIN  in  a time  -dependent 
manner.  Thus,  in an environment of hepatic  stellate cell  activation following pro- 
inflammatory  stimuli,  the  subsequent  release  of lipid  droplets  containing  retinoic 
acid  (216,  217)may  contribute  to  the  increased  expression  of NOSTRIN.  This 
requires further testing in an appropriate model system.  Moreover,  a recent report 
shows  that  increased  expression  of NOSTRINa  correlates  with  reduced  eNOS
177activity in placental tissue of women suffering from pre-eclampsia (218), supporting 
the concept that up-regulated NOSTRIN expression in an environment of increased 
oxidative stress and unbalanced cytokine milieu (219) translates into attenuated NO 
production.
This study also describes a novel NOSTRIN variant, NOSTRINp, lacking the first 
78  residues  at the N-terminus  of parent NOSTRIN,  and demonstrates  that this  is 
appreciably expressed in the liver of AH+C patients at both gene and protein level. 
NOSTRINp is also expressed in low amounts in cirrhotic livers but not detectable in 
non-cirrhotic livers.  In regard to understanding the functional impact of the “loss” of 
the N-terminal portion containing almost the entire FCH region of NOSTRINa, the 
FCH regions of NOSTRIN-related proteins and of NOSTRIN itself are known to be 
involved in their binding to membranes (220, 221). Consistent with this finding, we 
show here that the subcellular distribution patterns of NOSTRINa and NOSTRINp 
differ considerably; in. over-expression systems such as in Chinese Hamster Ovary 
cells,  NOSTRINa  is  distributed  over the  cytosol  and  associated  with  subcellular 
membranes,  whilst  NOSTRINp  is  localised  predominantly  to  the  nucleus.  This 
difference  in  localization  may  well  be  explained  by  the  absence  of a  significant 
portion of the membrane-associating FCH region. (221) Consequently, the molecular 
target(s) and possibly also the function of NOSTRINp is likely to be different from 
that of NOSTRINa. Of interest, a study by McNaughton et al, (84) demonstrated a 
translocation of eNOS to hepatocyte nuclei in end-stage cirrhotic patients compared 
to normal controls. This observation may be the result of an increased expression of 
mainly nuclear NOSTRINp but this assertion requires further investigation.
178Chapter 11 
Summary11. Summary
Patients  with  alcoholic  hepatitis  continue to  have  a high mortality with  currently 
available  supportive  management,  often  related  to  complications  associated  with 
severe portal hypertension.  Current knowledge on the factors that aggravate portal 
hypertension  in  these  patients  is  poorly  understood.  Moreover,  our  current 
pharmacological armamentarium to treat severe portal hypertension in these patients 
is limited to agents that attempt to decrease portal inflow by producing splanchnic 
vasoconstriction, but such agents are poorly tolerated and may further compromise 
liver  perfusion.  There  is,  therefore,  a  significant  clinical  need  to  understand  the 
pathophysiological elements that contribute to elevated portal pressure in alcoholic 
hepatitis  and  relate  this  to  the  known  inflammatory  mechanisms  that  have  been 
evaluated largely in animal models. An improved understanding of these processes 
would help in the design of more targeted therapies.
The studies described in this thesis were designed to systematically investigate the 
differences in inflammatory status and vascular dysfunction between patients with 
underlying  alcoholic  cirrhosis  and  those  who  develop  in  addition,  superadded 
inflammatory  alcoholic  hepatitis.  Subsequent  studies  in patients  and  experimental 
animal models explored the effects of inflammation on nitric oxide generation and its 
regulators,  and  their  potential  biological  significance  to  observations  of elevated 
portal pressure and outcome in patients.
Initial  studies  confirmed  that  inflammation,  when  superimposed  on  chronic  liver 
injury,  manifests  as  a more  advanced histological  stage  of disease  commensurate 
with  more  severe  liver biochemical  dysfunction  and  high  markers  of a  systemic 
inflammatory response. These features occur on a background of increased oxidative
180stress and are associated with more advanced features of liver decompensation when 
the patient presents. Poor outcomes were observed both in humans and in a bile-duct 
ligated rodent model of chronic liver disease. Given the high incidence of sepsis in 
alcoholic cirrhosis  and the  existing  literature  suggesting neutrophil dysfunction  in 
alcoholic  hepatitis,  the  contribution  of neutrophil  dysfunction  to  the  effects  of 
inflammation and its outcome  in alcoholic cirrhosis were  also  investigated.  These 
studies suggested that in cirrhosis there was an increase in unstimulated neutrophil 
oxidative burst and that this was further exaggerated in the context of inflammation, 
suggesting  a  prior  ‘priming’  of  neutrophil  responses  by  the  presence  of 
inflammation.  However,  further  bacterial  challenge  resulted  in  blunted  oxidative 
burst  responses  associated  with  decreased  phagocytic  capacity  and  an  increased 
incidence  of infection,  organ  failure  and  mortality  in  alcoholic  hepatitis  patients. 
Thus  neutrophil  dysfunction  in  alcoholic  hepatitis  may  contribute  to  the 
inflammatory  environment  through  increased  priming,  but  paradoxically,  there  is 
inadequate  neutrophil  phagocytic  function  in these patients  to  offset  an  increased 
bacterial load, resulting in a higher incidence of sepsis and poor outcome.
The  next  phase  of work  addressed  circulatory  differences  in  alcoholic  cirrhosis 
patients in the context of inflammation.  It confirmed a more severe hyperdynamic 
circulation in alcoholic hepatitis, whilst also demonstrating a markedly higher portal 
pressure in these patients which correlated with the level of systemic inflammatory 
response.  Moreover,  hepatic blood flow was  shown to be  further compromised in 
alcoholic hepatitis and the calculated intrahepatic resistance markedly elevated. This 
suggested that in the context of increasing inflammation in cirrhosis, there was an 
important element contributed by increasing resistance within the liver, and this was 
likely to be a variable component modulated by vasoactive mediators as have been
181previously identified. (38) Subsequent studies applying a single infusion of an anti- 
TNFa  monoclonal  antibody  (Infliximab)  or  albumin  dialysis  using  the  MARS 
system,  demonstrated  marked  reductions  in  portal  pressure  within  24  hours  of 
treatment.  This was  associated with an improvement in hepatic blood flow in the 
absence of changes in central venous filling,  suggesting an action on intra-hepatic 
resistance.  The  study with Infliximab  also  demonstrated an  improvement in renal 
blood flow and urinary sodium excretion post therapy,  which may imply that the 
mechanisms affecting regional vascular tone, and thereby function, were unlikely to 
be limited just to the liver.
Following these observations and data in the literature highlighting the importance of 
nitric oxide in the maintenance of hepatic vascular tone, studies were conducted to 
define  the  expression  and  function  of eNOS  in  patients.  These  studies  involved 
patients  with  and  without  inflammation  in  alcoholic  cirrhosis,  in  addition  to 
comparisons  with  an  animal  model  of  acute  liver  injury  to  which  a  further 
inflammatory  insult  (LPS)  was  added.  These  studies  showed  that  there  was  an 
enhanced  expression  of  eNOS  mRNA,  but  no  significant  difference  in  protein 
expression with additional inflammation.  In contrast, hepatic tissue eNOS activity 
was  markedly  reduced  in  alcoholic  hepatitis  and  correlated  inversely  with  portal 
pressure. This effect of inflammation on eNOS activity was confirmed in the animal 
model, and raised the possibility of action by inhibitors of eNOS activity, resulting in 
an intrahepatic ‘endotheliopathy’.
Given  the  weight  of  evidence  for  ADMA  as  a  potential  cause  of  endothelial 
dysfunction,  studies  were  conducted  to  determine  the  levels  of ADMA  in  liver 
disease  and  to  ascertain  if they  were  modified  by  the  presence  of  superadded 
inflammation. In patients with paracetomol induced acute liver failure, ADMA levels
182were significantly elevated compared with controls, and correlated with the plasma 
levels  of  pro-inflammatory  cytokines.  Furthermore,  at  the  time  of  liver 
transplantation,  restoration  of hepatic  perfusion via anastamosis  of the  portal  and 
hepatic  veins  was  accompanied  by  a  marked  decrease  in  ADMA,  suggesting  a 
restoration of hepatic clearance of ADMA and specifically, DDAH activity which is 
required for ADMA metabolism. A further study in a galactosamine rat model with 
an additional endotoxin insult confirmed the effects of superadded inflammation on 
the  dysfunctional  liver  in  promoting  increased ADMA  levels,  when  compared to 
galactosamine alone or sham animals treated with LPS.
The biological relevance of elevated ADMA in liver disease was established from a 
study in patients with  decompensated  alcoholic  cirrhosis,  showing  higher ADMA 
levels  in patients with alcoholic hepatitis,  and in those patients who  subsequently 
died  from  organ  failure.  SDMA  was  also  significantly  increased  in  patients  with 
organ failure and subsequently a dimethylarginine score (‘DAS’ =ADMA +SDMA) 
was defined, which provided a significantly improved predictive utility for mortality 
compared with  scores used in current  clinical practice  such as  MELD  and Child- 
Pugh. Patients with alcoholic hepatitis also had reduced expression of DDAH II and 
increased  PRMT-1  expression,  suggesting  decreased  metabolism  and  increased 
synthesis  of ADMA,  respectively.  Hepatic tissue  ADMA  also  correlated with the 
severity of portal pressure gradient, supporting a notion that elevated ADMA in the 
context  of  inflammation  in  liver  disease  decreases  eNOS  activity  resulting  in 
increased intrahepatic resistance.
A  final  phase  of work  addressed  other  novel  regulators  of  eNOS  activity  and 
established  increased  expression  of  caveolin-1  and  NOSTRIN  in  patients  with 
alcoholic  hepatitis,  compared  to  patients  with  alcoholic  cirrhosis  alone.  Further
183characterization  of NOSTRIN  noted  the  presence  of a  shortened  variant  with  a 
mainly  nuclear  localization,  which  was  not  found  in  normal  liver  specimens. 
NOSTRIN  was  shown  to  co-precipitate  with  eNOS  and  caveolin-1  suggesting  a 
complex relationship of protein interactions which determine eNOS function, which 
may be modified by the presence of inflammation.
In conclusion, the studies described in this thesis confirm a clear association between 
inflammation  in alcoholic  liver disease  and vascular dysfunction,  and importantly 
increased intrahepatic resistance. Furthermore, it was established that inflammation 
promotes a significant decrease in eNOS activity and it is suggested that this might 
be the result of the effects of inflammation on specific NOS regulators, especially 
ADMA and NOSTRIN.  Whether these findings can be extrapolated to all types of 
inflammatory liver injury, and whether the putative regulators of NOS activity are 
causal  in  the  vascular  dysfunction  will  be  important  areas  for  future  study,  the 
findings of which may help to devise more targeted therapy for portal hypertension.
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205Appendix A 
Future DirectionsFuture Directions:
Amongst the most important findings in the context of the studies presented in this 
thesis have been the observations of significantly elevated ADMA in patients with a 
more severe expression of disease (alcoholic hepatitis and acute liver failure) and in 
whom portal pressure is considerably raised, and also the identification of increased 
expression of NOSTRIN and its short-variant. These observations and their potential 
impact on the pathophysiology of liver disease are worthy of further study:
Firstly,  it  is  important  to  address  whether  the  observed  elevation  of ADMA  is 
causally related to the  progression  of injury  and/or the  development  of increased 
intrahepatic resistance, as this could not be confirmed by the studies performed so 
far. In the next phase of study, it would be interesting to address the question of a 
causal  relationship  by  application  to  a  rodent  model  of  liver  injury,  such  as 
galactosamine. The experimental questions to be considered should include:
1.  Does an infusion of ADMA into a galactosamine model evoke deterioration 
in  liver  biochemistry,  expression  of  disease/short  term  survival  and 
measured  vascular  parameters?  How  do  these  changes  compare  with  the 
effects of inflammation (injection of LPS) into a galactosamine model?
2.  Can the effects of an ADMA infusion be reversed by administration of intra­
venous arginine, i.e. support for the concept that the ADMA:arginine ratio is 
important?  Use  of  stable  isotopes  to  label  arginine  and  ADMA  in 
conjunction  with  selective  liver  vessel  cannulation  would  help  in  better 
defining the contribution of arginine in this setting.3.  What  is  the  level  of  hepatic  injury  and  vascular  dysfunction  in  a 
heterozygous  DDAH  knock-out  animal,  treated  with  galactosamine 
injection?  If the  injury  is  sub-lethal,  can  the  condition  be  improved  by 
administration of arginine?
4.  What are the potential mechanisms by which high ADMA results in poor 
outcome?- Is there evidence for impaired liver regeneration in the context of 
reduced  NO  signalling  and  pro-inflammatory  drive?  This  could  also  be 
tested in model systems such as partial hepatectomy, and by experimentation 
via incubation with hepatocyte cell lines.
5.  Considering  the  translation  to  man-  Does  an  infusion  of arginine  lower 
portal  pressure  in patients  with  alcoholic  liver  disease  through  effects  on 
intrahepatic  resistance? -A pilot  study would be  set up with efficacy and 
dose ranging studies.
6.  Are  ADMA  and  SDMA  reliable  markers  of  outcome  in  patients  with 
decompensated  cirrhosis,  who  are  at  risk  of progressing  to  multi-organ 
injury?- A large well powered prospective study with repeated measurements 
over the follow-up period, and continuous data collection would need to be 
set-up  to  evaluate  these  markers,  with  appropriate  statistical  analysis  to 
confirm the utility of a DAS score.
Secondly,  with  regards  to  the  observation  of increased  NOSTRIN  a  and  p  in 
alcoholic  liver disease,  it is  clearly going to be  important to  substantiate whether 
these findings can be extrapolated to other forms of liver injury through studies in 
different animal models and to ask the fundamental questions:1.  Which cell types express NOSTRIN and is it possible to over-express both 
variants  in these relevant cell types?- Assess  expression within endothelial 
cells, parenchymal cells and hepatic stellate cells.
2.  What factors govern NOSTRIN up-regulation?
3.  What are the  functions  of NOSTRIN a and  p? -   Studies to be conducted 
using  over-expression  systems  or  by  modification  of the  NOSTRIN  gene 
through application of a newly developed knock out
4.  Is NOSTRIN important for the regulation of NOS activity in the endothelial 
cell? What is the mechanism of translocation of eNOS to the nucleus and is 
this of biological importance?
These  questions  are  to  be  pursued  systematically  as  part  of on-going  studies  to 
develop this area of research further.Appendix B
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This article resulted from a phase of developmental work,  in an attempt to 
establish a working assay to measure tissue nitric oxide generation. Although 
the technique proved too time consuming and complex for measurement in 
human  samples  from  transjugular  biopsies,  the  results  on  defective 
guanylatye  cyclase  activity  in  a  cirrhotic  model provides  evidence for an 
alternative target for future therapy beyond the derangements in nitric oxide 
synthase activity.Appendix C 
List of  figures and tablesFig 1.1 
Fig 1.2 
Fig 1.3 
Fig 2.1 
Fig 2.2 
Fig 3.1 
Fig 3.2 
Fig 3.3 
Fig 3.4 
Fig 4.1 
Fig 4.2 
Fig 4.3 
Fig 4.4 
Fig 4.5 
Fig 5.1 
Fig 5.2 
Fig 5.3 
Fig 6.1 
Fig 6.2a+b 
Fig 6.2c 
Fig 6.3 
Fig 6.4 
Fig 6.5 
Fig 6.6 
Fig 7.1 
Fig 7.2 
Fig 7.3 
Fig 7.4 
Fig 8.1 
Fig 8.2 
Fig 8.3 
Fig 8.4 
Fig 8.5 
Fig 8.6 
Fig 9.1 
Fig 9.2a 
Fig 9.2b-c 
Fig 9.3 
Fig 9.4 
Fig 9.5 
Fig 9.6 
Fig 9.7 
Fig 10.1 
Fig 10.2 A,B 
Fig 10.3 A,B 
Fig 10.3 C 
Fig 10.4 A-C 
Fig 10.5 A-C 
Fig 10.6 A,B
List of Figures
Pg 17 
Pg 21 
Pg 29 
Pg 39 
Pg 45 
Pg 53 
Pg 55 
Pg 58 
Pg 59 
Pg 67 
Pg 68 
Pg 69 
Pg 72 
Pg 73 
Pg 83 
Pg 84 
Pg 86 
Pg 95 
Pg 96 
Pg 97 
Pg 97 
Pg 98 
Pg 108 
Pg 109 
Pg H7 
Pg H8 
Pg 119 
Pg 121 
Pg 130 
Pg 131 
Pg 132 
Pg 133 
Pg 136 
Pg 137 
Pg 151 
Pg 152 
Pg 153 
Pg 155 
Pg 156 
Pg 157 
Pg 158 
Pg 159 
Pg 169 
Pg 170 
Pg 171 
Pg 172 
Pg 173 
Pg 174 
Pg 175List of Tables
Table 4.1 Pg 71
Table 6.1 Pg 94
Table 6.2 Pg 110
Table 8.1 Pg 129
Table 9.1 Pg 149
Table 9.2 Pg 150
Table 9.3 Pg 154
xv